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It was estimated that about 12.7 million cancer cases and 7.6 million cancer deaths 
have occurred in 2008. Because of the aging and growth of the world population and 
increased adoption of cancer-causing behaviors, such as smoking, in the developing 
world, this number will increase (1). For many years it has been known that 
environmental factors, such as tobacco, alcohol, diet, and occupational exposures 
account for a great majority of cancer deaths (2). The great majority of the chemical 
carcinogens present in these environmental factors require metabolic activation to 
elicit detrimental effects (3). Therefore, alterations in the metabolism could influence 
the carcinogenicity of those compounds. A lot is known about the effect of 
polymorphisms on carcinogen metabolism; however there are more endogenous 
factors that could influence one’s susceptibility to carcinogens such as inflammation 
and oxidative stress. Moreover these factors might also alter the repair of the damage 
induced by the same carcinogens. In this thesis we focus on two endogenous oxygen-
related factors (hypoxia and oxidative stress) since previous research suggests that 
both factors might have an influence on carcinogen metabolism (4) and repair (5). Our 
goal was to further elucidate these mechanisms, and to prove the biological 
significance of these factors influencing the carcinogenic capabilities of carcinogens 
and subsequent genetic instability. 
 
Carcinogen-induced DNA damage 
 
Cancer induction is a multi-stage, multi-step process and includes multiple molecular 
and cellular events to transform a normal cell to a malignant neoplastic cell. However, 
three general steps can be identified in carcinogenesis; initiation, promotion, and 
progression. Initiation is the step where irreversibly, DNA of a normal cell is changed 
and a mutated cell is formed. During the next step, this single cell is encouraged to 
proliferate and form a population of mutated cells. This tumor promotion process is 
not necessarily a direct DNA reactive or damaging process, but involves modulation of 
gene expression that results in the increase in cell number through cell division and/or 
decrease in apoptotic cell death. The third step, progression, involves additional 
damage to the genome, and invasive expansion of the neoplastic cells. 
A cell or tissue has to acquire certain capabilities to follow this above mentioned 
multistep process of human tumor pathogenesis. In 2000, Hanahan and Weinberg 
described six capabilities (hallmarks) that enable cells to eventually form a tumor; cells 
have to become self-sufficient in growth signals, insensitive to anti-growth signals, cells 
must be able to avoid apoptosis, to induce angiogenesis, to invade local tissue and 
metastasize, and they must acquire limitless replicative potential (6). Eleven years later 
additional hallmarks were proposed such as the ability of cells to evade immune 
destruction and the deregulation of the energy metabolism inside the cell (7).  
To affect these hallmarks, expression of genes that are involved in pathways 
influencing these hallmarks of cancer, have to change. These changes can be a result of 
an alteration in the microenvironment of the cell due to for instance hypoxia or 
inflammation, or as a result of gene mutations. There is however a continuous 
surveillance of the genetic material to find and repair any DNA damage. The 
mechanisms involved are known as the DNA damage response pathways. Cells 
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respond to DNA damage by activating checkpoint pathways to delay the cell-cycle 
progression and repair the defects before the damage is converted into permanent 
mutations (8,9). When a cell is however not able to correct the damage properly or is 
not going into apoptosis, an irreversible DNA damage is formed and a hallmark can be 
acquired. 
 
Chemical carcinogenesis 
Chemical carcinogens have an impact on all three stages of carcinogenesis. The 
mechanisms by which carcinogens induce their effects and how they are involved in 
carcinogenesis have been studied extensively and can be divided into two main 
groups; genotoxic and non-genotoxic effects. 
A genotoxic carcinogen is capable, mostly after metabolic activation, of directly 
altering the genetic material of target cells by for instance inducing DNA breakage or 
binding to the DNA and form DNA-adducts. Non-genotoxic carcinogens on the other 
hand are chemicals that induce cancer without altering the DNA, but instead alter 
mechanisms involved in cell-cell communication, receptors activation, DNA 
methylation and DNA repair, among others (3,10,11). Therefore, investigating the 
consequences of these factors or the mechanisms inducing cancer is of great 
importance to come up with preventive measurements or treatments. 
 
Exposure to polycyclic hydrocarbons 
 
One of the most studied carcinogens is the polycyclic aromatic hydrocarbons (PAHs). 
PAHs are widely distributed environmental contaminants produced as by-products of a 
variety of combustion processes such as diesel exhaust, cigarette smoking, and 
charcoal grilling of food. The ability of PAH-containing mixtures to induce cancer has 
been known since 1775, when the British surgeon Sir Percival Pott demonstrated a 
relation between scrotal cancer incidence and the exposure of chimney sweepers to 
soot. The most studied PAH in the human population is benzo[a]pyrene (BaP), which 
has often been regarded as the prototypical PAH. There are three major exposure 
routes to BaP: skin exposure, dietary intake which is estimated to be around 76 ng per 
day and associated with colorectal adenomas (12), and inhalation by for instance 
smoking, which is estimated to be around 9 ng BaP per cigarette (13), or exposure to 
air pollution. In Berlin outdoor BaP levels were reported to be around 0.1 ng/m3 due to 
for instance motor vehicle traffic (14), while BaP concentrations in the developing 
world are much higher especially in urban areas. In La Plata (Argentina) almost 4 times 
higher levels of BaP (0.38 ng/m3) were observed compared to the rural area (0.11 
ng/m3), while in industrial areas 7.5 fold higher levels were observed. (15). Similar 
concentrations were observed in the city of Curitiba (southern Brazil), where BaP 
concentration ranges between 0.36-0.97 ng/m3 (16). Although smoking and air 
pollution are decreased in the developed world in the last few decades, in the 
developing world exposure to PAHs is still of great concern.  
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Cellular response to BaP 
Exposure to BaP is of major concern because, once entered into the body, BaP easily 
crosses the cell membrane as it is a lipophilic compound. In the cytoplasm, it binds to 
the aryl hydrocarbon receptor (AhR), which forms a complex with chaperone proteins: 
heat shock protein 90, XAP2 and p23 (17). Upon ligand binding, AhR translocates into 
the nucleus, dimerizes with the aryl hydrocarbon receptor nuclear translocator (ARNT), 
and activates gene expression by binding to the TNGCGTG consensus sequence in the 
xenobiotic-responsive elements of target genes (18). This leads to the up-regulation of 
a multitude of genes as has been shown in multiple gene expression studies in 
different cell types (19-21). BaP is mostly known for its capacity to stimulate its own 
metabolism by inducing the expression of the cytochrome P450 isoforms CYP1A1 (22) 
and CYP1B1 (23) which are two of the most important enzymes in the detoxification 
and bioactivation of BaP (24,25). 
The detoxification process of BaP (Figure 1.1) starts with the addition of an epoxide 
group to BaP by these mono-oxygenases (phase I). The resulting metabolites (e.g. BaP-
7,8-epoxide and BaP-9,10-epoxide) can be converted into BaP-glutathion conjugates, a 
reaction catalyzed by glutathione S-transferase (GST) (phase II). BaP-epoxides can also 
be converted nonenzymatically to phenols (e.g. BaP-3-phenol), or to dihydrodiols (e.g. 
BaP-7,8-diOH or BaP-9,10-diOH) by epoxide hydrolase. Phenols can be converted to 
water-soluble sulphate or glucuronide conjugates by sulfonyl transferase (SULT) and 
uridine diphosphate glucuronosyl transferase (UGT), respectively. Dihydrodiols can be 
glucuronidated (26) or transformed by CYP1A1 or CYP1B1 to diol epoxides (e.g. BaP-
7,8-diol-9,10-epoxide (BPDE)) (25).  
The last phase in the metabolism of BaP is the active transport over the membrane. 
Certain ATP binding cassette transporter proteins are able to transport BaP and other 
xenobiotics and their metabolites across the cell membranes (27). For instance, P-
glycoprotein mediates the efflux of BaP in human breast cancer cells (28) and the 
breast cancer resistance protein can actively transport BaP glutathione, glucuronide, 
and sulfate-conjugates (29). Changes in the activity of these transport proteins could 
have an effect on the carcinogenicity of a compound as for example a reduced BPDE 
glutathione conjugate removal resulted in an increased BPDE-DNA adduct formation 
(30). In addition BaP can be metabolized to o-quinones catalyzed by dihydrodiol 
dehydrogenases, which can undergo redox cycling. Redox cycling of these metabolites 
leads to the formation of large amounts of reactive oxygen species (ROS), which cause 
the formation of oxidative DNA damage which results in elevated levels of lipid 
peroxidation (31). 
 
BaP-induced DNA damage 
There are four isoforms of BPDE of which the (+)-anti-isomer is the most predominant 
and the most potent tumor initiator (24). BPDE can covalently bind to DNA, 
preferentially to the nucleotide guanine at the N2 position. This covalent binding result 
in the formation of highly mutagenic DNA adducts (BPDE-N2-dG lesion), which can 
become mutations, predominantly G to T transversions, when these adducts are not 
removed (32). Unrepaired damage can result in apoptosis or transcriptional changes, 
and mutations acquired in the process of DNA repair may lead to unregulated cell 
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growth and cancer. It is for instance known that these BPDE-induced G to T 
transversions in the p53 tumor suppressor gene are involved in lung cancer 
development (33). Furthermore, isothiocyanate, which is very effective against lung 
tumor development in a mouse model, caused a decrease in BPDE-DNA adduct levels 
in the mouse lung (34). 
 
Figure 1.1: Schematic overview of the metabolism of BaP by the phase I enzymes cytochrome 
P450 (CYP1A1 and CYP1B1) and phase II enzymes; glutathione S-transferase (GST), uridine 
diphosphate glucuronosyl transferase (UGT), and sulfonyl transferase (SULT). Adapted from 
Baird et al and Zhou et al (25,35). 
 
Polymorphisms affecting BaP metabolism 
These bulky DNA adducts formed after BaP exposure are considered to be markers of 
exposure to genotoxic aromatic compounds and of the ability of the individual to 
metabolically activate carcinogens and to repair DNA damage (36). Nevertheless, 
individuals with approximately similar exposures may have different DNA adduct levels 
as was for instance found by Rojas et al, who observed a 4-fold and 3-fold inter-
individual difference in smoker and non-smokers, respectively (37). These differences 
could be explained by polymorphisms in genes involved in the process of DNA adduct 
formation and repair. These variations have been studied extensively for both BPDE-
adduct formation as cancer risk and multiple polymorphisms have been found. 
Polymorphisms affecting BPDE-DNA adduct formation have been identified in phase I 
and II enzymes linked to BaP metabolism, including CYP1A1, GSTM1, GSTT1, GSTP1 
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(38-40). However, no CYP1B1 polymorphisms affecting BPDE-DNA adduct formation 
have been identified so far. 
Even more research has been performed on the effect of these polymorphisms on 
susceptibility to various kinds of cancers. Some of these polymorphisms have been 
shown to be a risk factor, however, factors as gender, ethnic background or smoking 
habits can have a tremendous influence on the effect of a polymorphism and cancer 
development. Polymorphisms of both phase I enzymes involved in BaP metabolism 
have been linked to cancer risk. For instance, the CYP1A1 Ile462Val polymorphism has 
been associated with the development of lung cancer, especially in Asians (41) and 
with risk of colorectal cancer in both Asians and Caucasians (42). Also the CYP1A1 MspI 
gene polymorphism, is associated with increased lung cancer risk (43). Both these 
polymorphisms have also been associated with increases in CYP1A1 catalytic activity 
(44,45). The CYP1B1 polymorphism Leu432Val, which results in an increased catalytic 
activity of CYP1B1, is associated with increased lung cancer among smokers (46,47). 
Phase II enzymes have also been studied and polymorphisms in GSTM1, GSTP1, and 
GSTT1 have been associated with altered catalytic activity, but concluding from 
numerous datasets, GSTs do not show to have a link with cancer risk (48,49). Overall, 
polymorphisms in genes of xenobiotic enzymes are of influence to adduct formation 
and associated with cancer risk. 
 
Repair of BaP-induced DNA damage 
To cope with DNA lesions, cells have specific mechanisms for tolerating and repairing 
the damage. There are 6 major DNA repair pathway involved in DNA repair, which can 
be subdivided into those who repair single-strand damage and those involved in the 
repair of double-strand breaks (DSBs). DSBs are usually repaired through two main 
pathways; homologous recombination (HR) and non-homologous end joining (NHEJ), 
while the single strand damages are repaired by direct reversal that corrects alkylated 
bases, mismatch repair (MMR) that corrects small insertions and deletions that take 
place during DNA replication, base excision repair (BER), which repairs damage to 
single bases, and nucleotide excision repair (NER), which repairs bulky helix-distorting 
lesions (50). The main repair mechanism of bulky adducts caused by for instance BaP is 
NER (51). The importance of NER can be observed in xeroderma pigmentosum (XP), 
where a mutation in one of the XP genes results in a non-functional NER and a 
subsequent increased cancer risk due to the inability to restore UV-induced DNA 
damage (52). Furthermore, reduced expression of NER related genes, such as ERCC1, 
has been linked to the development of lung cancer (53). NER is therefore an essential 
repair pathway responsible for the repair of bulky DNA adducts and UV-induced 
lesions. However, when these bulky DNA-adduct are not repaired, replication forks will 
stall during replication. To prevent DNA replication fork stalling, specific DNA repair 
mechanism called post-replication repair pathways are activated to simply bypass DNA 
damage. The stalling of a replication fork triggers monoubiquitination of proliferating 
cell nuclear antigen (PCNA) at Lys164, which is catalyzed by the Rad6/Rad18 complex 
and activates the predominately error-prone translesion synthesis (TLS). In contrast, 
polyubiquitination of PCNA by the Ubc13/Mms2/Rad5 complex triggers the error-free 
lesion bypass. (54-56). 
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Figure 1.2: Overview of the nucleotide excision pathway adapted from cleaver et al (52). 
 
Nucleotide excision repair pathway 
The repair of DNA damage by NER (Figure 1.2) can be divided in three steps: firstly, the 
recognition of the damage and a subsequent formation of a pre-incision complex; the 
excision of the damaged strand; and finally the gap is filled during DNA synthesis. 
There are two NER sub-pathways: the global genome NER (GG-NER) that detects and 
removes lesions in non-transcribed regions (A); and the transcription-coupled NER (TC-
NER), which repairs actively transcribed genes (B) (51,57). The difference between the 
two sub-pathways is in the damage recognition step. Where in the GG-NER pathway 
damage in transcriptionally inactive regions is detected by XPC and the XPE complex 
(A1), the TC-NER pathway recognizes the damage through the arrest of RNA 
polymerase I (RNAPI) and RNAPII. Subsequently, Cockayne syndrome A (CSA/ERCC8) 
and CSB (also known as ERCC6) proteins bind to the DNA. Arrested polyubiquitylated 
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RNAPII is removed and degraded, leaving the active gene accessible for repair (B1). 
Damage recognition of both pathways is followed by binding of XPA to the damaged 
DNA strand and RPA envelops the undamaged strand. XPB (also known as ERCC3) and 
XPD (also known as ERCC2), both part of transcription factor TFIIH bind to the DNA and 
unwind it (C). The DNA around the damaged site is then cleaved for 24-32 bases long 
by the XPG (ERCC5) and the XPF (ERCC4)–ERCC1 heterodimer (D). DNA polymerases ɷ 
or ɸ fills the gap and ligase connects the newly formed and original DNA strand (51,52). 
The rate limiting steps in NER are damage recognition and incision, as ATP is required 
for the cleavage and opening of the damaged DNA strand (58). 
 
Hypoxia and cancer 
 
Cellular responses to hypoxia, a reduction in normal oxygen tension, occur as a 
regulatory process in normal physiologic conditions. For instance under high altitude 
where hypoxic responses results in the increase of respiration rate while due to local 
hypoxia at for instance a site of injury, blood vessels are recruited.  
Hypoxia is also an important factor in cancer where it has an influence on the 
hallmarks of cancer. It stimulates for instance cells to express various growth signals. 
To evade apoptosis, hypoxia is able to induce the expression of anti-apoptosis proteins 
and it provides a physiological selective pressure in tumors for the expansion of cells 
that have lost their apoptotic potential. Furthermore, tissue hypoxia can induce a 
number of angiogenic factors that promote angiogenesis, such as VEGF and IL-8, but it 
can also decrease the activity of the angiogenic inhibitor thrombospondin, which will 
result in a sustained angiogenesis.(See (59) for a more extensive review on this topic).  
Due to abnormal vasculature of tumors, hypoxia is a characteristic feature in the vast 
majority of solid tumors and remains of therapeutic concern due to the reduction in 
the efficacy of conventional therapies. Resistance of hypoxic cells to chemotherapy is 
caused by the limited delivery of the agent to the cells due to the limited vasculature in 
the tumor and by the immunity of slowly proliferating cells at increasing distances 
from tumor blood vessels to agents that target cell proliferation, while resistance to 
radiotherapy is a result of the reduced formation of ROS  targeting the DNA after 
irradiation (60-62). Overall, hypoxia plays a central role in mutagenesis and 
carcinogenesis.  
 
Molecular responses to hypoxia 
Hypoxia inducible factor ɲ (HIFɲ) is regarded as the primary molecular switch to alter 
gene expression in response to reduced oxygen tension (Figure 1.3). There are three 
known family members (HIF-1ɲ, HIF-2ɲ, and HIF-3ɲ). Under normoxic conditions, 
hydroxyl groups are attached to HIFɲ by prolyl-4-hydroxylase (PHD), which requires 
oxygen, iron and 2-oxoglutarate for enzymatic activity (63). The hydroxylated HIFɲ is 
recognized by an ubiquitin ligase complex, which contains the von Hippel-Lindau 
protein (VHL). VHL binding of HIFɲ targets it for ubiquitination (64) and subsequent 
degradation by the 26S proteasome (65). Hypoxia prevents hydroxylase activity and 
the consequently stabilized HIFɲ subunit is translocated into the nucleus, where it 
forms HIF1, a heterodimer with HIF-1ɴ also known as ARNT (66). In contrast to HIFɲ, 
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HIF-1ɴ/ARNT is constitutively present irrespective of oxygen tension (67). After 
dimerization, HIF1 binds to the (A/G)CGTG consensus sequence in the hypoxia-
responsive elements of the promoter/enhancer regions in the DNA (68), where it 
promotes the transcription of a wide array of hypoxia-inducible genes, including genes 
involved in angiogenesis (vascular endothelial growth factor (VEGF)), glucose 
metabolism (glucose transporter 1), pH regulation (carbonic anhydrase IX (CA-IX)), and 
cell growth (insulin-like growth factor 2) (69). These proteins encoded by these genes 
are crucial in mediating the cellular adaptation or tolerance to hypoxia and in the 
survival of the cell.  
 
 
Figure 1.3: Schematic overview of the HIF pathway. Adapted from Baldewijns et al and Semenza 
et al (70,71). HIFɲ protein levels are regulated by the amount of synthesis and stabilitzation. 
Activation of the PI3K/AKT and MAPK pathway results in increased translation of HIFɲ mRNA. 
Oxygen-dependent prolyl hydroxylation by prolyl-4-hydroxylase (PHDs) on the other hand 
regulates the binding of the von Hippel-Lindau protein (VHL) that targets HIFɲ for ubiquitination 
and proteasomal degradation. 
 
Hypoxia independent HIFɲ stabilization 
In addition to changes in oxygen tension, various other stimuli can induce a HIFɲ 
response (Figure 1.3). The transition metal cobalt can inactivate the hydroxylases by 
occupying an iron-binding site on the proline hydroxylases (72) and by occupying the 
VHL-binding domain of HIFɲ, preventing the degradation of HIFɲ (73). HIF1 may also 
be activated by interaction with ROS, probably via inhibition of hydroxylation by PHDs 
(74). Growth factors such as insulin and TNFɲ have also been shown to generate a HIF1 
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response (75) by stimulating HIFɲ synthesis via activation of the phosphatidylinositol 3-
kinase (PI3K) or mitogen-activated protein kinase (MAPK) pathways (76). HIFɲ 
expression can also be induced by oncogenic activation (HRAS, HER2, or SRC) and 
tumorsupressor (VHL, PTEN, or p53) deactivation (76). For instance, mutations in the 
VHL gene result in constitutive HIFɲ activation since VHL is unable to recognize the 
hydroxylated HIFɲ and appear to be responsible for about 60 to 70 percent of the 
cases of sporadic clear-cell renal-cell carcinoma, which represents a major portion of 
all cases of renal-cell carcinoma (77). Since the stabilization of HIFɲ may already occur 
in the early phases of disease development, it could be of major relevance for the pre-
clinical stages of carcinogenesis and studying HIFɲ stabilization should not be limited 
to hypoxia. 
 
Cancer therapies targeting hypoxia 
As hypoxia has a major influence on cancer development, studies in the recent years 
have come up with therapies targeting hypoxia through a variety of molecular 
mechanisms. The major mechanisms of action are reducing HIFɲ mRNA or protein 
levels, HIF1 DNA-binding activity, or HIF1-mediated transactivation of target genes. 
(See (78,79) for a more extensive review of this topic). These drugs can improve cancer 
treatment outcomes or prevent further cancer development in the early stages of 
carcinogenesis. 
A second group of possible therapies are the bioreductive drugs. These drugs do not 
overcome hypoxia, but they are designed in such a way that they become active in the 
absence of oxygen and make it possible to target hypoxic cells. There are five different 
chemical groups (nitro groups, quinones, aromatic N-oxides, aliphatic N-oxides and 
transition metals) with the potential to be metabolized under hypoxic conditions. The 
general mechanism involves a one-electron reduction generating a prodrug radical 
that can be re-oxidized by oxygen in normoxic cells, but become active under hypoxic 
conditions, either by fragmentation of the prodrug radical or by its further reduction. 
The use of these drugs in combination with traditional therapies has the potential to 
improve treatment outcome of anticancer therapies (80,81). 
A third group is the bacterial-mediated cancer therapies. Anaerobic bacteria carrying a 
recombinant protein specifically targets hypoxic regions in solid tumors. These bacteria 
can either deliver proteins that have a direct cytotoxic effect, such as toxins and 
cytokines but also enzymes that convert a non-toxic prodrug into a toxic agent. Since 
the hypoxic environment supports the growth and proliferation of anaerobic bacteria, 
this therapy is very specific (82). 
 
Nucleotide excision repair and hypoxia 
There is a growing body of evidence showing that pathways involved in single-strand 
damage repair; BER and MMR, as well as those involved in DSB repair; HR and NHEJ, 
are inhibited by hypoxia. Hypoxia has also been linked with NER. (83). Yuan et al. were 
the first to show that NER is inhibited by hypoxia. They showed that mouse fibroblast 
cells under hypoxic conditions (0% oxygen for 24 hours) combined with low pH (6.5) 
had a decreased repair of UV damaged DNA that was transfected into the mouse 
fibroblast cells (84). However, more recently Dregoesc et al. showed a differential 
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pattern in 5 different cell lines, where in human fibroblasts under conditions of 
hypoxia (1% oxygen for 12 to 24 hours) or hypoxia and low pH (6.5) an increase in 
repair was observed, while at longer time periods a reduced repair was observed. In 
the tumor derived cells, a decrease was observed in repair, which increased after 30 
hours of hypoxic conditions (85). It is also known that HIF-1ɲ and NER are linked since 
HIF-1ɲ regulates the gene expression of XPC and XPD by binding to the hypoxia-
responsive elements within their promoter sites (86). Furthermore, miR-373 is 
upregulated in a HIF-1ɲ dependent manner and downregulates the NER protein 
RAD23B (87). Considering the contradictory results, probably due to different 
experiment conditions and cell lines used, more research is needed, especially on the 
actual phenotypic effects of hypoxia on NER activity. 
 
Crosstalk between the HIF and AhR pathway 
 
HIF-1ɴ/ARNT is a component of both the AhR and HIF1 signaling pathways and 
therefore HIF stabilization could reduce the availability of Hif-1ɴ/ARNT for the 
metabolism of carcinogens. This cross-talk between the two pathways has previously 
been demonstrated; however, these studies revealed inconsistent interactive results 
and did not determine biological significance.  
In 1996, Gradin et al. were the first to demonstrate in HepG2 cells that both the AhR-
pathway and HIF1-pathway required ARNT. An excess of activated AhR by 2,3,7,8-
tetrachlorodibenzofuran (TCDF) did not compete with HIF-1ɲ for recruitment of ARNT, 
while CoCl2 had an inhibitory effect on CYP1A1 mRNA expression (88). This conclusion 
was confirmed by Gassmann et al. who showed that VEGF expression was independent 
of HIF1 activation by indolo[3,2-b]carbazole (ICZ)-treatment in mouse Hepa1 
hepatoma cells (89). Also the AhR-ligand 2,3,7,8-tetrachlorodibenzodioxin (TCDD) 
showed in Hepa1 cells that hypoxic agents including CoCl2 inhibited dioxin-induced 
CYP1A1 transcription (90). These studies indicated that the HIF1-pathway activation 
inhibits the AhR pathway but not vice versa. 
Conversely, a number of reports have demonstrated an opposing effect stating that 
AhR pathway activation affects hypoxic response. For instance, Takacova et al. showed 
in Hela cells that TCDD-induced activation of the AhR pathway interfered with CA-IX 
mRNA and protein expression (91). The two-way competition was shown by Chan et al, 
who determined that in HepG2 and Hep3B cells, AhR driven transcription was inhibited 
by CoCl2 and the hypoxia enhancer driven transcription was inhibited by AhR agonists 
(92). These results were confirmed by Nie et al. showing that TCDD significantly 
reduced the hypoxia-mediated reporter gene activity in B-1 cells, while the hypoxia 
response inducers desferrioxamine (DFO) and CoCl2 inhibited AhR-mediated CYP1A1 
enzyme activity (93). These studies confirm that the HIF1-pathway activation inhibits 
the AhR pathway, but also indicate that AhR pathway activation results in a decreased 
HIF1 response. A plausible explanation for the differences observed could be a result 
of differences in cell lines used and different ways to induce a hypoxic response and a 
response of the AhR-pathway. Studies to better define this relationship would be 
helpful. 
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Possible mechanisms involved in the crosstalk 
Although the studies presented above demonstrated that HIF reduces the AhR 
response, the exact mechanism is largely unknown, and clearly complex. The most 
logical mechanism would be competition for ARNT as has been shown by Gradin et al, 
whose data showed that HIF-1ɲ exhibited an affinity for ARNT in HepG2 cell extracts 
that was considerably higher than that of AhR (88). On the other hand, Pollenz et al. 
showed that the amount of ARNT sequestered during hypoxia represented only 12-
15% of the total ARNT protein pool in mouse (Hepa-1), rat (H4IIE), and human (HepG2) 
hepatoma cell lines under hypoxic conditions (1% O2). Furthermore, the same level of 
AhR/ARNT complexes could be detected in cells treated with TCDD during hypoxic and 
normoxic conditions (94). These results suggest that there also might be other 
mechanisms interfering with hypoxia and AHR-mediated signaling. 
Another mechanism was proposed by Allen et al., who suggested that HIF-2ɲ played a 
role in the crosstalk. They found in wild-type mouse hepatocytes, being stimulated 
with hypoxia (1% oxygen) and 3-methylcholanthrene (an AhR ligand), that hypoxic 
conditions reduced the CYP1A1 gene expression. This was also observed in mouse 
hepatocytes lacking HIF-1ɲ, suggesting a HIF-1ɲ independent mechanism. (95). 
Moreover, Zhang et al. showed by gene silencing of HIF-2ɲ in primary human 
pulmonary microvascular endothelial cells exposed to hypoxia (1-2.5% oxygen) that 
CYP1A1 mRNA expression is reduced by hypoxia via a HIF-2ɲ-dependent mechanism. 
(96). Overall, there is strong evidence that there is crosstalk between the two 
pathways, the exact mechanism is however still largely unknown.  
 
Oxidative stress 
 
Although oxygen is an essential part of life, toxic oxygen species can be generated in 
the cells. Oxidative stress is the imbalance between the production of ROS and their 
removal resulting in an overall increase in cellular levels of ROS. These ROS are 
constantly generated in the mitochondria as respiration byproducts (0.1–2% of 
consumed O2 depending on the tissue type), and are therefore a major source of 
oxidative damage (97). ROS can also be produced by macrophages and neutrophils at 
sites of inflammation and infection (98) or induced by exogenous sources such as 
environmental agents and radiation, (99). Table 1.1 gives an overview of sources of 
different types of oxidative species. 
 
Inflammation-induced oxidative stress 
Inflammation is a normal response of tissues to defend itself from invading pathogens, 
chemicals and physical agents. Inflammation starts when pro-inflammatory cytokines 
and chemokines at a site of injury or infection releases chemical signals. As a response, 
inflammatory cells including neutrophils are attracted, and upon activation produce 
oxidant generating enzymes, such as NAPDPH oxidase, superoxide dismutase and 
myeloperoxidase (MPO) resulting in the production of ROS to attack invading 
infectious agents.  
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Inflammation has been linked to cancer for many decades and it is has been 
recognized as a major factor in cancer development (100) and has been suggested to 
be an important hallmark of cancer. Many mechanisms have been described to explain 
the cancer development due to inflammation, such as increasing proliferation and 
survival of malignant cells, promoting angiogenesis and metastasis, subverting 
adaptive immune responses, and altering responses to hormones and 
chemotherapeutic agents (101). 
These alterations in molecular pathways also have a clinical effect as observed in 
epidemiological studies showing that chronic inflammation predisposes individuals to 
various types of cancer. For example, people suffering from chronic obstructive 
pulmonary disease (COPD) have a 2.2 fold higher risk of developing lung cancer (102) 
and have a 1.4 fold higher overall cancer risk (103), which could be a result of 
increased oxidative stress or reduced DNA repair (104). Non-alcoholic steatotic 
hepatitis (NASH) has been associated with an increased risk of developing 
hepatocellular carcinoma (105).  
 
Table 1.1: Reactive oxygen generation in the cell. Adapted from Klaunig et al. (106). 
 
Oxidative stress and reduced repair capacity 
Oxidative stress can induce various forms of DNA damage and ultimately result in 
increased mutagenesis and carcinogenesis (107). Moreover, previous studies within 
our group have also indicated a role for oxidative stress in the reduction of NER. In 
vitro studies demonstrated that MPO-derived hypochlorous acid (HOCl) mediates NER 
capacity inhibition in A549 lung cancer cells by activated neutrophils (108). MPO is an 
important enzyme abundantly present in neutrophils and involved in the generation of 
H2O2 to HOCl (109). HOCl contributes to host tissue damage at sites of inflammation by 
causing side-chain modification, backbone fragmentation, and cross-linking of proteins 
(110) and by damaging DNA by oxidizing pyrimidine bases and chlorination of cytosine 
(111). 
Although 50% reduction was observed in a mouse model, the mechanisms may differ 
from the in vitro system as it appeared to be independent of MPO, but was rather due 
to ROS following the influx of neutrophils (5). This finding was confirmed by the fact 
that oxidative stress reduced NER capacity in colon tissue of newborn piglets (112).  
 
 
Cellular oxidants Source Oxidative species 
Endogenous Mitochondria O2
-•, H2O2, 
•OH 
 Cytochrome P450 O2
-•, H2O2 
 Inflammatory cells O2
-•, H2O2, OCl
- 
 Peroxisomes H2O2 
   
Exogenous Redox cycling compounds O2
-• 
 Metals (Fenton reaction) •OH 
 Radiation •OH 
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Aim and outline of the thesis 
 
BaP is an environmental agent capable of inducing DNA damage after metabolic 
activation. The balance between the induction of BaP-induced DNA damage and its 
repair determines the carcinogenicity of BaP. Endogenous factors can influence this 
balance. Understanding these endogenous factors influencing the carcinogenicity of 
chemical compounds is of great importance in the discovery of preventive measures or 
treatments. Therefore, the aim of this thesis was to investigate oxygen-related factors 
(hypoxia and oxidative stress) and their influence on the formation of BaP-induced 
DNA damage and its repair by NER. 
The influence of hypoxia and HIFɲ stabilization have been studied extensively and 
there is some level of cross-talk between the hypoxia pathways and the AhR-pathway; 
however, none of the previously published studies demonstrated that the cross-talk 
had any biological significance, as, for instance, increased genetic instability. 
Therefore, in chapter 2, the involvement of HIFɲ stabilization on the genetic instability 
caused by carcinogens was determined. A549 cells were co-incubated with the HIFɲ-
stabilizing agent CoCl2 and BaP. Not only was the level of crosstalk between the two 
pathways determined, but also its effect on genetic instability by measuring strand 
breaks, adduct formation and importantly mutation frequencies. 
This crosstalk was further investigated in chapter 3, where changes in the metabolic 
pattern of BaP due to HIFɲ induction were determined. Therefore, A549 cells were 
cultured under different oxygen concentrations and the expressions of genes involved 
in carcinogen metabolism, together with metabolite and adduct formation were 
measured. The next step in investigating this mechanism was to determine whether 
this effect is present in the naturally occurring VHL deficient renal cell carcinoma (RCC) 
cells. The most frequent observed genetic alteration in RCC is the somatic mutation of 
the VHL tumor suppressor gene, resulting in a continuous activation of the HIF-1 
pathway. To this end, in chapter 4, it was determined how VHL might impact the 
oncogenic capacity of BaP by determining the difference in metabolic profiles and NER 
between two renal cell lines with either a functional or a dysfunctional VHL gene. 
As changes in oxygen levels results in alterations in oxidative stress (113), we sought to 
determine if this oxidative stress could be a second factor influencing carcinogen 
metabolism. Catalase is involved in reducing the oxidative stress levels in the cell by 
catalyzing the conversion of H2O2 into water and oxygen. In chapter 5, the effect of a 
polymorphism in the promoter region of catalase on CYP1B1 gene expression and 
BPDE-DNA adducts induction in lymphocytes was investigated. 
Oxidative stress has also been linked to reduction in NER in A549 cells and in mice 
lung. In this thesis we investigated if this same effect could be observed in human liver 
samples. Therefore, in chapter 6, steatotic livers with or without NASH were tested for 
their NER capacity and the influence of oxidative stress on NER was determined. 
Finally, in chapter 7 the main findings of this thesis are summarized, discussed and 
suggestions for further research and for possible future usage of the obtained 
knowledge are given. 
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Abstract 
 
The HIF1-pathway is induced in many tumors and associated with poorer outcome. 
The hypoxia responsive transcription factor HIF-1ɲ dimerizes with the aryl 
hydrocarbon receptor nuclear translocator, which is also an important binding partner 
for the aryl hydrocarbon receptor (AhR). The AhR is an important mediator in the 
metabolic activation and detoxification of carcinogens, such as the environmental 
pollutant benzo[a]pyrene (BaP). We hypothesized that HIF-1ɲ activation attenuates 
the BaP induced AhR mediated gene expression, which may lead to increased genetic 
instability and malignant progression. Human lung carcinoma cells (A549) were 
simultaneously stimulated with CoCl2 which leads to HIF-1ɲ stabilization and varying 
concentrations of BaP. Both quantitative PCR and immunoblotting analysis indicated 
that the induction of the hypoxic response pathway significantly reduced the levels of 
AhR downstream targets CYP1A1 and CYP1B1 and AhR protein binding to ARNT. We 
further demonstrated that the BaP-induced HPRT-mutation frequency and ɶH2AX foci 
were markedly amplified when the HIF1-pathway was induced. BaP-DNA adducts were 
only marginally increased and transient strand breaks were diminished by HIF-1 
induction, indicating changes in DNA repair. These data indicate that concurrent 
exposure of tumor cells to hypoxia and exogenous genotoxins can enhance genetic 
instability.  
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Introduction 
 
Hypoxia is a characteristic of a number of pathologies including cancer (1), 
inflammation (2), and kidney disease (3). It promotes genetic instability, as exposure of 
cultured cells to hypoxia results in an elevated mutation frequency (4,5). Several 
mechanisms have been proposed for this observation including downregulation of 
DNA repair (6) and induction of DNA damage by reactive oxygen species produced 
during reoxygenation (7). In many tumors, the hypoxia responsive transcription factor 
HIF-1ɲ (hypoxia inducible factor 1ɲ) is overexpressed (8) and is associated, together 
with its downstream targets with poorer outcome (9). We propose a novel alternative 
mechanism whereby overexpression of the HIF1-pathway alters the mutagenicity of 
exogenous carcinogens, which lead to a mutagenic phenotype.  
HIF-1ɲ is regarded as the primary molecular switch to alter gene expression in 
response to reduced oxygen tension. Under normoxia, HIF-1ɲ is hydroxylated by an 
oxygen-dependent prolyl hydroxylase (HIF-PH). This modification targets it for 
ubiquitination and subsequent degradation (10). In contrast, under hypoxic conditions, 
HIF-1ɲ becomes stabilized and is translocated into the nucleus, where it forms HIF-1, a 
heterodimer with HIF-1ɴ also known as aryl hydrocarbon receptor nuclear translocator 
(ARNT). ARNT is constitutively expressed irrespective of oxygen tension (11). 
Subsequently, HIF-1 binds to the (A/G)CGTG consensus sequence in the hypoxic 
responsive elements of the promoter/enhancer regions in the DNA (12), where it 
drives the expression of a wide array of hypoxia-inducible genes, including vascular 
endothelial growth factor (13), glucose transporter 1 (14) and carbonic anhydrase IX 
(CA-IX) (15). These genes are crucial in mediating the cellular responses to hypoxia.  
Interestingly, in addition to HIF-1ɲ, ARNT also forms a dimer with the aryl hydrocarbon 
receptor (AhR). AhR is a receptor for environmental pollutants such as dioxins (e.g 
2,3,7,8-tetrachlorodibenzo-p-dioxin, TCDD) and polycyclic aromatic hydrocarbons 
(PAH; e.g benzo[a]pyrene, BaP). PAHs are widely distributed environmental 
contaminants produced as byproducts of combustion processes such as in coke ovens, 
cigarette smoking and charcoal grilling of food. On ligand binding, AhR translocates 
into the nucleus, dimerizes with ARNT, and activates gene expression by binding to the 
TNGCGTG consensus sequence in the xenobiotic response elements of target genes 
(16). This leads to the upregulation of a multitude of genes including the cytochrome 
P450 isoforms CYP1A1 and CYP1B1. These enzymes metabolize their PAH substrates to 
more soluble and excretable products, but at the same time may activate certain 
metabolites into highly reactive forms (17). BaP is a classic example, and is 
enzymatically activated to BaP-7,8-dihydrodiol-9,10-epoxide (BPDE) by cytochrome 
P450s. BPDE can covalently bind to DNA forming highly mutagenic DNA adducts (18). 
Since HIF-1ɴ/ARNT is a component of the AhR as well as the HIF1-signalling pathway, it 
has been suggested that simultaneous activation of the two pathways can result in 
competition for ARNT thereby reducing the activity of both the HIF-1 and AhR 
mediated response (19). This implies that in hypoxic regions, the availability of HIF-
ϭɴ/ARNT for the metabolism of carcinogens is attenuated. Cross-talk between both 
these two pathways has previously been demonstrated, but studies on the exposure of 
various hepatoma cell lines to hypoxia and AhR ligands (mostly TCDD) revealed 
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inconsistent interactive results. While Chan et al and Nie et al demonstrated mutual 
inhibition between the HIF-1 and AhR-pathways (20,21), Gradin et al, Gassmann et al, 
and Pollenz et al showed that HIF1-pathway activation inhibits the AhR-pathway, but 
not vice versa (19,22,23). All these studies showed some level of crosstalk between the 
two pathways; however none demonstrated that the crosstalk had any biologic 
significance, as for instance increased genetic instability. The above mentioned studies 
used TCDD as an activator of AhR and although TCDD is the strongest activator of AhR, 
it is not metabolized by the CYPs induced by the AhR pathway. Importantly, in the 
present study, we used BaP as it induces downstream CYP expression that results in 
self-metabolism. Thus, we are studying an interaction that is physiological and relevant 
to carcinogenesis. 
The aim of the present study was to determine the involvement of HIF-1 induction on 
detoxification of carcinogens. Firstly, we determined the level of HIF-1 and AhR-
pathway crosstalk by qPCR, immunoprecipitation and immunoblot. Secondly, to 
investigate the genetic instability, we used ɶH2AX-staining and a mutation sensitive 
cell line to assess the influence of HIF-1 induction on BaP-induced mutation 
frequencies (24). Finally, we measured BPDE-DNA adducts levels and transient strand 
breaks to further investigate the relationship between the crosstalk and the changed 
genetic instability. 
 
Materials and methods 
 
Cell culture and treatment 
A549 cells (human epithelial lung carcinoma cells), obtained from the American Tissue 
Culture Collection (ATCC, Rockville, MD, USA), were cultured in DMEM (Sigma, St. 
Louis, MO, USA) supplemented with 10% heat inactivated fetal calf serum (FCS, 
Invitrogen, Breda, The Netherlands) and 1% penicillin/streptomycin (Sigma) and 
maintained at 37°C in a 5% CO2 atmosphere. 1 x 10
6 cells were treated with or without 
the HIF1ɲ stabilizing agent cobalt chloride (300µM; Sigma). After 1 hour at 37°C, BaP 
(Sigma), in DMSO, was added to the medium to final concentrations of 0-10µM. 
Concentrations of DMSO did not exceed 0.5%. After a further 18 hours, the cells were 
harvested. For the determination of the effect on adduct formation and mutation 
frequency we used previously established A549 cell lines stably expressing ubiquitin 
Lys63 mutants (K63R-Ub) (24).  
 
Real-Time Quantitative PCR 
After 18 hours of incubation medium was removed. Cells were washed twice with PBS 
and Trizol (Invitrogen) was added. Total RNA was isolated according to the 
manufacturer’s instructions. The quantity and quality of each RNA sample were 
measured spectrophotometrically using Nanodrop 1000 (Thermo Scientific, Waltham, 
MA, USA). cDNA synthesis was performed using the iScript cDNA Synthesis kit (Biorad, 
Veenendaal, The Netherlands) starting with 1µg of RNA. cDNA was diluted 25x in 
RNase free water. Real-time PCR was performed using the MyiQ Single Color RT-PCR 
detection system (Biorad) using SYBR Green Supermix (Biorad), 5µl diluted cDNA and 
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0.3µM primers (Table 2.1) in a total volume of 25µl. Samples were amplified under the 
following conditions: 95°C for 3 minutes, followed by 40 cycles of 95°C for 15 second 
and 60°C for 45 seconds. PCR was checked for a-specific products by performing a 
melting curve analysis (65°C-95°C). Data were analyzed using the MyiQ Software 
system (Biorad) and were expressed as relative gene expression (fold increase) using 
the 2ͲȴȴCt method. Two stably expressed genes, ɴ-actin and GAPDH, were included as 
reference.  
 
Table 2.1: Primer sequences for real time RT-PCR 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) 
ɴ-actin CCTGGCACCCAGCACAAT GCCGATCCACACGGAGTACT 
GAPDH GCACCACCAACTGCTTAGCA TGGCAGTGATGGCATGGA 
CA-IX CATCCTAGCCCTGGTTTTTGG GCTCACACCCCCTTTGGTT 
CYP1A1 TCCTGGAGACCTTCCGACACT CTTTCAAACTTGTGTCTCTTGTTGTG 
CYP1B1 AGTGCAGGCAGAATTGGATCA GCGCATGGCTTCATAAAGGA 
 
Western blot assay 
Following treatment with CoCl2 and BaP, cells were washed twice and proteins were 
extracted in RIPA buffer (150mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS, 
50mM Tris pH 7.5) for 30 minutes on ice. Samples were sonicated and protein 
concentrations were determined by a Lowry assay (Bio-Rad) with BSA as standard. 
Proteins were separated on a 10% SDS–polyacrylamide gel (150V, 2 hours) and 
transferred (100V, 1 hour) to a nitrocellulose membrane (GE Healthcare, Little 
Chalfont, UK). Membranes were blocked for one hour with 5% BSA and subsequently 
incubated overnight at 4°C with a 1:2000 dilution of mouse monoclonal CA-IX antibody 
(Novus Biologicals, Littleton, USA), a 1:1000 dilution of rabbit polyclonal Chk1 
Phospho-Ser317, (Cell Signaling, Danvers, MA, USA) or a 1:1000 dilution of mouse 
monoclonal Chk1 (Abcam, Cambridge, UK). After washing, blots were incubated for 1 
hour with either a 1:5000 dilution of goat anti-rabbit HRP conjugated IgG (Cell 
Signaling) or goat anti-mouse HRP conjugated IgG (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA). Proteins were visualized by an Enhanced Chemiluminescence (GE 
Healthcare). Mouse monoclonal ɴ-actin (Sigma) was used as loading control. 
 
Immunoprecepitation 
After CoCl2 and BaP treatment as described above, cells were washed twice and 
proteins were extracted in lysisbuffer (150mM NaCl, 1% NP-40, 50mM Tris pH 7.5) for 
30 minutes on ice. Samples were sonicated, soluble fractions were recovered and 
proteins were quantified using the Lowry protein assay, and 250µg protein was 
incubated with a 1:50 dilution of rabbit HIF1ɴ/ARNT (C15A11) antibody (Cell Signalling) 
overnight at 4°C. The following day, lysates were incubated for 48 hours at 4°C with 
100µl of Gamma-Bound Sepharose Beads (GE Healthcare). Beads were washed 5 times 
in lysis buffer, and proteins were eluted by boiling in Laemmli's SDS sample buffer for 5 
minutes at 95 °C. Western blot was performed as described above using mouse HIF-1ɲ 
monoclonal antibody (1:1000; BD Biosciences, San Jose, CA) or mouse AhR monoclonal 
antibody 3B12 (1:500; Abnova, Heidelberg, Germany). 
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HPRT-mutation analysis 
Cells were cultured in hypoxanthine, aminopterin, and thymidine (HAT) supplemented 
culture medium for one week to eliminate background mutations. Cells were then 
seeded at 1x106 cells per 10cm dish and exposed to CoCl2 and BaP as described 
previously. Subsequently, cells were passaged for one week to allow for phenotypic 
expression of the acquired mutations. HPRT mutant cells were selected in medium 
supplemented with 30µM 6-thioguanine (6-TG). After 14-21 days, cells were fixed and 
stained with 2% bromophenol blue in 70% ethanol. After staining, the colonies were 
counted and corrected for plating efficiency. 
 
ɶH2AX-staining 
Cells were seeded on glass cover slides before treatment with CoCl2 and BaP. After 
treatment, cells were fixated with 4% formaldehyde at RT for 10 minutes, washed in 
PBS and permeabilized with 0.2% Triton X-100 for 5 minutes at 4°C, washed twice for 5 
minutes with PBS and blocked in PBS with 1% BSA and 0.5% Tween-20 for 1 hour at 
37°C. The coverslips were incubated with a 1:1000 dilution of anti-ɶ-H2AX antibody 
Clone JBW 301 (Upstate, Billerica, MA) for 2 hours at 37°C, washed twice in PBS for 5 
minutes, and incubated with a 1:1000 dilution Alexa Fluor 488 goat anti-mouse 
(Invitrogen) for 1 hour at 37°C. Cells were washed twice in PBS for 5 minutes and 
dehydrated in 70, 90 and 100% ethanol, 3 minutes each. Cells were stained with 4,6-
diamidino-2-phenylindole and mounted with Vectashield mounting medium (Vector 
Laboratories, Peterborough, UK). Digital fluorescence images were taken and damage 
was assessed. Positive cells were defined as greater than 3 foci per cell. 
 
32P-postlabeling of BPDE-DNA adducts 
After removal of the aqueous phase during RNA isolation using Trizol, the remaining 
phases were used for DNA isolation according to the manufacturer's protocol. DNA 
adduct levels were determined according to the nuclease P1 enrichment technique 
originally described by Reddy and Randerath (25) with the modifications described by 
Godschalk et al (26). In all experiments, three BPDE-DNA standards with known BPDE-
DNA adduct levels (one adduct per 106, 107, and 108 normal nucleotides) were 
analyzed in parallel for quantification purposes. Adduct spots on the chromatograms 
were quantified using Phosphor-Imaging technology (Fujifilm FLA-3000, Rotterdam, 
The Netherlands).  
 
Comet assay 
Following CoCl2 and BaP treatment, cell suspensions were diluted 1:4 in 0.5% low 
melting point agarose and added to microscope slides pre-coated with a layer of 1.5% 
normal melting-point agarose and put at 4°C for 45 minutes. Cells were lysed (0.25M 
NaOH, 0.1M EDTA, 0.01M Tris, 2.5M NaCl, 1% Triton X-100 and 10% DMSO, adjusted 
to pH 10) for 1 hour at 4 °C, washed with PBS, placed in electrophoresis buffer (1mM 
EDTA, 300mM NaOH, pH 13) for 40 minutes for denaturation, and subsequently 
separated by electrophoresis for 30 minutes at 25V and 300mA. The slides were 
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washed twice with PBS for 10 minutes and stained with ethidium bromide (10ʅg/ml) 
and visualized using a Zeiss Axioskop fluorescence microscope. 50 randomly selected 
nuclei were analyzed per slide using the Comet assay III software program (Perceptive 
Instruments, Havervill, UK). 
 
Statistical Analysis 
Results are expressed as the mean ± standard error of the mean, and experiments 
were repeated up to five times. GraphPad Prism 4 was used for statistical analysis. To 
examine differences between cells incubated with or without CoCl2 a two-way analysis 
of variance test (ANOVA) with Bonferroni post-hoc multiple comparison correction was 
used. To assess differences between different BaP concentrations a one-way ANOVA 
was used. Differences were considered to be statistically significant when p<0.05. 
 
Results 
 
BaP down regulates in a dose-dependent manner the CoCl2-mediated induction of CA-
IX.  
The effect of BaP on the HIF1-pathway was tested by determining changes in mRNA 
and protein levels of CA-IX. A549 cells were exposed to 300µM CoCl2, to stabilize HIF-
ϭɲ, and to various concentrations of BaP (Figure 2.1). After exposure to CoCl2, a у17-
fold increase in CA-IX mRNA levels was observed compared to cells without CoCl2. 
After addition of BaP, a dose dependent decrease was detected that reached 36% at 
10µM BaP (p<0.05). In addition, CA-IX was also statistically significantly down 
regulated when incubated only with BaP (p<0.05).  
 
Figure 2.1: BaP attenuates the induction of 
the HIF-1 target CA-IX. A549 cells were 
incubated without (ප) or with (Ŷ) 300µM 
CoCl2 and with 0-10µM BaP. Data are 
presented as fold increase compared to no 
CoCl2 and no BaP. 
 
 
 
 
 
 
The same conditions were used to test the effect of BaP on the protein levels of CA-IX. 
A у31 fold increase in CA-IX protein levels was observed when cells were exposed to 
CoCl2 compared to cells without CoCl2 exposure (Figure 2.2). This increase was in 
agreement with the mRNA levels and was dose-dependently down regulated by 
addition of BaP. A 53% reduction was already observed after incubation with 1µM BaP 
(p<0.05). After treatment with 10µM BaP, reduction in CA-IX protein levels was further 
increased to у66% (p<0.05). In contrast to the mRNA analysis, the influence of BaP 
alone on the CA-IX protein levels was absent. 
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Figure 2.2: BaP downregulates in a dose-
dependent manner the CoCl2-mediated 
induction of CA-IX. A549 cells were 
incubated without (ප) or with (Ŷ) 300µM 
CoCl2 and with 0-10µM BaP. Data are 
presented as fold increase compared to no 
CoCl2 and no BaP corrected for actin. The 
figure presented is a representative 
western blot. (*p<0.05). 
 
 
 
 
 
 
 
 
 
 
HIF-1 induction reduces BaP induced CYP1A1 and CYP1B1 mRNA expression.  
To determine the influence of the induction of the HIF1-pathway on the AhR-pathway, 
the mRNA levels of CYP1A1 and CYP1B1 was investigated in CoCl2 treated cells. BaP, as 
expected, caused a dose-dependent increase in both CYP1A1 (Figure 2.3A) and CYP1B1 
(Figure 2.3B) mRNA levels. This dose-dependent increase in CYP1A1 mRNA levels was 
down regulated by incubation with CoCl2. Without CoCl2, cells showed a у24 to у30 
fold increase when incubated with 1µM and 10µM BaP, respectively, but by 
simultaneous incubation with CoCl2, this induction of mRNA levels was approximately 
60% lower. CYP1B1 mRNA levels showed the same pattern, although the increase by 
BaP was less pronounced; cells incubated with BaP alone showed a у8 and у9 fold 
increase when incubated with 1µM or 10µM BaP, respectively. When simultaneously 
Figure 2.3: BaP induced CYP1A1 and CYP1B1 mRNA expression are reduced by HIF-1 induction. 
A549 cells were incubated without (ප) or with (Ŷ) 300µM CoCl2 and with 0-10µM BaP and mRNA 
expression of (A) CYP1A1 and (B) CYP1B1 was measured. Data are presented as fold increase 
compared to no CoCl2 and no BaP. (**p<0.01, ***p<0.001) 
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Figure 2.4: Competition for ARNT 
results in a reduction in HIF-1ɲ and 
AhR protein bound to ARNT. A549 
cells were incubated without or with 
300µM CoCl2 and with 0-1µM BaP. The 
representative Western blots show the 
amount of HIF-1ɲ and AhR bound to 
ARNT. Data are presented as fold 
increase compared to no CoCl2 and no 
BaP corrected for amount of protein 
loaded. 
 
incubated with CoCl2 this induction only reached 68% and 56% of the levels found 
without CoCl2 incubation, respectively. 
 
Competition for ARNT results in a reduction in HIF-1ɲ and AhR protein bound to ARNT.  
To directly assess the influence of pathway convergence on protein complex 
interaction, HIF-1ɲ and AhR bound ARNT was determined by immunoprecipitation. 
HIF-1ɲ bound to ARNT increased у7-fold after exposure to CoCl2 (Figure 2.4). After 
addition of BaP, a dose dependent decrease was detected in the CoCl2 treated cells of 
у24% and у48%, at 0.1µM and 1µM BaP, respectively. AhR bound to ARNT was 40-75% 
lower when the HIF1-pathway was induced compared to the cells without the addition 
of CoCl2 (Figure 2.4). 
Figure 2.5: HIF-1 induction increases 
BaP induced mutation frequency. 
A549 cells expressing the ubiquitin 
K63R mutant were incubated without 
;ප)  or  with  (Ŷ) 300 µMCoCl2 and with 
0-1µM BaP. Data are presented as 
mutations per 105 cells. (**p<0.01)  
 
 
 
 
 
 
 
HIF-1 induction increases BaP induced mutation frequency.  
To further determine whether this HIF1 mediated attenuation of the AhR-pathway 
results in changes to the mutagenic phenotype. A549 cells stably expressing K63R-Ub 
were exposed to CoCl2 and various concentrations of BaP and mutations in the HPRT 
gene were assessed. This cell line has a diminished capacity to perform error-free 
bypass of DNA lesions, greatly enhancing the carcinogen associated mutagenicity of 
BaP without changing its metabolic activation (27). Cells incubated with CoCl2 alone 
already showed a slight although not yet significant increase in mutation frequency 
compared to the control cells (у6 fold) (Figure 2.5). In addition, the mutation 
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frequency was significantly induced with у10 and у21 times when cells were incubated 
with 0.1µM and 1µM BaP, respectively, without CoCl2. Interestingly, after the 
combined incubation with CoCl2 and 0.1 and 1µM BaP, mutation frequencies were 
further increased to у46 and у66 times, respectively as compared to unexposed cells. 
 
HIF-1 induction increases the BaP induced ɶH2AX foci.  
To further confirm the increased genomic instability we assessed ɶH2AX foci formation 
following treatment with CoCl2 and BaP. Addition of BaP increased the amount of 
damaged cells to у46% (from у24% in untreated and CoCl2 alone treated cells) (Table 
2.2). With the addition of CoCl2 to the BaP treated cells, the number of damaged cells 
further increased to у59% and у53%, at 0.1µM and 1µM BaP respectively. 
 
Table 2.2: HIF-1 induction increases the BaP induced ɶH2AX foci. A549 cells were incubated 
without or with 300 µM CoCl2 and with 0-1µM BaP. Data is presented as percentage cells with 
more than 3 foci per cells. Exposure to BaP significantly increased the number of cells with >3 
ɶH2AX foci (p<0.001, exposed to BaP vs. 
unexposed), and was further increased by 
addition of CoCl2 (P=0.007, addition of CoCl2 vs. 
no CoCl2 in the combined group of 0.1 and 1 µM 
BaP).  
 
HIF-1 induction increases Chk1 phosphorylation.  
To determine if the observed increase in ɶH2AX foci was associated with replication 
fork blockage, Chk1 phosphorylation was measured by immunoblotting. Interestingly, 
CoCl2 alone was sufficient to induce a 1.6 fold increase in phosphorylation of Chk1 
(Figure 2.6) while BaP alone induced a у1.5 fold increase compared to no treatment. 
This BaP effect was further augmented with the addition of CoCl2 to a combined 
maximum effect of 2.4 fold increase at 0.1µM BaP. 
 
Figure 2.6: HIF-1 induction increases 
Chk1 phosphorylation. A549  cells  
were incubated without or with 
300µM CoCl2 and with 0-1µM BaP. 
The representative Western blots 
show the amount of phosphorylated 
CHK1 at Ser317. Data are presented 
as fold increase compared to no CoCl2 
and no BaP corrected for total amount of CHK1. 
 
HIF-1 induction may alter BaP induced adduct formation. 
Since the expression of metabolic enzymes for BaP were altered by HIF induction, one 
possible explanation for the increased mutant frequency by the combined exposure to 
BaP and CoCl2 would be an increased formation of reactive derivatives and subsequent 
formation of pro-mutagenic BPDE-DNA adducts. Therefore, BPDE-DNA adducts were 
measured in cells incubated with both CoCl2 and 0.1µM or 1µM BaP. DNA adducts 
BaP (µM) - CoCl2 + CoCl2 
0 24.0 ± 8.1 24.7 ± 6.9 
0.1 46.5 ± 5.1 58.7 ± 3.1 
1 46.4 ± 3.9 52.5 ± 5.4 
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showed a trend to be higher (20-50%) under HIF-1 induction as compared to BaP alone 
(Figure 2.7). 
 
HIF-1 induction decreases the DNA repair associated strand breaks.  
One known mechanism that could further explain the increased mutagenicity of 
combined BaP and CoCl2 would be inhibition of DNA repair processes. DNA repair 
induces transient strand breaks that can be detected by the comet assay. Indeed, as 
expected the amount of strand breaks was dose dependently increased by addition of 
BaP and importantly, induction of the HIF1-pathway reduced the comet size by 12-25% 
(Figure 2.8). 
 
Discussion 
 
Hypoxia has been reported in several studies to increase mutation frequencies (4,5). 
Understanding the cause for this mutation induction is important in determining the 
role of hypoxia in genetic instability. We propose a novel mechanism in which the 
interaction between induction of the HIF1-pathway and the AhR receptor leads to an 
increase in chemical induced mutations, which is of major relevance for the pre-clinical 
stages of carcinogenesis; humans are continuously exposed to carcinogens and 
hypoxia may already occur in the early phases of disease development. In this report 
we provide evidence that the combined stimulation of the AhR by BaP and the HIF1-
pathway leads to an increase in HPRT mutations and thus disrupts genetic stability. 
To determine whether AhR stimulation could result in an alteration of HIF1-mediated 
signaling cells were simultaneously incubated with BaP to induce the AhR-pathway and 
with CoCl2 to induce the HIF1-pathway. Cells under hypoxic conditions have to undergo 
metabolic adaptations to survive and the expression of many genes changes as a 
result. We used CA-IX as an exemplary downstream gene to test the influence of BaP 
on the HIF1-pathway, because CA-IX is strongly up regulated by hypoxia (15) and it is a 
Figure 2.7: HIF-1 induction marginally 
augments BaP induced adduct formation. 
A549-K63R cells were incubated without (ප) 
or  with  (Ŷ) 300µM CoCl2 and with 0-1µM 
BaP. Data are presented adducts per 108 
nucleotides. 
Figure 2.8: HIF-1 induction decreases the 
amount of strand breaks. A549 cells were 
incubated without (ප) or with (Ŷ) 300µM 
CoCl2 and with 0-1µM BaP and strand breaks 
were measured. Data are presented as tail 
moment. (*p<0.05) 
Chapter 2 
 
 40
prognostic factor for many cancers (28). Our results showed that BaP exposure 
inhibited both the basal levels as the induction of CA-IX by CoCl2 (Figure 2.1). Although 
the mechanisms responsible for expression of basal levels of CA-IX regulation have not 
been studied, this could suggest that CA-IX is partly induced by HIF1 independent 
mechanisms. A recently published study of Takacova et al. (29) showed that next to 
mRNA levels, the protein levels decreased similarly after exposure to TCDD. To confirm 
that this effect also occurs with BaP, we measured the CA-IX protein levels and indeed, 
a combined exposure to CoCl2 and BaP leads to a statistically significant dose-
dependent decrease in protein concentrations. This dose-dependent decrease in 
protein levels was even stronger compared to the mRNA levels (Figure 2.2). In contrast 
with the mRNA results, BaP alone did not reduce CA-IX protein levels. These results 
confirm the hypothesis that induction of the AhR pathway leads to downstream effects 
in the HIF1-pathway. 
To determine whether HIF1-induction may influence the metabolism of BaP, we 
studied the effect of HIF1 activation on CYP1A1 and CYP1B1 gene expression induced 
by BaP. Consistent with previous reports, we found a decrease in BaP-induced CYP1A1 
mRNA levels (Figure 2.3A) due to CoCl2 (20,30). This CoCl2 reduced AhR-mediated 
induction was also observed for CYP1B1 expression, although to a lesser extent (Fig. 
3B), which was also observed in a previous study (30). We also confirm that CYP1B1 
levels were already reduced by CoCl2 even without the addition of BaP, while CYP1A1 
was only reduced when simultaneously incubated with BaP (20,30). This could be 
explained by the lower baseline expression of CYP1A1 than CYP1B1. However, the 
effect of CoCl2 on CYP1A1 expression was stronger compared to its effect on CYP1B1, 
which is biologically relevant because CYP1A1 has a greater capacity for BaP 
metabolism than CYP1B1 (31). These results indicate that induction of the HIF1-
pathway leads to downstream effects in the AhR-pathway.  
To investigate if this mutual interaction is a result of the competition for ARNT, we 
determined the amount of HIF-1ɲ and AhR protein bound to ARNT and whether this is 
influenced by costimulation with CoCl2 and BaP. The present results showed that ARNT 
bound HIF-1ɲ decreases in a dose dependent manner with increasing BaP 
concentrations (Figure 2.4). Furthermore, AhR bound to ARNT was also reduced upon 
HIF1 induction. This confirms our mRNA transcription results suggesting that fewer 
complexes are available to bind to xenobiotic and hypoxic response elements on the 
DNA, which leads to decreased mRNA and protein levels of CYP1A1, CYP1B1 and CA-IX. 
Our data is in agreement with Chan et al and Nie et al, who both observed that AhR 
inhibited HIF1ɲ-ARNT interaction with the DNA and that HIF-1ɲ lowers the amount of 
AhR-ARNT complexes bound to the DNA (20,21). Taken together, our results 
demonstrate a mutual interaction between the AhR-pathway and the HIF1-pathway. 
We further investigated whether this interaction leads to an increase in HPRT mutation 
frequency by using a previously developed highly sensitive A549 mutant cell line (24). 
We earlier described that the mutants and A549 cells behave in an identical manner 
with regards to cell growth, clonogenic survival, and BPDE-DNA adduct formation 
(18,24). The present results showed that the amount of BaP-induced mutant cells was 
significantly higher when the HIF1-pathway was accordingly induced. A more than 
additive effect is observed since the amount of mutations caused by both CoCl2 and 
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BaP is more than the sum of CoCl2 and BaP alone. These results imply that when both 
pathways are triggered at the same time the mutagenic effects of chemical 
carcinogens may be potentiated resulting in enhanced genetic instability. Additionally 
the well-established DNA damage marker ɶH2AX was used to further investigate 
genetic instability (Table 2.2). HIF1 induction itself does not induce more damaged 
cells. Treatment with BaP on the other hand enhances the amount of damaged cells, 
which was further increased by the concomitant induction of the HIF1-pathway. As this 
induction of ɶH2AX staining may be associated with replication fork blockage (32), we 
examined Chk1 phosphorylation. Upon stalling of the replication machinery, ataxia 
telangiectasia and Rad3 related protein (ATR) is recruited to these sites where it 
phosphorylates Chk1 at Ser317 and Ser345 (33). We determined that the BaP induced 
phosphorylation of Chk1 was further increased by HIF1 induction (Figure 2.6). Taken 
together, these experiments additionally confirmed the hypothesis that inducing both 
pathways leads to a greater genomic instability.  
Since we observed an effect of HIF1 induction on the expression of BaP metabolizing 
enzymes, the increased mutation frequency may be explained by an accumulation of 
pro-mutagenic DNA adducts (Figure 2.7). Interestingly, there was only a small rise in 
adduct levels due to incubation with CoCl2. As the bulk of adducts are removed by the 
NER pathway, this may mask the significance of remaining lesions entering S-phase. 
This is further supported by the observed increase in ɶH2AX foci and increased 
phosphorylation of Chk1, suggesting adduct associated blockages of replication forks. 
Alternatively, other mechanisms related to BaP mutagenicity may be involved. For 
example, it has been reported that the most relevant repair mechanism for BPDE-DNA 
adducts, nucleotide excision repair (NER) is inhibited by hypoxia (34). Therefore, 
although the initial adduct levels do not differ substantially it may be that under HIF1 
induction crucial DNA lesions may be less well removed, leading to higher mutation 
rates upon proliferation. Still, the relation between BaP adducts and mutagenesis is 
complex and multiple factors both structural and biological, are able to influence the 
mutagenicity of BaP-related DNA adducts (35).  
To further elucidate the mechanism behind the increased mutation frequency, we 
quantitated DNA strand breaks using the comet assay. BaP does not induce strand 
breaks directly, because damage is induced after metabolism to BPDE and the 
formation of adducts. During the repair of these adducts, transient single strand breaks 
are generated (36). Our data showed that the amount of strand breaks is lower when 
the HIF1-pathway is induced compared to control conditions. It is interesting to note 
that even without treatment with BaP, the number of breaks is lower under conditions 
where HIF1 is induced compared to normal conditions. The data are highly suggestive 
that the decrease we observe in breaks due to the induction of HIF1 is not explained by 
a decrease in DNA damage but is rather a decrease in repair incisions. This indicates 
and confirms that hypoxia reduces NER capacity (34), which is relevant for removal of 
bulky polymerase blocking lesions. 
We showed that alteration of the HIF1-pathway by CoCl2 results in a mutagenic 
phenotype. It is interesting to note that a secondary mode of HIF induction has been 
attributed to either oncogene activation (37,38) or by loss of function mutations in 
tumor suppressor genes (39,40). This may suggests an important role in malignant 
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progression as oncogenes or tumor suppressor genes alteration may lead to 
subsequent genetic instability via HIF1 modulation of carcinogen detoxification. 
Interestingly, our results suggest an overall detrimental effect on survival and one may 
question the evolutionary benefits of this complex pathway interaction. This further 
underscores the poorly understood physiological role of AhR as even its natural ligand 
is still unknown. In this study, we demonstrate that there is a two-way interaction 
between the HIF1-pathway and the AhR-pathway. We provide evidence that CoCl2 
results in an increase of BaP induced mutation frequency. These data support the idea 
that modulation of carcinogen metabolism may be an important mechanism for the 
observed HIF1 mediated genetic instability suggesting a potential role in cancer 
development. 
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Abstract 
 
Hypoxia promotes genetic instability and is therefore an important factor in 
carcinogenesis. We have previously shown that activation of the hypoxia responsive 
transcription factor HIFɲ can enhance the mutagenic phenotype induced by the 
environmental mutagen benzo[a]pyrene (BaP). To further elucidate the mechanism 
behind the ability of hypoxia to increase mutagenicity of carcinogens, we examined the 
activation and detoxification of BaP under hypoxic conditions. To this end, the human 
lung carcinoma cell line A549 was treated with BaP under 20% or 0.2% oxygen for 18 
hours and alterations in BaP metabolism were assayed. First, BaP-induced expression 
of key metabolic enzymes was analyzed; expression levels of the activating CYP1A1 
and CYP1B1 were increased, while the detoxifying enzymes UGT1A6 and UGT2B7 were 
significantly reduced by hypoxia. To evaluate whether these changes had an effect on 
metabolism, levels of BaP and several of its metabolites were determined. Cells under 
hypoxia have a reduced capacity to metabolize BaP leaving more of the parent 
molecule intact. Additionally, BaP-7,8-dihydrodiol, the pre-cursor metabolite of the 
reactive metabolite BaP-7,8-dihydroxy-9,10-epoxide (BPDE), was formed in higher 
concentrations. Finally, under hypoxia, DNA adducts accumulated over a period of 168 
hours, whereas adducts were efficiently removed in 20% oxygen conditions. The 
delayed detoxification kinetics resulted in a 1.6 fold increase in DNA adducts. These 
data indicate that the metabolism under hypoxic conditions has shifted towards 
increased activation of BaP instead of detoxification and support the idea that 
modulation of carcinogen metabolism is an important additional mechanism for the 
observed HIF1 mediated genetic instability. 
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Introduction 
 
Although hypoxia plays an important role in normal development and physiology, 
disruption of oxygen homeostasis is an important characteristic of a number of 
pathologies including cancer (1) and chronic inflammation (2). Therefore, 
understanding the mechanisms by which cells respond to hypoxia can be of etiological 
as well as therapeutic interest. We recently demonstrated that hypoxia inducible 
factor ɲ (HIFɲ) stabilization augmented benzo[a]pyrene (BaP) induced DNA adduct 
levels and subsequent mutation frequencies. These data indicated that concurrent 
exposure of hypoxia and exogenous genotoxins could enhance genetic instability (3). 
For example, in pathologies in which oxygen intake is decreased such as chronic 
obstructive pulmonary disease (COPD), changed carcinogen metabolism could explain 
the increased cancer risk observed in these patients (4). 
HIFɲ is regarded as the primary molecular switch to alter gene expression in response 
to reduced oxygen tension. Hydroxyl groups are attached to HIFɲ, via an oxygen-
dependent prolyl hydroxylase (5). The hydroxylated HIFɲ is then targeted for 
ubiquitylation (6) and subsequent proteasomal degradation (7). Under hypoxic 
conditions, HIFɲ becomes stabilized and translocated into the nucleus, where it forms 
a heterodimer with the aryl hydrocarbon receptor nuclear translocator (ARNT) (8). 
Subsequently, the HIF-1 heterodimer binds to hypoxic responsive elements (9) and 
induces the expression of a wide array of genes able to augment oxygen delivery or 
provide alternative pathways for energy production and cell metabolism (10). 
As hypoxia is a common characteristic of many tumors and because HIFɲ can also be 
induced by aberrant oncogenic activation or loss of tumor suppressor function, HIFɲ is 
often found overexpressed in many cancers (11,12). HIFɲ overexpression and its 
downstream effectors are associated with increased tumor invasion and metastasis, 
resistance to chemo-, radio- and immunotherapy, and increased mortality (8,11,13). In 
addition, exposure of cultured cells to hypoxia results in an elevated mutation 
frequency (14,15). Several mechanisms have been proposed for this observation 
including downregulation of DNA repair (16), induction of reactive oxygen species 
mediated DNA generated during reoxygenation (17), and competition for ARNT (3). 
In addition to forming heterodimers with HIFɲ, ARNT also dimerizes with the aryl 
hydrocarbon receptor (AhR). AhR is a receptor for environmental pollutants such as 
polycyclic aromatic hydrocarbons (PAH), which are widely distributed environmental 
contaminants produced as byproducts of combustion processes as in vehicle exhaust 
and cigarette smoking. BaP is a classic example of PAH and is readily absorbed by 
inhalation, ingestion and through the skin. Given the lipophilic behavior of BaP, it can 
easily diffuse into cells, where it can bind AhR. Upon binding, AhR translocates 
together with its ligand into the nucleus, dimerizes with ARNT, and binds to xenobiotic 
response elements of target genes (18). This results in the transcription of genes that 
encode for enzymes involved in xenobiotic detoxification, including the cytochrome 
P450 (CYPs) isoforms CYP1A1 and CYP1B1 (19,20).  
The detoxification of BaP is a multistep process involving a number of critical enzymes. 
The first stage requires an epoxidation reaction by the mono-oxygenases CYP1A1 and 
CYP1B1 (phase I) that requires NADPH and molecular oxygen. One of the resulting 
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metabolites (e.g. BaP-7,8-epoxide) can be converted to a dihydrodiol (e.g. BaP-7,8-
dihydrodiol) by epoxide hydrolase. BaP-7,8-dihydrodiols can be further metabolized by 
CYP1A1 or CYP1B1 to diol epoxides (e.g. BaP-7,8-diol-9,10-epoxide (BPDE)) or 
conjugated by uridine diphosphate glucuronosyl transferase (UGT) (phase II) (20). 
BPDE is the active mutagenic compound as it can covalently bind to DNA to form pro-
mutagenic adducts (19). 
We recently demonstrated that under normal oxygen conditions chemical stabilization 
of HIFɲ augmented BaP induced adduct levels. Furthermore, we observed a marked 
increase in adduct levels under hypoxic exposure (3). Interestingly, as the metabolism 
of BaP is oxygen dependent, exposure of cells to low oxygen concentrations was 
expected to generate less bioactive BaP metabolites, which in turn would lead to 
reduced BPDE-DNA adduct levels. To further elucidate the mechanism behind the 
ability of hypoxia to increase mutagenicity of carcinogens, alterations in metabolism 
and adduct kinetics were determined. In this current report, we show that hypoxia 
alters the pro-mutagenic capacity of BaP by increasing the formation of BaP-7,8-
dihydrodiol (BaP-7,8-diOH), the precursor of BPDE and prolonging the exposure to the 
parent BaP compound, which results in an increased BPDE-DNA-adducts. 
 
Materials and Methods 
 
Cell culture and treatment 
A549 cells (human epithelial lung carcinoma cells), obtained from the American Tissue 
Culture Collection (ATCC, Rockville, MD, USA), were cultured in DMEM (Sigma, St. 
Louis, MO, USA) supplemented with 10% heat inactivated fetal calf serum (FCS, 
Invitrogen, Breda, The Netherlands) and 1% penicillin/streptomycin (Sigma) and 
maintained at 37°C in a 5% CO2 atmosphere. Cells were seeded one day before 
treatment and maintained at 37°C in a 5% CO2 atmosphere and different oxygen 
concentrations (20% or 0.2% O2). All cells were treated with 0 or 0.1µM BaP (Sigma) 
dissolved in DMSO (final DMSO concentrations did not exceed 0.5%). After treatment, 
medium was removed and cells were harvested using trypsin. All samples were stored 
at -20°C. 
 
Real-Time Quantitative PCR 
Cells were washed twice with PBS followed by Qiazol (Qiagen, Hilden, Germany) 
addition. Total RNA was isolated according to the manufacturer’s instructions. The 
RNA samples were quantified spectrophotometrically using a Nanodrop 1000 (Thermo 
Scientific, Waltham, MA, USA). cDNA synthesis was performed using the iScript cDNA 
Synthesis kit (Biorad, Veenendaal, The Netherlands) starting with 1µg of RNA. cDNA 
was diluted 25x in RNase free water. Real-time PCR was performed using the MyiQ 
Single Color RT-PCR detection system (Biorad) using SYBR Sensimix Sybr Green 
(Quantace, London, UK), 5µl diluted cDNA and 0.3µM primers (Table 3.1) in a total 
volume of 25µl. Samples were amplified under the following conditions: 95°C for 3 
minutes, followed by 40 cycles of 95°C for 15 second and 60°C for 45 seconds. PCR was 
checked for aspecific products by performing a melting curve analysis (65°C-95°C). 
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Data were analyzed using the MyiQ Software system (Biorad) and were expressed as 
relative gene expression (fold increase) using the 2ͲȴȴCt method. The stably expressed 
gene cyclophilin A was included as reference. 
 
Table 3.1: Primer sequences for real time RT-PCR 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) 
Cyclophilin A TTCCTGCTTTCACAGAATTATTCC GCCACCAGTGCCATTATGG 
CYP1A1 GAGGCCAGAAGAAACTCCGT CCCAGCTCAGCTCAGTACCT 
CYP1B1 AGTGCAGGCAGAATTGGATCA GCGCATGGCTTCATAAAGGA 
UGT1A6 GGAACCCGACCATCGAATC TCGGGTGACCAAGCAGATC 
UGT2B7 TCCCATCAAATCTCCACAGA GGTGTTTTCTCTGGGGTCAA 
 
DNA isolation 
Cells were harvested and resuspended in 400ʅl SET/SDS (100mM NaCl, 20mM EDTA, 
50mM Tris, 0.5% SDS) and incubated at 37°C for 2 hours. 50ʅl of DNAse-free RNAse-
solution (RNAse A (0.1mg/ml) and RNAse T1 (1000 U/mL) in SET, incubated at 80°C for 
5 minutes) was added and samples were incubated at 37°C for 1 hour followed by 
addition of 50ʅl DNAse-free proteinase K (10mg/ml in SET-SDS, pre-incubated at 37°C 
for 30 minutes) and samples were incubated overnight at 37°C. After addition of 500ʅl 
phenol/chloroform/isoamyl alcohol (25:24:1), samples were rotated for 5 minutes and 
centrifuged for 5 minutes at 14000 rpm. To the upper aqueous phase, 500ʅl 
chloroform/Isoamyl alcohol (24:1) was added and samples were rotated for 5 minutes, 
centrifuged for 5 minutes (14000 rpm) and 1/30 volume NaAc (3M, pH 5.2) was added 
to the upper phase. Samples were mixed for a few seconds and two volumes ethanol 
100% (4°C) were added, samples were mixed and incubated at -20°C for 30 minutes. 
Samples were centrifuged for 5 minutes and DNA pellets were washed with ethanol 
70%. DNA pellets were dried and resuspended in Mili-Q H2O. The quantity of the DNA 
was measured using the Nanodrop 1000. 
 
32P-postlabeling of BPDE-DNA adducts 
DNA adduct levels were determined according to the nuclease P1 enrichment 
technique originally described by Reddy and Randerath (21) with the modifications 
described by Godschalk et al (22). In all experiments, three BPDE-DNA standards with 
known BPDE-DNA adduct levels (one adduct per 106, 107, and 108 normal nucleotides) 
were analyzed in parallel for quantification purposes. Adducts spots in DNA from BaP 
treated A549 cells that chromatographed at the same position as the BPDE-DNA 
adducts standards were considered to be derived from BPDE, and were quantified 
using Phosphor-Imaging technology (Fujifilm FLA-3000, Rotterdam, The Netherlands). 
 
HPLC 
In order to determine BaP-metabolite composition, 4ml medium or cell lysate was 
extracted with 1ml ethyl acetate after addition of 1ml 3M NaCl. Samples were 
vortexed for 10 minutes, centrifuged for 5 minutes at 1000rpm and after briefly 
vortexing, centrifuged again for 10 minutes at 1500rpm. The ethyl acetate fraction was 
collected and the extraction step was repeated twice. The second time and third time, 
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only ethyl acetate was added and the third time, also two droplets of ethanol were 
added to the samples for better separation. The ethyl acetate fractions were 
combined, evaporated to dryness under N2, and residues were resuspended in 0.5ml 
methanol. For chromatographic separation, a 50µl volume of the sample was injected 
onto a Hypersil 5µm ODS HPLC column (250x3mm i.d.) (Supelco 54933, Bellefonte, PA, 
USA) at a flow rate of 0.5ml/min. Mobile phase A and B were 100% methanol (Biosolve 
Chemicals, Valkenswaard, The Netherlands) and 40% methanol in water, respectively. 
The time program for the multi-step gradient was: 0-5min: isocratically 40/60 (A/B, 
v/v), 5-30min: gradient from 40/60 (A/B, v/v) to 90/10 (A/B, v/v), 30-35min: 
isocratically 90/10 (A/B, v/v), 35-37min: gradient from 90/10 (A/B, v/v) to 40/60 (A/B, 
v/v), 37-40min: 40/60 (A/B, v/v). The total run time was 40 minutes. For quantitation 
purposes, a standard mix consisting of 50ng/ml BaP-9,10-diol, 50ng/ml BaP-7,8-diol, 
and 50ng/ml 3-hydroxy-BaP (Midwest Research Institute, Kansas City, Missouri, USA) 
was used. Samples were analyzed on a Gynkotek P580A HPLC system (Separations 
Analytical Instruments, Hendrik Ido Ambacht, The Netherlands) with a Spark SP830 
autosampler (Spark Holland, Emmen, The Netherlands) and a Perkin Elmer LS-30 
programmable fluorescence detector (Perkin Elmer, Foster City, CA, USA). 
Excitation/emission wavelengths were 257/ >350nm. For quantification, the area of 
each metabolite peak on the chromatogram was determined. 
 
Statistical analysis 
Results are expressed as the mean ± standard error of the mean. GraphPad Prism 4 
was used for statistical analysis. To examine differences between cells incubated with 
or without BaP a two-way analysis of variance test (ANOVA) with Bonferroni post-hoc 
multiple comparison correction was used. To assess differences between various 
oxygen concentrations a t-test was used. Area under the curve was computed using 
the trapezoidal method. Differences were considered to be statistically significant 
when p<0.05.  
 
Results 
 
BaP-mediated induction of phase I enzymes CYP1A1 and CYP1B1 is increased under 
hypoxia.  
To determine whether oxygen levels affect the induction of CYP1A1 (Figure 3.1A) and 
CYP1B1 (Figure 3.1B) and the subsequent metabolic activation of BaP, gene 
expressions were determined in A549 cells treated with or without 0.1µM BaP for 18 
hours. Both CYP isoforms showed higher mRNA levels under hypoxic conditions. BaP 
induced CYP1A1 levels were у1.3 fold higher in cells cultured under 0.2% oxygen 
compared to cells cultured in 20% oxygen (p<0.05). CYP1B1 gene expression under 
hypoxic conditions was induced by у1.6 fold (p<0.001) and у2.1 fold (p<0.001) 
compared to 20% oxygen, in the absence and presence of BaP respectively. This 
induction of phase I enzyme expression suggests an increased metabolic activation of 
BaP. 
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Figure 3.1: Changes in oxygen tension alters the expression of the phase I metabolic enzymes 
Cyp1a1/1b1 and the phase II enzymes Ugt1a6, and Ugt2b7. A549 cells were treated with DMSO 
;ප) or 0.1µM BaP (Ŷ) and incubated in an atmosphere containing 20% or 0.2% oxygen. CYP1A1 
(A), CYP1B1 (B), UGT1A6 (C), and UGT2B7 (D) mRNA levels were measured. Data are presented 
as fold increase compared to 20% oxygen levels and DMSO. # and * indicate statistical significant 
differences compared to 20% oxygen and DMSO and BaP treatment, respectively. 
 
Hypoxia decreased phase II enzymes UGT1A6 and UGT2B7 gene expression.  
To investigate whether enzymes involved in the detoxification of BaP are altered under 
hypoxic conditions, gene expression was measured for the UDP 
glucuronosyltransferases, UGT1A6 and UGT2B7, two enzymes responsible for the 
conjugation of BaP metabolites and subsequent excretion of BaP. Both enzymes 
showed lower mRNA levels under hypoxic conditions. UGT1A6 gene expression was 
у37% (p<0.001) lower for cells in 0.2% oxygen, independent of BaP treatment (Figure 
3.1). When cells were under hypoxic conditions, a statistical significant у41% (p<0.01) 
and у35% (p<0.05) decreased level of UGT2B7, for DMSO and BaP treated cells 
respectively, was observed compared to 20% oxygen (Figure 3.1). This induction in 
gene expression of BaP activating enzymes and reduction of detoxifying gene 
expression under hypoxic conditions suggests that metabolism is directed towards an 
increased activation of BaP. 
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Figure 3.2: Hypoxia diminishes BaP 
metabolism. A549 cells were treated with 
0.1µM BaP and incubated in an atmosphere 
containing 20% or 0.2% oxygen. BaP levels were 
measured after 18 hours, extracellularly (ප) and 
intracellularly (Ŷ). Data are presented as area 
under the curve. # and * indicate statistical 
significant differences compared to 20% oxygen 
extracellularly and intracellularly, respectively. 
 
 
 
The parent BaP compound remains unmetabolized in cells treated 18h under hypoxia.  
To determine if increased CYP mRNA levels results in increased BaP metabolism, 
remaining unmetabolized BaP was measured extracellular and intracellular after 18 
hours of incubation. Importantly, extracellular BaP levels in hypoxic cells were 9 fold 
higher (p<0.001) compared to cells incubated under 20% oxygen, while intracellular 
the difference was 36 times (p<0.001) (Figure 3.2). The hypoxia induced increase in 
BaP parent compound suggests that, although an increased CYP expression is 
observed, lack of oxygen prevents the metabolism of BaP under hypoxic conditions, 
while in the normoxic cells BaP is conjugated.  
 
Table 3.2: Higher BaP-7,8-diOH levels in cells exposed to BaP under hypoxic conditions. A549 
cells were treated with 0.1µM BaP and incubated in an atmosphere containing 20% or 0.2% 
oxygen for 18 hours and the extracellular and intracellular BaP metabolites; BaP-9,10-diOH, BaP-
7,8-diOH, and BaP-3-OH were measured and normalized for the amount present at 20% oxygen. 
Data are presented as mean ± standard error * indicates statistical significant difference. 
 Oxygen 
(%) 
Extracellular  
(Fold change) 
Intracellular  
(Fold change) 
BaP-9,10-diOH 20 1.00 ± 0.11 1.00 ± 0.13 
 0.2 0.47 ± 0.06* 0.91 ± 0.10 
BaP-7,8-diOH 20 1.00 ± 0.13 1.00 ± 0.19 
 0.2 3.66 ± 0.05* 8.07 ± 0.14* 
BaP-3-OH 20 1.00 ± 0.12 1.00 ± 0.09 
 0.2 0.68 ± 0.03* 1.24 ± 0.12 
 
The active metabolite BaP-7,8-diOH is enriched in cells treated with hypoxia for 18h.  
To determine whether hypoxia directs the metabolism of BaP towards unfavorable 
activation, three important BaP metabolites, BaP-9,10-dihydrodiol (BaP-9,10-diOH), 
BaP-7,8-dihydrodiol (BaP-7,8-diOH) and 3-hydroxy-BaP (BaP-3-OH), were measured 
extracellular and intracellular (Table 3.2). Extracellular BaP-9,10-diOH and BaP-3-OH 
metabolite levels were significantly lower in hypoxic cells compared to the 20% oxygen 
condition, у53%, (p<0.01) and  у32% (p<0.05) respectively. In hypoxic cells the amount 
of both extracellular and intracellular levels of BaP-7,8-diOH were increased у3.6 
(p<0.001) and у8.1 (p<0.001) fold respectively, compared to cells cultured under 20% 
oxygen. So despite reduced BaP metabolism, more BaP-7,8-diOH is observed under 
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hypoxic conditions suggesting an increased opportunity for the formation of BPDE-
DNA adducts.  
 
Figure 3.3: Hypoxia diminishes BaP metabolism, but increases metabolite and adduct 
formation. A549 cells were treated with 0.1µM BaP and incubated in an atmosphere containing 
20% (Ŷ),  or 0.2% oxygen (Ÿ). BaP metabolite levels of BaP-7,8-diOH (A) and BaP-3OH (B), BaP 
levels (C) and BPDE-DNA adduct levels (D) were measured.  
 
Hypoxia prolongs exposure to BaP by altering metabolism kinetics. 
A well-documented and logical factor critical for carcinogenesis is the duration of BaP 
exposure (23). To determine if indeed under hypoxic conditions the exposure to BaP 
and its metabolites was increased, a time kinetic experiment was performed to 
compare the regular culturing oxygen concentration with hypoxic conditions for a 
prolonged exposure period. Up to 32 hours, similar levels of both BaP-7,8-diOH (Figure 
3.3A) and BaP-3-OH (Figure 3.3B) were observed under oxygen conditions, although 
the metabolic rate was reduced in the cells under hypoxic conditions as there was less 
BaP metabolized (Figure 3.3C). The metabolites in the medium of cells cultured under 
20% oxygen could be detected up to 56 hours after BaP addition, while in the hypoxic 
cells the amount of metabolites increased further to a у1.8 fold and у1.5 fold higher 
level compared to 20% oxygen for BaP-7,8-diOH and BaP-3-OH respectively. Under 
hypoxic conditions, the metabolites remained present for a significantly longer time 
and could be detected up to 144 hours after BaP addition. 
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Hypoxia induced increase in BaP exposure time leads to more DNA adducts.  
To determine whether the hypoxia induced changes in BaP metabolism results in more 
adducts, BPDE-DNA adducts were measured in the time kinetic experiment. The 
adduct levels in cells cultured under 20% oxygen were for the first 56 hours higher 
than under hypoxic conditions (Figure 3.3D). At 48 hours, the amount of adducts was 
у6.5 adducts per 107 nucleotides, after which the adduct levels decreased, while in the 
hypoxic cells the amount of adducts increased to a у4.5 adducts per 107 nucleotides 96 
hours after BaP addition. To determine the total amount of adducts formed during the 
whole incubation period, the area under the curve was measured. Importantly, under 
hypoxic conditions, the amount of adducts formed was у1.6 times higher compared to 
cells under cultured under 20% oxygen. These data indicate that under hypoxic 
conditions the BaP metabolism has shifted towards increased activation of BaP. 
 
Discussion 
 
The link between hypoxia and pathologies such as cancer may be the result of the 
previously reported increased mutation frequencies (14,15). Understanding the 
mechanisms involved in mutation induction is important in determining the role of 
hypoxia in genetic instability. Previously, we have shown a novel mechanism in which 
the interaction between induction of the HIF1 pathway and the AhR-pathway led to an 
increase in BaP-induced mutations (3). In this current study we further elucidated the 
mechanism behind the ability of hypoxia to increase mutagenicity of carcinogens. We 
provide evidence that hypoxia changes carcinogen metabolism towards a more 
activating metabolic pattern and alters kinetics of BaP-metabolism resulting in an 
increase in BaP and BaP-7,8-diOH exposure and subsequent increase in BPDE-DNA 
adduct formation. 
The induction of CYP1A1 is believed to be an activating event leading to enhanced 
levels of reactive metabolites and subsequent carcinogenesis. For example, a positive 
correlation was found between CYP1A1 activity and pulmonary PAH-associated DNA 
adduct formation (24) while high CYP1A1 inducibility in lymphocytes has been related 
to a high lung cancer risk (25,26). Conversely, CYP1A1 knockout mice were more 
susceptible to form adducts indicating the dual role of CYPs in activating and 
deactivating carcinogens (27). In this study, we showed that BaP induced CYP1A1 and 
CYP1B1 gene expression were augmented under hypoxia compared to cells cultured 
under 20% oxygen (Figure 3.1). This induced expression suggests an increased 
conversion of BaP and a subsequent enhanced elimination by conjugation, which 
however depends on phase II enzymes. Therefore, we assessed the expression of UGTs 
as these enzymes have a profound effect in both detoxification and promotion of BaP 
excretion and in particular, UGT2B7 exhibited strong activity towards BaP-7,8-diOH 
(28). The UGT gene expressions in this study showed lower levels under hypoxic 
conditions independent of the addition of BaP. The increased phase I enzymes and 
decreased phase II enzyme gene expression under hypoxia suggests a possible 
diversion of the metabolism towards the formation of BPDE. Decreased UGTs reduces 
the amount of BaP-7,8-diOH conjugation while at the same time the increase in CYPs 
may result in an increased metabolism of BaP-7,8-diOH towards BPDE.  
Reduced carcinogen detoxification by hypoxia 
 57 
To investigate the effect of BaP metabolic gene expression alteration, BaP metabolites 
were measured both extracellular and intracellular (Table 3.2). Under hypoxic 
conditions, very little BaP was metabolized within 18 hours of incubation. 
Unmetabolized BaP levels in cells incubated under 20% oxygen were 9 fold and 36 fold 
lower compared to hypoxic cells, extracellular and intracellular, respectively. This 
suggests that the metabolism of BaP is not only reduced but also its removal from the 
cell is decreased under hypoxic conditions. Extracellular levels of BaP-3-OH, a non 
mutagenic metabolite of BaP and BaP-9,10-diOH, a precursor of BaP-9,10-diol-7,8-
epoxide, which is much less carcinogenic compared to BPDE, were lower at 0.2% 
oxygen compared to 20% oxygen. On the other hand, levels of the BPDE precursor 
BaP-7,8-diOH were much higher under hypoxic conditions. Interestingly, higher 
intracellular levels of BaP-7,8-diOH were present under hypoxic conditions compared 
to extracellular levels, which may suggest a reduced removal of this metabolite from 
the cell. Very little is known about the transport of BaP unconjugated metabolites and 
thus may be an avenue of further studies. Overall, the levels of the metabolites are 
much higher under hypoxic conditions while the metabolism of BaP itself is decreased.  
Incubation times of up to 168 hours were used to determine the differences in the 
formation of BPDE-DNA-adducts over a prolonged exposure period in cells cultured at 
regular culturing conditions and at hypoxic conditions (Figure 3.3). The BaP 
metabolism was reduced under hypoxic conditions, which however did not result in a 
decreased formation of metabolites. In fact, this reduced metabolism resulted in a 
prolonged formation of BaP-7,8-diOH, and BaP-3-OH metabolites and in the end, more 
ethyl acetate extractable metabolites were formed in the cell during the metabolism of 
BaP. Importantly, the alteration in metabolism resulted in a 1.6 times more DNA 
adducts being formed under hypoxic conditions compared to cells cultured in 20% 
oxygen. This correlates well with the study by Ross et al. in which a relation between 
the total amount of adducts present in time and tumor induction in mouse lung was 
observed and concluded that area under the curve is a better predictor of cancer risk 
than peak adducts levels (23). This suggests that in BaP exposure studies, the timing of 
kinetics must be carefully considered. Our data indicate that the observed CYP induced 
gene expression under hypoxic conditions does not increase BaP metabolism, but 
rather the metabolism of BaP-7,8-diOH to BPDE. This in combination with a reduced 
detoxification of BaP-7,8-diOH results in an increased formation of BPDE-DNA adducts. 
The prolonged presence of adducts under hypoxic conditions could result in a greater 
genetic instability. That our in vitro findings can be translated to the in vivo situation is 
exemplified by results obtained in skin exposed Ahr (-/-) mice that showed a lower 
metabolic clearance of BaP resulting in increased formation of BaP-7,8-diOH 
metabolites, and higher levels of unmetabolised BaP and DNA adduct levels in tissues, 
especially lung. So, in intact animals hypoxic interference of the Ahr signaling pathway 
is very well anticipated to lead to similar effects upon exposure to BaP (29).  
Taken together, these results suggest that cells exposed to low oxygen concentrations 
generate more bioactive intracellular BaP metabolites. Importantly, we demonstrate 
that the time in which cells were exposed to BaP was elongated under hypoxic 
conditions. This ultimately led to prolonged time to form BPDE-DNA adducts in the 
cells, which is associated with increased tumorigenesis. Interestingly, this suggests that 
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pathologies that limit the oxygen tension such as COPD or local hypoxia due to for 
example inflammation or poor angiogenesis can result in a disturbed oxygen balance 
and a subsequent dysregulation of the carcinogen detoxification and increased cancer 
risk. 
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Abstract 
 
Mutations of the von Hippel-Lindau (VHL) tumor suppressor gene occur in the majority 
of sporadic renal-cell carcinomas (RCC). Loss of VHL function is associated with 
stabilization of hypoxia-inducible factor ɲ (HIFɲ). We and others have shown that 
there is a two-way interaction between the aryl hydrocarbon receptor (AhR), which is 
an important mediator in the metabolic activation and detoxification of carcinogens, 
and the HIF1-pathway leading to an increased genetic instability when both pathways 
are simultaneously activated. The aim of this study was to investigate how 
environmental carcinogens, such as benzo[a]pyrene (BaP), which can be metabolically 
activated to BaP-7,8-diOH-9,10-epoxide (BPDE) play a role in the etiology of RCC. To 
this end, we exposed VHL deficient RCC4 cells, in which HIFɲ is stabilized regardless of 
oxygen tension, to 0.1µM BaP for 18 hours. In this study we demonstrated that the 
mutagenic BPDE-DNA adduct levels were increased in HIFɲ stabilized cells. Using qRT-
PCR, we demonstrated that absence of VHL significantly induced the mRNA levels of 
the AhR downstream target CYP1A1. Furthermore, HPLC analysis indicated that loss of 
VHL increased the concentration of BaP-7,8-dihydroxydiol, the pre-cursor metabolite 
of BPDE. Interestingly, the capacity to repair BPDE-DNA adducts in the HIFɲ stabilized 
RCC4 cells was markedly reduced. Taken together, these data indicate that loss of VHL 
affects BaP-mediated genotoxic responses in RCC and decreases repair capacity. 
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Introduction 
 
Renal-cell carcinoma (RCC) is the most common type of kidney cancer in adults and 
accounts for 4% of all cancers (1). The most frequently observed genetic alteration in 
RCC is the somatic mutation of the von Hippel-Lindau (VHL) tumor suppressor gene 
(2,3). The protein encoded by VHL is a crucial regulator of the oxygen sensing pathway, 
which involves the transcription factor hypoxia-inducible factor (2,4). In the presence 
of oxygen, HIFɲ is hydroxylated by an oxygen-dependent prolyl hydroxylase (HIF-PH) 
(5). An E3 ubiquitin ligase complex containing the von Hippel-Lindau protein (pVHL) 
recognizes the hydroxylated HIFɲ, and targets it for ubiquitination (6) and 
subsequently proteasomal degradation (7). Under hypoxic conditions, HIFɲ is not 
prolyl-hydroxylated and thus unrecognized by pVHL. Therefore, the stabilized HIFɲ can 
translocate to the nucleus where it forms a heterodimer with HIF-1ɴ, also referred to 
as aryl hydrocarbon receptor nuclear translocator (ARNT) (8). HIF1 then binds to the 
(A/G)CGTG consensus sequence in the hypoxic responsive elements of the 
promoter/enhancer regions in the DNA (9), where it drives the expression of a wide 
array of hypoxia-inducible genes to augment oxygen delivery or to provide alternative 
pathways for energy production and cell metabolism. 
The functional loss of pVHL in some RCCs results in an aberrant stabilization of HIFɲ 
independent of the oxygen tension. The subsequent overexpression of proteins 
encoded by HIFɲ regulated target genes contributes to the creation of a 
microenvironment favorable for cell proliferation (2,10-12). In many tumors including 
RCC, the hypoxia-responsive transcription factor HIFɲ is overexpressed, (13) and is 
associated, together with its downstream targets, with poorer outcome (14). Patients 
diagnosed with such hypoxic tumors will often have a poor clinical prognosis due to 
the formation of metastases and the resistance to chemotherapeutics (15). Kallio and 
colleagues have proposed that this negative prognosis may occur due to low oxygen 
concentrations having the capacity to induce genetic instability, leading to increased 
rates of mutagenesis and angiogenesis, decreased rates of apoptosis and upregulation 
of genes involved in the metastatic cascade (16). Suppression of the DNA damage 
response pathways within the hypoxic tumors may also play a critical role (9). 
In addition to forming a complex with HIFɲ, HIF1ɴ/ARNT also dimerizes with the aryl 
hydrocarbon receptor (AhR). AhR is known to interact with environmental pollutants 
such as dioxins and polycyclic aromatic hydrocarbons (PAH). PAHs are widely 
distributed contaminants produced as byproducts of combustion processes such as in 
vehicle exhaust, cigarette smoking and charcoal grilling of food. Benzo[a]pyrene (BaP) 
is a classic example of PAH and is readily absorbed by inhalation, ingestion, and 
through the skin. As BaP is lipophilic, it can easily diffuse into cells where it binds to 
AhR, translocates into the nucleus and subsequently heterodimerizes with 
HIF1ɴ/ARNT. This complex can then bind to the TNGCGTG consensus sequence in the 
xenobiotic response elements of target genes (17) where it acts as a transcription 
factor for a number of genes, which encode for enzymes involved in xenobiotic 
detoxification, including the cytochrome P450 (CYPs) isoforms CYP1A1 and CYP1B1 
(18,19). The detoxification process of BaP begins with an epoxidation reaction by the 
mono-oxygenases CYP1A1 and CYP1B1 (phase I). The resulting metabolites (e.g. BaP-
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7,8-epoxide and BaP-9,10-epoxide) can be converted nonenzymatically to phenols (e.g. 
3-OH BaP) or enzymatically to dihydrodiols (e.g. BaP-7,8-diOH or BaP-9,10-diOH) by 
epoxide hydrolase. Phenols can subsequently be converted to water-soluble sulphate 
or glucuronide conjugates (phase II) and dihydrodiols can be further transformed by 
CYP1A1 or CYP1B1 to diol epoxides (e.g. BaP-7,8-diol-9,10-epoxide (BPDE)) or 
conjugated by uridine diphosphate glucuronosyl transferase (UGT) (19). An 
unfortunate consequence of the detoxification reaction is the production of the 
intermediate BPDE, which can covalently bind to DNA forming highly mutagenic DNA 
adducts, where it preferentially binds to the nucleotide guanine at the N2 position 
(BPDE-N2-dG lesion) (18). When unrepaired, these lesions may result in mutations, for 
example, BPDE induces G to T transversions in the p53 tumor suppressor gene and is 
as such evidenced to be involved in lung cancer development (20) 
Previously, we have shown that exposure of cells to hypoxia markedly enhances the 
genetic instability caused by exogenous genotoxins and that HIF activation decreases 
nucleotide excision repair (NER) (21). Furthermore, we have demonstrated that the 
kinetics of BaP metabolism is altered under hypoxia resulting in a prolonged time of 
exposure and a higher amount of BPDE-DNA adducts being formed (Schults, M.A. et al, 
submitted for publication). From these initial studies in which we induced HIFɲ 
expression using chemicals or hypoxia, we observed an important link between the 
HIF1 mediated response pathway and the cellular response pathway that counteracts 
chemical carcinogens. In the present study, we hypothesize that in naturally occurring 
RCC cells that have a defect in HIF regulation, the observed genetic instability may be 
the result of a faulty response to environmental carcinogens such as BaP. In this 
current report, we show that loss of VHL affects BaP-mediated genotoxic responses by 
inducing CYP1A1 mRNA levels, which mediated a significant change in BaP-7,8-diOH, 
the pre-cursor metabolite of BPDE. Secondly, the capacity to repair DNA by NER is 
reduced in these cells, thereby preventing the repair of those BPDE-DNA adducts 
 
Materials and Methods 
 
Cell culture and treatment  
RCC4 (VHL-/-) cells, a VHL-deficient cell line and RCC4-VHL (VHL+/+), RCC4 
reconstituted with VHL, were cultured in Dulbecco’s Modified Eagle Medium (DMEM; 
Sigma-Aldrich, UK) supplemented with 10% heat inactivated Fecal Calf Serum (FCS; 
Invitrogen Breda, The Netherlands) and 1% penicillin streptomycin (P/S; Gibco, 
Invitrogen, Paisley, UK) at 37°C in a 5% CO2 and 20% O2 atmosphere. Cells were seeded 
one day before treatment and maintained at 37°C in a 5% CO2 atmosphere. All cells 
were treated with 0 or 0.1µM BaP (Sigma) dissolved in DMSO (final concentrations did 
not exceed 0.5%) for 18 hours. After treatment medium was removed and cells were 
harvested using trypsin. All samples were stored at -20°C. 
 
Quantitative Real-Time PCR  
Cells were washed twice with PBS and lyzed with Trizol (Invitrogen). Total RNA was 
isolated according to the manufacturer’s instructions. The quantity of each RNA 
sample was spectrophotometrically assessed by a Nanodrop 1000 (Thermo Scientific, 
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Waltham, MA, USA). cDNA synthesis was performed using the iScript cDNA Synthesis 
kit (Biorad, Veenendaal, The Netherlands) starting with 1µg of RNA. cDNA was diluted 
25x in RNase free water. Real-time PCR was performed using the MyiQ Single Color RT-
PCR detection system (Biorad) using Sensimix Sybr Green (Quantace, London, UK), 5µl 
diluted cDNA and 0.3µM primers (Table 4.1) in a total volume of 25µl. Samples were 
amplified under the following conditions: 95°C for 3 minutes, followed by 40 cycles of 
95°C for 15 second and 60°C for 45 seconds. PCR was checked for a-specific products 
by performing a melting curve analysis (65°C-95°C). Data were analyzed using the 
MyiQ Software system (Biorad) and were expressed as relative gene expression (fold 
increase) using the 2ͲȴȴCt method. The stably expressed gene cyclophilin A was included 
as reference.  
 
Table 4.1: Primer sequences for real time RT-PCR 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) 
Cyclophilin A TTCCTGCTTTCACAGAATTATTCC GCCACCAGTGCCATTATGG 
CYP1A1 TCCTGGAGACCTTCCGACACT CTTTCAAACTTGTGTCTCTTGTTGTG 
CYP1B1 AGTGCAGGCAGAATTGGATCA GCGCATGGCTTCATAAAGGA 
XPA CCGACAGGAAAACCGAGAAA TTCCACACGCTGCTTCTTACTG 
XPC CCCAGCCCGCTTTACCA TGCATTAACTGTAAATGTTCCAATGA 
ERCC4 CACCTCCCTCGCCGTGTA CGCAAATATAACACCACCTTGTG 
ERCC5 GCATGAAATCTTGACTGATATGAAAGA TAAGCAAGCCTTTGAGTTGGTACTG 
ERCC1 ACCCCTCGACGAGGATGAG CAGTGGGAAGGCTCTGTGTAGA 
GSTP1 CTCAAAAGGCTTCAGTTGCC ACCTCCGCTGCAAATACATC 
EPHX1 CTTCACGTGGATGAAGTGGA CTGGCGGAATGAATTTGACT 
UGT1A6 GGAACCCGACCATCGAATC TCGGGTGACCAAGCAGATC 
UGT2B7 TCCCATCAAATCTCCACAGA GGTGTTTTCTCTGGGGTCAA 
 
DNA isolation 
Cells were harvested and resuspended in 400ʅL SET/SDS (100mM NaCl, 20mM EDTA, 
50mM Tris, 0.5% SDS) and incubated at 37°C for 2 hours. 50 ʅL of DNAse-free RNAse-
solution (RNAse A (0.1mg/mL) and RNAse T1 (1000U/mL) in SET, incubated at 80°C for 
5 minutes) was added and samples were incubated at 37°C for 1 hour followed by 
adding 50ʅL DNAse-free proteinase K (10mg/mL in SET-SDS, heat-inactivated at 37°C 
for 30 minutes) and samples were incubated overnight at 37°C. After addition of 500ʅL 
phenol/chloroform/Isoamylalcohol (25:24:1), samples were rotated for 5 minutes and 
centrifuged for 5 minutes at 14000rpm. To the upperphase, 500ʅL 
chloroform/Isoamylalcohol (24:1) was added and samples were 5 minutes rotated, 
centrifuged for 5 minutes (14000rpm) and 1/30 volume NaAc (3M, pH 5.2) was added 
to the upperphase. Samples were mixed for a few seconds and two volumes ethanol 
100% (4°C) were added, samples were mixed and incubated at -20°C for 30 minutes. 
Samples were centrifuged for 5 minutes and DNA pellets were washed with ethanol 
70%. DNA pellets were dried and resuspended in Mili-Q H2O. The quantity and quality 
of DNA was measured using the Nanodrop 1000. 
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32P-postlabeling of BPDE-DNA adducts  
DNA adduct levels were determined according to the nuclease P1 enrichment 
technique originally described by Reddy and Randerath (22) with the modifications 
described by Godschalk et al. (23). In all experiments, three BPDE-DNA standards with 
known BPDE-DNA adduct levels (one adduct per 106, 107, and 108 normal nucleotides) 
were analyzed in parallel for quantification purposes. Adducts spots in DNA from BaP 
treated RCC4 cells that chromatographed at the same position as the BPDE-DNA 
adducts standards were considered to be derived from BPDE, and were quantified 
using Phosphor-Imaging technology (Fujifilm FLA-3000, Rotterdam, The Netherlands). 
 
HPLC 
In order to determine BaP-metabolite composition, 4ml medium was extracted with 
1ml ethyl acetate after addition of 1ml 3M NaCl. Samples were vortexed for 10 
minutes, centrifuged for 5 minutes at 1000rpm and after briefly vortexing, centrifuged 
again for 10 minutes at 1500rpm. The ethyl acetate fraction was collected and the 
extraction step was repeated twice. The second time and third time, only ethyl acetate 
was added and the third time, also two droplets of ethanol were added to the samples 
for better separation. The ethyl acetate fractions were combined, evaporated to 
dryness under N2, and residues were resuspended in 0.5ml methanol. For 
chromatographic separation, a 50µl volume of the sample was injected onto a Hypersil 
5µm ODS HPLC column (250x3mm i.d.) (Supelco 54933, Bellefonte, PA, USA) at a flow 
rate of 0.5ml/min. Mobile phase A and B were 100% methanol (Biosolve Chemicals, 
Valkenswaard, The Netherlands) and 40% methanol in water, respectively. The time 
program for the multi-step gradient was: 0-5min: isocratically 40/60 (A/B, v/v), 5-
30min: gradient from 40/60 (A/B, v/v) to 90/10 (A/B, v/v), 30-35min: isocratically 
90/10 (A/B, v/v), 35-37min: gradient from 90/10 (A/B, v/v) to 40/60 (A/B, v/v), 37-
40min: 40/60 (A/B, v/v). The total run time was 40 minutes. For quantitation purposes, 
a standard mix consisting of 50ng/ml BaP-9,10-diOH, 50ng/ml BaP-7,8-diOH, and 
50ng/ml 3-OH BaP (Midwest Research Institute, Kansas City, Missouri, USA) was used. 
Samples were analyzed on a Gynkotek P580A HPLC system (Separations Analytical 
Instruments, Hendrik Ido Ambacht, The Netherlands) with a Spark SP830 autosampler 
(Spark Holland, Emmen, The Netherlands) and a Perkin Elmer LS-30 programmable 
fluorescence detector (Perkin Elmer, Foster City, CA, USA). Excitation/emission 
wavelengths were 257/ >350nm. For quantification, the area of each metabolite peak 
on the chromatogram was determined. 
 
Measurement of repair capacity 
To assess NER capacity in the liver samples, we applied a well characterized and 
validated modified comet assay (24). This assay measures the ability of NER-related 
enzymes that are present in cell extracts, to incise substrate DNA containing BPDE-DNA 
adducts. The substrate nucleoids were prepared from untreated A549 cells (human 
epithelial lung carcinoma cells) obtained from the American Tissue Culture Collection 
(ATCC, Rockville, MD, USA). The cells were cultured in DMEM supplemented with 10% 
heat-inactivated FCS and 1% penicillin/streptomycin and maintained at 37°C in a 5% 
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CO2 atmosphere. A549 cells were embedded in LMP agarose on glass microscope 
slides and subsequently lyses overnight in cold (4°C) lysis buffer (2.5M NaCl, 0.1M 
EDTA, 0.01M Tris, 0.25M NaOH plus 1% Triton X-100 and 10% DMSO). The resulting 
nucleoids were then either exposed to 1µM BPDE (NCI Chemical Carcinogen Reference 
Standard Repository, Midwest Research Institute, Kansas City, MO, USA) in PBS or 
vehicle control (DMSO, 0.5%) for 30 minutes at 4°C. To prepare protein/enzyme 
extracts, RCC4 and RCC4-VHL cells were harvested and resuspended in buffer A (45mM 
HEPES, 0.4M KCl, 1mM EDTA, 0.1mM dithiothreitol, 10% glycerol, adjusted to pH 7.8 
using KOH). Resulting aliquots were snap-frozen, thawed again and 30ʅl of 1% Triton 
X-100 in buffer A per 100ʅl of extract was added. Protein concentrations were 
determined by the BioRAD DC protein assay using bovine serum albumin as a standard. 
Tissue extracts were diluted to a concentration of 1mg/ml. Next, 4 volumes of reaction 
buffer B (45mM HEPES, 0.25mM EDTA, 2% glycerol, 0.3mg/ml BSA, adjusted to pH 7.8 
with KOH) were added and 50ʅl of the mixture was added to the gel-embedded 
nucleoids and incubated for 20 minutes at 37°C. Alkaline treatment (40 minutes) and 
electrophoresis (30 minutes) were conducted as described in the standard comet assay 
(25). Comets were visualized using a Zeiss Axioskop fluorescence microscope and 
quantified as tail moment. Samples were tested in two independent incubations within 
each single experiment. On every slide, 50 cells were analyzed randomly using the 
Comet assay III software program (Perspective Instruments, Haverhill, UK). The 
increased DNA strand breakage (tail moment) in the BPDE-modified nucleoids vs. the 
DMSO-treated nucleoids is indicative for the NER capacity of the cell extracts. The final 
repair capacity was calculated according to Langie et al.(24). 
 
Statistical analysis 
Results are expressed as the mean ± standard error of the mean. GraphPad Prism 4 
was used for statistical analysis. A two-way analysis of variance (ANOVA) with 
Bonferroni post-hoc multiple comparison correction was used to assess differences in 
mRNA levels. To analyze differences in metabolite levels, adduct levels, and repair 
capacity a t-test was used. Differences were considered to be statistically significant 
when p<0.05.  
 
Results 
 
BPDE-DNA adduct levels are higher in cells deficient in VHL 
To examine the influence of VHL deletion on BaP-mediated genotoxic responses, we 
quantified the amount of BPDE-DNA adducts in VHL deficient RCC4 cells and compared 
it with the genetically wild type RCC4-VHL cells, and normalized it to the total amount 
of DNA (Figure 4.1). Exposure to 0.1µM BaP resulted in a у1.7 fold higher induced 
formation of pro-mutagenic BPDE-DNA adduct levels in RCC4 cells, compared to RCC4-
VHL cells (p<0.05). To our knowledge, this is the first demonstration of enhanced 
carcinogen activity in VHL deficient RCC cells. 
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Figure 4.1: BPDE-DNA adduct levels are 
higher in cells deficient in VHL. RCC4-VHL 
and RCC4 cells were incubated with 0.1µM 
BaP. DNA was isolated after 18 hours and 
BPDE-DNA adduct levels were measured 
by 32P-postlabeling. Data (n=4) are 
presented as mean adduct level per 107 
nucleotides ± standard error (*p<0.05) 
 
 
 
 
Cells deficient in VHL have changes gene expression of metabolic enzymes 
To determine whether metabolism may be the underlying cause of the increase in 
BPDE-DNA adducts in cells deficient in VHL, we assessed the mRNA expression of 
several key phase I and II metabolic enzymes (Figure 4.2). Of the phase I enzymes 
responsible for the activation of BaP, CYP1A1 mRNA levels significantly differs between 
the two cell lines (Figure 4.2A). The CYP1A1 mRNA levels were у31 times and у5.8 
times higher in the RCC4 cells compared to the RCC4-VHL cells (p<0.01), for untreated 
and BaP treated cells, respectively. CYP1B1 gene expression was not statistically 
different between the two cell lines (Figure 4.2B). Gene expression of four phase II 
enzymes responsible for the conjugation of BaP metabolites was alsomeasured (Figure 
4.3). The expression of the glutathione S-transferases GSTP1 was у24% lower in RCC4 
cells compared to RCC4-VHL cells (p<0.05, Figure 4.3A). Epoxide hydrolase 1 (Figure 
4.3B) and the UDP glucuronosyltransferases UGT1A6 (Figure 4.3C) showed no 
difference between the two cell lines. Conversely, UGT2B7 was у1.5 and у1.6 times 
higher (DMSO and BaP treatment respectively) in RCC4 cells compared to the RCC4- 
VHL cells (Figure 4.3D). This induction in gene expression of the BaP activating enzyme  
 
Figure 4.2: CYP1A1, but not CYP1B1 mRNA expression is markedly enhanced in VHL defective 
cells. RCC4-VHL (ප) and RCC4 cells (Ŷ)  were incubated with DMSO or 0.1µM BaP for 18 hours.  
RNA was isolated and mRNA levels were measured of A. CYP1A1 and B. CYP1B1. Data (n=4) are 
presented as mean fold change ± standard error (**p<0.01) 
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CYP1A1 and the unchanged or small increased gene expression of the detoxifying 
genes in the absence of VHL suggests that metabolism is directed towards an increased 
activation of BaP 
Figure 4.3: Loss of VHL increases UGT2B7, but decreases GSTP1 gene expression. RCC4-VHL (ප) 
and RCC4 cells (Ŷ) were incubated with DMSO or 0.1µM BaP for 18 hours. RNA was isolated and 
mRNA levels were measured of A. GSTP1, B. EPHX1, C. UGT1A6, and D. UGT2B7. Data (n=4) are 
presented as mean fold change ± standard error (**p<0.01, ***p<0.001) 
 
Absence of VHL in cells directs BaP metabolism toward unfavorable activation 
To determine whether the observed differences in BaP metabolic enzymes between 
the two cell lines resulted in the expected detrimental changes in BaP metabolism, we 
assessed BaP and its metabolites BaP-9,10-diOH, BaP-7.8-diOH and 3-OH BaP by HPLC 
analysis with fluorescence detection (Figure 4.4). RCC4 and RCC4-VHL were exposed 
for 18 hours to 0.1µM BaP and the medium was collected. The rate of metabolism was 
determined from measuring the remaining amount of unmetabolized BaP. In the 
medium, a non-statistically significant у2 fold higher level of BaP was measured in the 
RCC4 cells compared to the control RCC4-VHL cells (Figure 4.4A). For all three 
metabolites assessed, statistically significant higher levels of metabolites were found in 
the medium of the RCC4 cells compared to the RCC4-VHL cells. A у1.7 and у2.7 fold 
induction of BaP-9,10-diOH and 3-OH BaP, respectively, was observed in RCC4 cells 
compared to RCC4-VHL cells (Figure 4.4B and C). Furthermore, compared to RCC4-VHL 
cells, BaP-7,8-diOH levels, the BPDE precursor, were у2.9 times higher in RCC4 cells 
(Figure 4.4D), suggesting an increased opportunity for the formation of BPDE-DNA 
adducts. 
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Figure 4.4: Absence of VHL decreased BaP metabolism, but increased BaP metabolites. RCC4-
VHL  (ප)  and  RCC4  cells  (Ŷ) were incubated with 0.1µM BaP for 18 hours and extracellular 
unmetabolized BaP (A), BaP-9,10-diOH (B), BaP-7,8-diOH (C), and 3-OH BaP (D) metabolites were 
measured. Data (n=5) are presented as mean area under the curve ± standard error (*p<0.05, 
**p<0.01) 
 
Table 4.2: Relative NER gene expression 
BaP  XPA XPC ERCC4 ERCC5 ERCC1 
0 µM RCC4-VHL 1.00±0.02 1.00±0.14 1.00±0.08 1.00±0.10 1.00±0.09 
RCC4 0.94±0.05 0.98±0.12 0.98±0.03 1.16±0.11 1.09±0.06 
0.1 µM 
RCC4-VHL 1.02±0.04 1.04±0.16 0.95±0.08 0.98±0.08 1.01±0.02 
RCC4 1.15±0.05 1.17±0.19 0.89±0.02 1.21±0.12 1.17±0.09 
 
Nucleotide excision repair capacity is reduced in VHL deficient cells 
As we have previously reported a down regulation of NER capacity in HIFɲ stabilized 
cells, we sought to determine whether diminished DNA repair may also play a role in 
the observed differences in BPDE-DNA adduct level induction between the RCC4 and 
RCC4-VHL cells. Firstly, we determined the influence of DNA repair gene expression in 
the matched cells. The mRNA levels of the critical nucleotide excision repair genes XPA, 
XPC, ERCC1, ERCC5, and ERCC4 were not altered in the cell lines (Table 4.2). Secondly, 
as DNA repair is often not regulated at the transcription level, we used a validated 
modified comet assay to determine the functional NER capacity. Interestingly, a 
markedly reduced repair capacity was observed in the VHL deficient cells compared to 
the reconstituted RCC4-VHL cells (Figure 4.5). These results suggest that absence of 
VHL is indeed an important mechanism in influencing functional DNA repair. 
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Figure 4.5: NER capacity is decreased 
in RCC4 cells. The ability to repair 
BPDE-DNA adducts in RCC4-VHL and 
RCC4 cells were measured using the 
modified comet assay (24). Data (n=4) 
are presented as mean fold change ± 
standard error (*p<0.05). 
 
 
 
 
 
Discussion 
 
Since the most frequent observed genetic alteration in RCC is the somatic mutation of 
the von Hippel-Lindau tumor suppressor gene, understanding how VHL-deficiency 
leads to genetic instability may prove to be invaluable. To this end, we sought to 
determine how VHL may impact the carcinogenic capacity of the important 
environmental carcinogen BaP. Previously we demonstrated that the stabilization of 
HIFɲ by CoCl2 enhances the carcinogenic effect of BaP in lung cancer cells and reduced 
repair (21). Furthermore, we have demonstrated that the kinetics of carcinogen 
metabolism is altered under hypoxic conditions, resulting in a higher amount of BPDE-
DNA adducts being formed (Schults, M.A. et al, submitted for publication). The aim of 
the current study was to determine whether similar genetic instability mechanisms 
hold true in a naturally occurring VHL deficient RCC cells. In this report, we 
demonstrate that loss of VHL and presumably via the stabilization of HIFɲ affects both 
genetic stability related processes of BaP-mediated as well as DNA repair capacity in 
RCC cells. 
Cytochrome P450 enzymatically converts BaP into the active metabolite BPDE, which 
subsequently binds covalently to DNA forming highly mutagenic DNA adducts (18). To 
investigate the effect of metabolically activated BaP on RCC4 cells, we focused on the 
formation of BPDE-DNA adducts. Interestingly, our data demonstrated that VHL 
deficiency resulted in increased BPDE-DNA adduct levels in RCC4 cells, compared to 
RCC4-VHL cells, when treated with 0.1µM BaP. This is in agreement with our previously 
observed results, where the formation of BPDE-DNA adducts was increased due to 
stabilization of HIFɲ by CoCl2 in A549 cells. (21). 
We have previously shown that HIFɲ stabilization by chemicals or reduced oxygen 
tension changes gene expression of important metabolic enzymes (Schults, M.A. et al, 
submitted for publication). Therefore, we assessed whether these changes in gene 
expression also occur in the VHL deficient RCC cells. CYP1A1 and CYP1B1 are two of the 
most important enzymes in the detoxification and bioactivation of BaP by adding an 
epoxide group to BaP. (18,19). Furthermore, CYP1A1 is the critical enzyme in the 
bioactivation of BaP-7,8-diOH to the ultimate carcinogenic BPDE metabolites in human 
lung cell lines in vitro (26). In this study we demonstrate that CYP1A1 mRNA levels 
were strongly upregulated in the HIFɲ stabilized RCC4 cells compared to the 
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reconstituted genetically wild type cells. As CYP1B1 mRNA levels were unaffected by 
VHL loss, CYP1A1 appears to be the critical player in RCC metabolism of BaP in these 
cells. Induction of CYP1A1 in HIFɲ stabilized cells may result in an increased level of 
BPDE formation which may subsequent induce carcinogenicity. This correlates with 
studies in other cell types where CYP1A1 activity has been positively correlated with 
pulmonary PAH (BPDE)-associated DNA adduction (27), and high CYP1A1 inducibility in 
lymphocytes has been related to a high lung cancer risk (28,29). 
The resulting BaP metabolites can be converted into hydrophilic products by phase II 
enzymes. Alterations in these conjugation reactions could result in changed 
elimination of these compounds and subsequently BPDE-DNA adducts level. No 
pattern was observed for phase II enzymes, suggesting that they are not likely involved 
in the observed different BPDE-DNA adduct levels identified between the two cell 
lines. Nevertheless, measuring BaP metabolites provides a better insight into 
differences in BaP metabolism between the two RCC4 cell lines. To this end, we 
focused on the formation of dihydrodiols and phenols; BaP-7,8-diOH can be oxidized to 
BPDE, while BaP-,9,10-diOH leads to the formation of BaP-9,10-diol-7,8-epoxide, which 
is far less carcinogenic than BPDE, and 3-OH BaP, which is considered one of the major 
detoxification products. Most abundantly present in the media of both cell lines was 
BaP-9,10-diOH. We further observed that the raised levels of metabolites and in 
particular BaP-7,8-diOH correlates well with the observed increased DNA adducts 
levels. Together, these data indicate that VHL deficient RCC cells are able to 
differentially bioactivate BaP as compared to RCC4-VHL cells suggesting a plausible 
explanation for the increased DNA adduct formation in RCC4 cells. 
The level of DNA adducts is influenced by the balance between the induction of the 
damage and its repair. Therefore, in addition to the formation of adducts, we further 
analyzed whether loss of VHL is able to affect NER since the bulk of adducts are 
removed by the NER pathway (30). Our data indicate that the loss of VHL had no effect 
on DNA repair gene expression. As DNA repair is often regulated in multiple manners 
in addition to transcriptional control, we sought to determine whether HIFɲ 
stabilization impairs overall functional NER. To this end, we used a previously validated 
modified comet assay, which predominantly assesses the cellular capacity in the 
recognition and incision phase of NER to remove bulky DNA adducts (24). Interestingly, 
a dramatically lower repair capacity was observed in the VHL deficient RCC4 cells. 
Reduced NER capacity under hypoxic conditions has been previously demonstrated in 
mouse fibroblasts (31) and in HIFɲ stabilized A549 cells (21). In the present study, we 
show for the first time that lack of VHL in cells also results in a decreased repair 
capacity. The reduced NER repair further explains the observed higher BPDE-DNA 
adduct levels in VHL deficient RCC cells. 
In this study, we provide evidence that loss of VHL presumably via the stabilization of 
HIF affects the BPDE-DNA adduct levels in RCC cells and is in fact a double edged 
sword. Firstly, the absence of VHL is associated with induced CYP1A1 mRNA levels, 
which mediated a significant change in BaP-7,8-diOH levels among other metabolites. 
This could significantly induce the formation of BPDE-DNA adduct levels. Secondly, the 
capacity to repair DNA by NER is reduced in HIFɲ stabilized cells, thereby preventing 
the repair of those BPDE-DNA adducts. Taken together, these data indicate that loss of 
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VHL increases carcinogen genotoxicity in renal cell carcinoma in-vitro and provides 
potential insight in the malignant progression into RCC. 
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Abstract 
 
Genetic polymorphisms can partially explain the large inter-individual variation in DNA 
adduct levels following exposure to polycyclic aromatic hydrocarbons. Effects of 
genetic polymorphisms on DNA adduct formation are difficult to assess in human 
studies, because exposure misclassification attenuates underlying relationships. 
Conversely, ex vivo studies offer the advantage of controlled exposure settings, 
allowing the possibility to better elucidate genotype-phenotype relationships and 
gene-gene interactions. Therefore, we exposed lymphocytes of 168 non-smoking 
volunteers ex vivo to the environmental pollutant benzo[a]pyrene (BaP) and BaP-7,8-
dihydrodiol-9,10-epoxide (BPDE)-DNA adducts were quantified. Thirty four genetic 
polymorphisms were assessed in genes involved in carcinogen metabolism, oxidative 
stress and DNA repair. Polymorphisms in catalase (CAT, rs1001179) and cytochrome 
P450 1B1 (CYP1B1, rs1800440) were significantly associated to DNA adduct levels, 
especially when combined. Moreover, RT-PCR analysis in a subset of 30 subjects 
revealed that expression of catalase correlated strongly with expression of CYP1B1 
(R=0.92, p<0.001). To further investigate the mechanism by which catalase influences 
CYP1B1 and how they simultaneously affect BPDE-DNA adduct levels, catalase 
expression was transiently knocked down in the human lung epithelial cell line A549. 
Although catalase knockdown did not immediately change CYP1B1 gene expression, 
recovery of catalase expression 8 hours after the knock-down, coincided with a 2.2-
fold increased expression of CYP1B1 (p<0.05). We conclude that the genetic 
polymorphism in the promoter region of catalase may determine the amount and 
activity of catalase, which may subsequently regulate the expression of CYP1B1. As a 
result, both genetic polymorphisms modulate DNA adduct levels in lymphocytes by 
BaP ex vivo. 
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Introduction 
 
Genetic stability is challenged by many factors, including exposure to genotoxic 
chemical compounds such as polycyclic aromatic hydrocarbons (PAHs). PAHs such as 
benzo(a)pyrene (BaP) are widely distributed environmental contaminants that are able 
to up-regulate a multitude of genes, including the cytochrome P450 isoforms CYP1A1 
and CYP1B1. These enzymes metabolize BaP to more soluble and excretable products, 
but at the same time activate certain metabolites into the highly reactive form BaP-
7,8-dihydrodiol-9,10-epoxide (BPDE) that is able to bind to DNA to form bulky DNA 
adducts. When unrepaired, DNA adducts can lead to mutations that initiate 
carcinogenesis. Therefore, bulky DNA adducts are markers for both exposure to 
genotoxic aromatic compounds and of the ability of the individual to metabolically 
activate carcinogens and to repair DNA damage (1). Nevertheless, individuals with 
similar exposures have highly different DNA adduct levels (2), which may in part be 
explained by genetic polymorphisms in genes involved in the process of DNA adduct 
formation and repair. These variations have been studied extensively and multiple 
genetic polymorphisms affecting BPDE-DNA adducts have been identified, including 
genes involved in metabolism; CYP1A1, GSTM1, GSTT1 (3-5), DNA repair; ERCC1, XPD 
(6), and oxidative stress (7).  
We previously showed that single genetic polymorphisms are unable to adequately 
account for the inter-individual variation, but rather by combinations of relevant 
genetic polymorphisms and the level of exposure (8). The level of exposure is often 
insufficiently characterized in large epidemiological studies that investigate the impact 
of genetic variation on DNA damage or disease, leading to misclassification and 
attenuation of underlying relationships. On the other hand, exposure can be well 
controlled in in vitro or ex vivo studies, offering the possibility to elucidate genotype-
phenotype relationships and gene-gene interactions more reliably. Interestingly, the 
level of BPDE-DNA adduct formation ex vivo in lymphocytes was related to lung cancer 
risks (9), further offering support for using ex vivo experiments to investigate sources 
of inter-individual variation in cancer susceptibility. Therefore, lymphocytes of healthy 
volunteers were incubated with 1µM BaP for 18 hours. We assessed 34 SNPs based on 
a priori knowledge (10) and determined which SNPs were responsible for differences in 
BPDE-DNA adduct levels. One SNP in catalase (CAT, rs1001179) and one in CYP1B1 
(rs1800440) had a significant impact on BPDE-DNA adduct formation and further 
experiments were performed to study genotype-phenotype relationships and gene-
gene interactions in lung epithelial cells (A549) in which catalase was transiently 
knocked down by siRNA. 
 
Materials and methods 
 
Study population 
The previously described study population consisted of 114 females and 54 males, 
aged 18–45 years (10). These healthy volunteers were recruited through 
advertisements in local newspapers and were non-smokers and did not use medication 
(except for oral contraceptives) or vitamin supplementation. Subjects were fully 
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informed about the details of the study and gave their written informed consent. The 
Medical Ethical Committee of Maastricht University and the Academic Hospital 
Maastricht approved the protocol.  
 
Table 5.1: List of SNPs, their position, amino acid change, and polymorphism frequencies. 
SNP Change SNP ID Frequencies wt/hz/v* 
CYP1A2*1F  rs762551 86 69 13 
GSTM1*0 Deletion  90 — 78 
GSTP1*2 I105V rs947894 61 85 22 
GSTP1*3 A114V rs1799811 140 28 0 
GSTT1*0 Deletion  139 — 29 
NAT2*5 I114T rs1801280 66 76 26 
NAT2*6 R197Q rs1799930 84 67 17 
NAT2*7 G286E rs1799931 161 7 0 
XRCC1*2 R194W rs1799782 147 20 1 
XRCC1*3 R280H rs25489 142 25 1 
XRCC1*4 Q399R rs25487 66 77 25 
XRCC3*1 T241M rs861539 71 71 26 
XPD*5 K751Q rs1052559 27 85 56 
XPD*6 R156 rs238406 35 85 48 
OGG1*2 S326C rs1052133 100 60 8 
BrCA2*1  rs1799943 102 55 11 
BrCA2*3 N372H rs144848 90 57 21 
GPX1*1 P198L rs1050450 71 80 17 
APEX1*1 D148E rs3136820 48 87 33 
mEH*2 Y113H rs1051740 79 77 12 
mEH*3 H139R rs2234922 105 55 8 
CAT*1  rs1001179 104 48 16 
MnSOD2*1 V16A rs1799725 46 81 41 
NQO1*2 R139W rs4986998 153 15 0 
NQO1*1 P187S rs1800566 95 67 6 
CYP1A1*2A  rs5030838 145 22 1 
CYP1A1*2C I462V rs1048943 159 8 1 
CYP1A1*4 T461N rs1799814 160 8 0 
CYP1B1*5 V432L rs1056836 55 83 30 
CYP1B1*7 N453S rs1800440 115 46 7 
CYP2E1*5  rs6413420 151 16 1 
CYP3A4*1B  rs2740574 154 12 2 
MPO  rs2333227 94 64 10 
COMT*1 V158M rs4680 41 84 43 
*wt = homozygous wild-type, hz = heterozygous, v = homozygous variant. The numbers reflect 
the numbers of subjects carrying that genotype; a hyphen indicates that the method was not 
able to distinguish between heterozygous or homozygous wild-type (in case of a deletion), 
therefore both of these polymorphisms were combined under wt. 
 
Collection and treatment of samples 
Venous blood samples were collected between 8 and 9 AM in 10 ml vacuum lithium 
heparin tubes (venoject II, Terumo-Europe, Leuren, Belgium). For isolation of 
lymphocytes, heparinized blood was 1:1 diluted with phosphate-buffered saline (PBS, 
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pH 7.4) and layered on Lymphoprep™ (Axis-shield, Oslo, Norway) in a leucosep tube 
(Greiner Bio-one, Frickenhausen, Germany). Lymphocytes were separated by 20 
minutes 860g centrifugation at room temperature and subsequently washed and 
treated with 25ʅM hydrogen peroxide for 1 hour at 37°C or 1µM BaP for 18 hours at 
37°C as described by Wilms et al (10). 
 
Comet assay 
Following incubation with hydrogen peroxide, cell suspensions were diluted 1:4 in 
0.5% low melting point agarose and added to microscope slides pre-coated with a 
layer of 1.5% normal melting-point agarose and put at 4°C for 45 minutes. Cells were 
lysed (0.25M NaOH, 0.1M EDTA, 0.01M Tris, 2.5M NaCl, 1% Triton X-100 and 10% 
DMSO, adjusted to pH 10) for 1 hour at 4°C, washed with PBS, placed in 
electrophoresis buffer (1mM EDTA, 300mM NaOH, pH 13) for 40 minutes for 
denaturation, and subsequently separated by electrophoresis for 30 minutes at 25V 
and 300mA. The slides were washed twice with PBS for 10 minutes and stained with 
ethidium bromide (10ʅg/ml) and visualized using a Zeiss Axioskop fluorescence 
microscope. 50 randomly selected nuclei were analyzed per slide using the Comet 
assay III software program (Perceptive Instruments, Havervill, UK). 
 
Genotyping 
DNA was isolated from lymphocytes by standard phenol extraction procedures. The 
Cancer SNP 500 database was used to obtain DNA sequences and allele frequencies 
(http://snp500cancer.nci.nih.gov) of 34 SNPs (Table 5.1). SNPs were analyzed using a 
multiplex polymerase chain reaction method developed by Knaapen et al. (11) and 
further refined by Ketelslegers et al. (8). 
 
32P-postlabeling of BPDE-DNA adducts  
DNA adduct levels were determined according to the nuclease P1 enrichment 
technique originally reported by Reddy and Randerath (12) with the modifications 
described by Godschalk et al (13). Three BPDE-DNA standards with known BPDE-DNA 
adduct levels were analyzed in parallel for quantification purposes. Adducts spots that 
chromatographed at the same position as the BPDE-DNA adducts standards were 
considered to be derived from BPDE, and were quantified using Phosphor-Imaging 
technology (Fujifilm FLA-3000, Rotterdam, The Netherlands). 
 
Cell culture and siRNA transfection 
The human epithelial lung carcinoma cell line A549 obtained from the American Tissue 
Culture Collection (ATCC, Rockville, MD, USA) were cultured in DMEM (Sigma, St. Louis, 
MO, USA), supplemented with 10% heat inactivated fetal calf serum (FCS, Invitrogen, 
Breda, The Netherlands) and 1% penicillin/streptomycin (Sigma), and maintained at 
37°C in a 5% CO2 atmosphere. Cells were seeded at 10% confluence one day before 
treatment in antibiotic free medium and maintained at 37°C in a 5% CO2 atmosphere. 
Cells were transfected with 10nM siGENOME SMARTpool siRNA specific for human 
catalase (Dharmacon, Lafayette, CO, USA) using DharmaFECT (Dharmacon). The 
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transfections were performed according to manufacturer’s instructions. After 24 
hours, the medium was removed and replaced with regular culture medium for a 
further 8 hours. 
 
Real-Time Quantitative PCR  
RNA for real-time quantitative PCR was isolated from lymphocytes or A549 cells by 
standard phenol extraction procedures. The RNA samples were spectrophotometrically 
quantified using Nanodrop 1000 (Thermo Scientific, Waltham, MA, USA). cDNA 
synthesis was performed using the iScript cDNA Synthesis kit (Biorad, Veenendaal, The 
Netherlands) starting with 1µg of RNA. The generated cDNA was diluted 25x in RNase 
free water. Real-time PCR was performed using the MyiQ Single Color RT-PCR 
detection system (Biorad) and Sensimix Sybr Green (Quantace, London, UK). 5µl 
diluted cDNA and 0.3µM primers (Table 5.2) in a total volume of 25µl were used. 
Samples were amplified under the following conditions: 95°C for 3 minutes, followed 
by 40 cycles of 95°C for 15 second and 60°C for 45 seconds. The PCR was checked for 
nonspecific products by performing a melting curve analysis (65°C-95°C). Data were 
analyzed using the MyiQ Software system (Biorad) and were expressed as relative gene 
expression (fold increase) using the 2ͲȴȴCt method. The stably expressed gene, ɴ-actin 
was included as reference. 
 
Table 5.2: Primer sequences for real time RT-PCR 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) 
Actin CCTGGCACCCAGCACAAT GCCGATCCACACGGAGTACT 
Catalase GACTGACCAGGGCATCAAAAA CGGATGCCATAGTCAGGATCTT 
CYP1B1 AGTGCAGGCAGAATTGGATCA GCGCATGGCTTCATAAAGGA 
NQO1 GGTGGAGTCGGACCTCTATGC CCTTCAGTTTACCTGTGATGTCCTT 
 
Statistical analysis 
Results are expressed as means ± standard error of the mean. SPSS was used for 
statistical analysis. BPDE-DNA adducts were not normally distributed and were 
therefore log-transformed before statistical analysis. To examine differences between 
the three groups of polymorphic genotypes (i.e. homozygous wildtype, heterozygotes 
and homozygous variant), a one-way analysis of variance test with Bonferroni post-hoc 
multiple comparison correction was used. Linear regression was used to assess 
relations. The two-way analysis of variance test with Bonferroni post-hoc multiple 
comparison correction was used to examine the effect of catalase knockdown. 
Differences were considered to be statistically significant when p<0.05. 
 
Results 
 
SNPs in CYP1B1 and catalase are linked to ex vivo BPDE-DNA adducts formation 
Of the 34 SNPs we obtained (Table 5.1); only two were related to BPDE-DNA adduct 
levels ex vivo. These were the polymorphisms in CYP1B1 (rs1800440) and catalase 
(rs1001179). Individuals carrying one or both variant allele of CYP1B1-N453S showed a 
statistically significant lower amount of BPDE-DNA adducts compared to individuals 
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that were homozygous for the wild-type allele (Figure 5.1A). Individuals carrying one or 
both variant alleles of CAT -262 C/T had higher levels of BPDE-DNA adducts compared 
to individuals that were homozygous for the wild-type allele (Figure 5.1B). Lowest 
BPDE-DNA adduct levels were observed in subjects that carried the combined 
homozygous CYP1B1 variant alleles and the homozygous wild type alleles for CAT. 
 
Figure 5.1: Modulation of ex vivo induced BPDE-DNA adduct levels by SNPs in catalase and 
CYP1B1. Lymphocytes of 166 volunteers were incubated with 1µM BaP for 18 hours and DNA 
adducts were measured using 32P-postlabeling. The effect of the A. CYP1B1-N453S 
polymorphism and the B. CAT -262 C/T polymorphism on BPDE-DNA adduct formation was 
determined. DNA adduct data were log transformed and presented as mean ± S.E. (n=167 
*p<0.05, **p<0.01) 
 
 
 
Figure 5.2: SNP in the promoter region of 
catalase affects CAT expression. The effect 
of the CAT -262 C/T polymorphism on 
catalase gene expression was determined in 
unexposed lymphocytes. Data are presented 
as fold increase compared to the C/C 
genotype. (n=30, 10 in each group, 
***p<0.001) 
Figure 5.3: CAT polymorphism reduces H2O2
induced single strand breaks. The effect of 
CAT -262 C/T polymorphism on catalase gene 
expression was determined in unexposed 
lymphocytes. Lymphocytes were incubated 
with 25µM H2O2 for 1 hour and single strand 
breaks were measured using the comet 
assay. Data are presented as mean ± S.E. 
(n=135 ***p<0.001) 
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Phenotypic effect of SNP in promoter region of CAT  
As the SNP in catalase was found in the promoter region, we sought to determine 
whether gene-expression would be affected. Therefore, mRNA levels were determined 
(Figure 5.2) in unexposed peripheral blood lymphocytes of 30 subjects selected on 
basis of their genotype (10 of each genotype). Individuals homozygous for the wild-
type allele of CAT (CC) had у1.9 fold lower catalase mRNA levels than individuals that 
were homozygous for the variant allele (p<0.001). To assess whether this increased 
expression of CAT also resulted in a concomitant increased catalase activity, the ability 
to prevent single strand breaks (SSB) induced by H2O2 was determined (Figure 5.3). To 
this end, lymphocytes were incubated with H2O2 and a comet assay was performed to 
measure SSB. Samples from individuals that were homozygous for the wild-type allele 
of CAT (CC) had у1.5 fold higher amount of SSB than samples from subjects carrying at 
least one T allele (p<0.001). This is consistent with the lower mRNA expression levels 
observed in lymphocytes of subjects carrying at least one T allele. 
 
Figure 5.4: Expression of 
catalase correlates strongly 
with expression of CYP1B1. 
mRNA levels of catalase and 
CYP1B1 were measured in 
unexposed lymphocytes n=30 
(circle) and A549 cells n=9 
(triangle). Data are presented as 
Ct value difference between CAT 
and the housekeeping gene. 
Regression line shown belongs 
to gene expression of 
lymphocytes, but also fits the 
results in A549 cells. 
 
 
 
Expression of catalase strongly correlated with expression of CYP1B1 
To further define how catalase expression effects BPDE-DNA adduct levels, catalase 
mRNA levels were correlated with the expression of CYP1B1 and a strong significant 
correlation was observed (p<0.001, R = 0.92, Figure 5.4). The genetic polymorphism in 
CAT, which regulates the level of gene expression of CAT, thus seems to co-regulate 
the expression of CYP1B1 in human lymphocytes. Indeed, the expression of CYP1B1 
was approximately 2-fold higher in carriers of the CAT TT-genotype than in the CC-
genotype subjects, but this did not reach statistical significance (p=0.08). 
 
In vitro modulation of catalase expression alters CYP1B1 mRNA levels  
To further investigate the mechanism by which catalase affects CYP1B1 gene 
expression, A549 lung epithelial cell line was used to investigate the effect of changing 
catalase gene expression on CYP1B1. A similar statistically significant correlation in the 
expression of catalase and CYP1B1 was observed in unexposed cells (p<0.001, R=0.96, 
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Figure 5.4). From the ex vivo observation, we hypothesized that knocking down the 
expression of catalase, would also down regulate the expression of CYP1B1. After 
knock down of catalase expression, only 15% of the catalase mRNA remained following 
24 hours of siRNA treatment (Figure 5.4). The expected simultaneous down regulation 
of CYP1B1 gene expression was not observed. On the other hand, the removal of the 
siRNA resulted in the recovery of CAT expression which coincided with a 2.2 fold 
upregulation of CYP1B1 expression (p<0.001). 
Down regulation of catalase is expected to increase intracellular oxidative stress, the 
resulting activation of the Nrf2 pathway may be a potential explanation for the initial 
lack of response in CYP1B1 expression since CYP1B1 is known to be modulated by Nrf2 
(14). Therefore, gene expression of the reporter gene NADPH quinine oxidoreductase 
(NQO1), which is regulated via the Nrf2 pathway, was determined and interestingly, a 
significant upregulation of NQO1 (у1.4 fold) was observed during catalase knock down. 
This suggests that an activation of the Nrf2 pathway prevents CYP1B1 to be 
downregulated in parallel with catalase after its knock down. On the other hand, the 
subsequent removal of the siRNA and resultant restoration of catalase expression 
coincided with an upregulation of CYP1B1 expression. These in vitro studies confirm 
that catalase may affect CYP1B1 gene expression. 
 
Figure 5.5: CYP1B1 mRNA levels are 
increased upon recovery of catalase 
mRNA levels 8 hours after a 
transient knock down. mRNA levels 
of catalase, CYP1B1 and NQO1 in 
A549 were measured after no 
treatment (white), 24 hours of 
catalase siRNA (striped), or 24 hours 
of catalase siRNA followed by 8 hours 
recovery without siRNA (black). Data 
are presented as mean ± S.E. fold 
increase compared to no treatment. 
(n=3 for each bar, *p<0.001) 
 
Discussion 
 
PAHs such as BaP are carcinogens that humans are unknowingly and/or unavoidably 
exposed to on a daily basis. The ability of an individual to cope with these carcinogens, 
determines the risk of developing cancer. This intrinsic risk varies within the 
population and genetic polymorphisms in genes such as those involved in BaP 
metabolism may be a source of this disparity. To this end, previous studies showed 
that certain genetic polymorphisms are related to an increase in adduct formation 
(3,15). However, phenotypic effects of certain genetic polymorphisms are difficult to 
assess in epidemiological studies, because exposure misclassification attenuates 
underlying relationships. Therefore, we exposed cells to a single compound to further 
elucidate genotype-phenotype relationships and report that genetic polymorphisms in 
catalase and CYP1B1 interact in determining the levels of BPDE-DNA adducts ex vivo.  
Chapter 5 
 
 88
Of the 34 polymorphisms investigated, only two resulted in a difference in BPDE-DNA 
adduct formation. The CYP1B1-N453S polymorphism has previously been linked to 
altered cancer risks and aggressiveness of hormone dependent cancers (16,17), most 
likely by influencing estrogen metabolism. Interestingly, estrogen metabolism shows 
large overlap with the metabolism of PAH, such as BaP. CYP1B1 is also capable of 
metabolizing BaP to its reactive metabolites. This metabolic activation is usually 
ascribed to CYP1A1, but the expression of CYP1A1 is minimal in lymphocytes. In our 
sample population, expression of CYP1A1 was more than 18-fold lower than the 
expression of CYP1B1 (data not shown). The CYP1B1-N453S variant alleles appear to be 
protective since individuals carrying one or two variant alleles had lower levels of 
BPDE-DNA adducts after ex vivo exposure to BaP (Figure 5.1). 
The other polymorphism that influenced BPDE-DNA adduct formation in our 
population was catalase C-262T in the promoter region (rs1001179). Catalase reduces 
oxidative stress by catalyzing the conversion of H2O2 into water and oxygen. The 
location of this polymorphism in the promoter suggests that it is involved in the 
regulation of catalase gene expression. Therefore, we measured catalase mRNA levels 
in lymphocytes from individuals carrying different alleles. The subjects carrying the 
variant allele had higher expression of CAT compared to subjects with the wild-type 
allele. This finding is in concordance with Forsberg et al who showed that the C/T 
polymorphism, in the promoter region of the CAT gene induced the transcriptional 
activity of the promoter (18). The induced catalase gene expression also coincide with 
induced activity of catalase in subjects carrying at least one T-allele, since they had 
lower levels of SSB breaks induced by H2O2.  
The observation that the expression of CYP1B1 was approximately 2-fold higher in 
carriers of the CAT TT-genotype than in the CC-genotype subjects and because a strong 
correlation was observed between the expression of CAT and the expression of 
CYP1B1, led to the hypothesis that the genetic polymorphism in CAT would affect DNA 
adduct formation induced by BaP via its effect on CYP1B1 expression. Previous studies 
in hepatoma cells have shown that oxidative stress decreased the expression of 
CYP1A1, which like CYP1B1, is a member of the CYP1 family (19-21). This oxidative 
stress-mediated repression was mediated by a nuclear factor 1 (NF1) binding to the 
promoter region of these CYPs (20). The expression of CYP1A1 and CYP1B1 is activated 
by binding of a ligand, such as BaP, to the aryl hydrocarbon receptor (AhR). Upon 
ligand binding, AhR translocates into the nucleus and dimerizes with the aryl 
hydrocarbon receptor nuclear translocator (ARNT), which can bind to the TNGCGTG 
consensus sequence in the xenobiotic- responsive elements of target genes (22). This 
AhR-ARNT complex synergizes with other transcription factors including NF1 thereby 
activating gene expression, suggesting that high levels of H2O2 could result in reduced 
transcription of CYP1B1. We indeed found a strong correlation between catalase 
expression and CYP1B1 expression (R > 0.92) in lymphocytes and A549 cells. Thus, we 
hypothesized that the SNP in catalase determines the amount of CYP1B1 and the SNP 
in CYP1B1 subsequently determines the activity of the enzyme.  
To further study the combined effect of CAT and CYP1B1 polymorphisms on BPDE-DNA 
adduct formation; we transiently knocked down catalase by siRNA. Indeed, the 
recovery of CAT expression after removal of the siRNA coincided with increasing levels 
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of CYP1B1 mRNA levels. However, the effective knock down of catalase expression to 
less than 15% of the original level, did not result in the expected decrease of CYP1B1 
gene expression. This suggests that under circumstances of oxidative stress, other 
mechanisms are capable of keeping CYP1B1 gene expression intact. A likely candidate 
was the nuclear erythroid 2-related factor 2 (Nrf2), which when activated, significantly 
induced AhR, CYP1A1 and CYP1B1 transcription in mouse embryonic fibroblasts (14). In 
response to oxidative stress, Nfr2 is activated and upregulates antioxidant and 
detoxifying genes, including NAD(P)H dehydrogenase quinone 1 (NQO1) (23). In our 
study, the increase in NQO1 mRNA levels suggests that the knock down of catalase is 
indeed related to increased oxidative stress levels and activation of Nfr2. The opposing 
effects of both NF1 and Nfr2 eventually resulted in an initial unchanged CYP1B1 gene 
expression. However, when catalase mRNA levels started to increase after removal of 
the siRNA, oxidative stress quickly decreased and the Nfr2 was deactivated (since 
NQO1 expression went back to baseline levels). We speculate that as a result of the 
restored expression of catalase, CYP1B1 expression further increased and was over-
compensated (>2 fold increased expression). Our in vitro studies confirm that catalase 
affects CYP1B1 gene expression. 
We propose a model in which the genetic polymorphism in the promotor region of CAT 
-262 C/T determines the amount of intracellular oxidative stress, which co-regulates 
the expression of CYP1B1 by reducing the amount of H2O2 present in the cells. This 
would inactivate or activate relevant transcription factors (NF1 and Nrf2, respectively). 
The genetic polymorphisms in CYP1B1 subsequently modulates BaP metabolism ex 
vivo in lymphocytes. Thus, the SNP in CAT determines the amount of CYP1B1, whereas 
the SNP in CYP1B1 determines its activity. These ex vivo data indicate that inter-
individual variations in DNA adduct levels depend on gene-gene interactions, which 
need further attention for application in in vivo studies. Understanding gene-gene 
interactions allows the identification of relevant combinations of SNP’s to assess an 
individual’s cancer susceptibility.  
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Abstract 
 
Chronic inflammation is characterized by the influx of neutrophils and is associated 
with an increased production of reactive oxygen species that can damage DNA. 
Oxidative DNA damage is generally thought to be involved in the increased risk of 
cancer in inflamed tissues. We previously demonstrated that activated neutrophil 
mediated oxidative stress results in a reduction in nucleotide excision repair (NER) 
capacity, which could further enhance mutagenesis. Inflammation and oxidative stress 
are critical factors in the progression of nonalcoholic fatty liver disease that is linked 
with enhanced liver cancer risk. In this report, we therefore evaluated the role of 
neutrophils and the associated oxidative stress in damage recognition and DNA repair 
in steatotic livers of 35 severely obese subjects with either nonalcoholic 
steatohepatitis (NASH) (n = 17) or steatosis alone (n = 18). The neutrophilic influx in 
liver was assessed by myeloperoxidase (MPO) staining and the amount of oxidative 
DNA damage by measuring M1dG adducts. No differences in M1dG adduct levels were 
observed between patients with or without NASH and also not between individuals 
with high or low MPO immunoreactivity. However, we found that high expression of 
MPO in the liver, irrespective of disease status, reduced the damage recognition 
capacity as determined by staining for histone 2AX phosphorylation (ɶH2AX). This 
reduction in ɶH2AX formation in individuals with high MPO immunoreactivity was 
paralleled by a significant decrease in NER capacity as assessed by a functional repair 
assay, and was not related to cell proliferation. Thus, the observed reduction in NER 
capacity upon hepatic inflammation is associated with and may be a consequence of 
reduced damage recognition. These findings suggest a novel mechanism of liver cancer 
development in patients with nonalcoholic fatty liver disease. 
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Introduction 
 
Hepatic inflammation plays a fundamental role in liver cancer development (1) and is 
increasingly observed in parallel with the high prevalence of nonalcoholic fatty liver 
disease (NAFLD). NAFLD is characterized by the accumulation of fat within the liver. 
Increased levels of hepatic free fatty acids are thought to initiate an inflammatory 
response culminating in the recruitment of neutrophils and other leukocytes (2,3) and 
eventually in the progression of the benign steatotic stage of NAFLD to the more 
advanced stages of nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis (4,5). 
Importantly, there is a link between NASH and the development of hepatocellular 
carcinoma (HCC), which accounts for more than 80% of primary liver cancer cases (6). 
Several groups have suggested that HCC could in fact be the end-point of NASH (7,8). 
Although the mechanisms by which NASH can lead to the development of HCC are not 
fully understood, it is known that development of HCC occurs in a significant 
proportion of people with cirrhosis (6). Oxidative stress caused by reactive oxygen 
species (ROS) is an important characteristic of cancer development (9). Furthermore, 
many animal studies have revealed a link between oxidative stress and increased 
hepatocarcinogenesis by inducing (10) and promoting tumors (11) and causing DNA 
damage (12). 
Inflammation occurs when pro-inflammatory cytokines and chemokines at a site of 
injury or infection release chemical signals causing an influx of inflammatory cells 
including neutrophils, monocytes, and eosinophils. The influx of some of these cells 
results in prolonged production of ROS such as nitric oxide, superoxide, hydrogen 
peroxide (H2O2) (13), and in the release of myeloperoxidase (MPO). ROS accumulation 
results in various forms of DNA damage via oxidation, nitration, depurination, or 
deamination. In addition, it leads to DNA strand breaks and sister chromatid 
exchanges, all of which can lead to increased mutagenesis and carcinogenesis (14). 
MPO is an important enzyme abundantly present in neutrophils and involved in the 
catalysis of H2O2 to hypochlorous acid (HOCl) (15). HOCl contributes to host tissue 
damage at sites of inflammation through reactions with a wide range of biological 
substrates (16). It damages proteins by causing side-chain modification, backbone 
fragmentation, and cross-linking (17). Furthermore, Spencer et al. showed that HOCl is 
involved in DNA damage in epithelial cells by oxidizing pyrimidine bases and 
chlorination of cytosine (18). Interestingly, we previously showed that NASH is 
associated with increased MPO activity (19). 
Recently we have also demonstrated that MPO-derived HOCl mediates the strong 
inhibition of nucleotide excision repair (NER) capacity in A549 lung cancer cells by 
activated neutrophils (20). We confirmed that acute lung inflammation caused a у50% 
reduction in NER capacity due to down-regulation of the NER associated genes XPA 
and ERCC4 in mice. However, Mpo-deficient mice were shown to also have a reduction 
in NER capacity, suggesting that the suppression of NER in vivo was not dependent on 
MPO release, but rather due to ROS following the influx of neutrophils (21). Previous 
studies within our group have also indicated a role for oxidative stress in reduction of 
NER in colon tissue of newborn piglets, which could be reversed by administration of 
antioxidants (22). This suggests that release of MPO is not the major cause of 
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decreased NER capacity, but it still plays a role in increasing the risk of cancer in 
inflammation related diseases. Furthermore, reduced expression of NER related genes, 
such as ERCC1, has been linked to development of lung cancer (23). NER-deficient 
individuals are at a significantly higher risk of developing certain forms of cancer, 
including those associated with chronic inflammation (23,24), as there is no ‘back-up’ 
pathway for NER malfunction (25). 
The mechanisms, by which inflammation and the subsequent influx of neutrophils can 
cause the inhibition of NER, and how this increases the risk of cancer, are not yet 
elucidated. Potential mechanisms include a failure to recognise the damage; 
downregulation of NER related genes, or inhibition of the repair related proteins. Large 
amounts of ROS are produced during inflammatory NAFLDs such as NASH that put 
patients at a higher risk of developing HCC, which could be the result of lower NER 
capacity. In this report, we demonstrate that there is a decrease in damage recognition 
in subjects with NAFLD and high MPO expression, which correlates with a decrease in 
NER capacity. 
 
Materials and Methods 
 
Liver Specimens 
Human liver specimens were obtained during bariatric surgery from 35 severely obese 
patients (body mass index >40). None of the patients had suffered from viral hepatitis 
or autoimmune-related disorders or reported excessive alcohol consumption (>20 
g/day). Biopsies were fixed in formaline stained and analyzed to differentiate liver 
samples in <33% steatosis without inflammation (steatosis group) and NASH as 
previously described (19). As we have previously shown that there is a clear relation 
between extracellular MPO activity and neutrophil influx in inflamed tissues (26), MPO 
in the liver was detected by immunohistochemical staining and was used as a measure 
for MPO activity. Patient characteristics are summarized in Table 6.1. This study was 
approved by the Medical Ethical Board of the Maastricht University Medical Centre in 
line with the ethical guidelines of the 2008 Declaration of Seoul, and informed consent 
in writing was obtained from each subject. 
 
Table 6.1: Clinical characteristics of patients studied 
 Low MPO  High MPO  
 Steatosis NASH Steatosis NASH 
No. of patients 9 8 9 9 
Sex (female/male) 5/4 3/5 7/2 9/0 
Age (years) 48±3.5 41±3.8 45±2.4 52±2.5 
BMI (kg/m2) 44±2.4 51±3.0 44±2.8 56±4.3 
Fasting glucose (mmol/L) 6.3±0.4 5.6±0.1 5.7±0.2 8.3±0.4 
ALT (IU) 26.0±6.5 21.1±3.2 23.7±3.0 25.7±3.3 
AST (IU) 22.8±3.8 26.6±4.2 8.2±2.3 27.2±3.8 
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Quantitative Real-Time PCR  
Total RNA was isolated from 50mg liver tissue by homogenization in Tri-reagent 
(Sigma), according to the manufacturer’s instructions. RNA (750ng) was converted to 
cDNA using the iScript cDNA synthesis kit (Bio-Rad). Quantitative real-time PCR was 
performed with the Sensimix Sybr Green (Quantace, London, UK) and the MyiQ Single 
Color RT-PCR detection system (Biorad). The MyiQ Software system (Biorad) was used 
for data analysis. Using the 2ͲѐѐCt method, relative gene expression (fold increase) was 
calculated. All data were normalized to the housekeeping genes ɴ-actin and cyclophilin 
A. Sequences of the used PCR primers are listed in table 6.2. 
 
Table 6.2: Primer sequences for real time RT-PCR 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) 
ɴ-actin CCTGGCACCCAGCACAAT GCCGATCCACACGGAGTACT 
Cyclophilin A TTCCTGCTTTCACAGAATTATTCC GCCACCAGTGCCATTATGG 
XPA CCGACAGGAAAACCGAGAAA TTCCACACGCTGCTTCTTACTG 
XPC CCCAGCCCGCTTTACCA TGCATTAACTGTAAATGTTCCAATGA 
ERCC4 CACCTCCCTCGCCGTGTA CGCAAATATAACACCACCTTGTG 
ERCC5 GCATGAAATCTTGACTGATATGAAAGA TAAGCAAGCCTTTGAGTTGGTACTG 
ERCC1 ACCCCTCGACGAGGATGAG CAGTGGGAAGGCTCTGTGTAGA 
 
Quantification of M1dG  
After removal of the aqueous phase during RNA isolation using Trizol (Invitrogen), the 
remaining phases were used for DNA isolation according to the manufacturer's 
protocol. DNA was resuspended in 100ʅL H2O. The quantity and quality of DNA was 
measured using the Nanodrop 1000 (Thermo Scientific). The 32P-postlabelling 
technique was used to analyze the levels of 3-(2-Deoxy-ɴ-D-erythro-
pentofuranosyl)pyrimido [1,2-ɲ]purin-10(3H)-one (M1dG) adducts, as previously 
reported (27). M1dG adduct separation was carried out by PEI-cellulose TLC 
chromatography according to published conditions (28). Detection and quantification 
of M1dG adducts and total nucleotides were obtained by phosphor imaging technology 
(Typhoon 9210, Amersham) and ImageQuant software (Molecular Dynamics, 
Sunnyvale, CA). After background subtraction, the levels of DNA adducts were 
expressed as relative adduct labelling (RAL = adducted nucleotides/total nucleotides). 
Standard MDA modified (29) and unmodified DNA were routinely processed in the 
analysis as controls. 
 
Immunohistochemistry 
MPO abundance was detected by immunohistochemical staining using polyclonal 
rabbit anti-human MPO antiserum (dilution 1:1000; Dako) as a primary antibody and 
semi-quantitative evaluation of MPO positive cells was performed on a four-point scale 
by two independent observers (19). In the present study we used the patients with 
hardly any MPO positive cells (category 1) versus those who contain a large amount of 
MPO positive cells in their liver (category 4). For the ɶH2AX and Ki-67 staining, paraffin 
embedded tissue sections were deparaffinized and rehydrated 3 times for 10 minutes 
in xylol, twice for 5 minutes in 100% EtOH, twice for 5 minutes in 96% EtOH, 5 minutes 
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in 70% EtOH and 5 minutes in PBS. Slides were heated 3 times for 5 minutes in 0.01M 
citrate buffer (pH 6.0) followed by treatment with 2% H2O2 in methanol for 30 minutes 
at room temperature. Nonspecific binding was blocked with 3% BSA/PBS for 30 
minutes at room temperature and slides were subsequently incubated for 1 hour at 
room temperature with a 1:1000 dilution of the primary antibody, mouse anti-ɶH2AX 
JBW301 (Upstate, Billerica, MA) or mouse anti-human Ki-67 (Dako). The secondary 
antibody, biotinylated Rabbit anti Mouse P0161 (Dako) was diluted in 1% BSA/PBS for 
1 hour at 37°C followed by BrightVision+ (Immunologic, the Netherlands) according to 
the manufacturer’s instructions. Slides were incubated with DAB (0.7mg/ml) and urea 
(2mg/ml) for 7 minutes and counterstained with haematoxylin for 1 minute. Slides 
were dehydrated for 5 minutes in 70% EtOH after washing with tap water, twice for 5 
minutes in 96% EtOH, twice for 5 minutes in 100% EtOH and twice for 10 minutes in 
xylol. Finally the slides were mounted in Entellan (Merck). At least 100 randomly 
selected cells per slide were microscopically scored blindly. For the ɶH2AX staining, 
cells were graded on a gradual scale in which 0 was considered no staining (only 
counterstaining visible) and 4 was considered highly positive in which over 80% of the 
nucleus was brown. For the Ki-67 staining, the percentage of positive cells (brown 
nucleus) was determined.  
 
Measurement of NER capacity 
To measure NER capacity in the liver samples, we applied a previously validated 
modified comet assay (30) which measures the ability of NER-related enzymes that are 
present in the “test” extracts, to incise substrate DNA containing BPDE-DNA adducts. 
The substrate nucleoids were prepared from untreated A549 cells (human epithelial 
lung carcinoma cells) obtained from the American Tissue Culture Collection (ATCC, 
Rockville, MD). The cells were cultured in DMEM supplemented with 10% heat-
inactivated FCS and 1% penicillin/streptomycin and maintained at 37°C in a 5% CO2 
atmosphere. A549 cells were embedded in LMP agarose on glass microscope slides 
and subsequently lysed overnight in cold (4°C) lysis buffer (2.5M NaCl, 0.1M EDTA, 
0.01M Tris, 0.25M NaOH plus 1% Triton X-100 and 10% DMSO). The resulting nucleoids 
were then either exposed to 1µM BPDE (NCI Chemical Carcinogen Reference Standard 
Repository, Midwest Research Institute, Kansas City, MO) in PBS or vehicle control 
(DMSO, 0.5%) for 30 minutes at 4°C. To prepare protein/enzyme extracts, ground 
frozen liver tissues were thawed and resuspended in 45mM HEPES, 0.4M KCl, 1mM 
EDTA, 0.1mM dithiothreitol, 10% glycerol, adjusted to pH 7.8 using KOH. Resulting 
aliquots were snap-frozen, thawed again and 30ʅl of 1% Triton X-100 in buffer A per 
100ʅl of extract was added. Protein concentrations were determined by the BioRAD 
DC protein assay using bovine serum albumin as a standard. Tissue extracts were 
diluted to a concentration of 1mg/ml. Next, 4 volumes of 45mM HEPES, 0.25mM EDTA, 
2% glycerol, 0.3mg/ml BSA, adjusted to pH 7.8 with KOH were added and 50ʅl of the 
mixture was added to the gel-embedded nucleoids and incubated for 20 minutes at 
37°C. Alkaline treatment (40 minutes) and electrophoresis (30 minutes) were 
conducted as in the standard comet assay (31). Comets were visualized using a Zeiss 
Axioskop fluorescence microscope and quantified as tail moment and percentage DNA 
in tail (tail intensity). Samples were tested in two independent incubations within each 
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single experiment. On every slide, 50 cells were analyzed randomly using the Comet 
assay III software program (Perspective Instruments, Haverhill, UK). The increased DNA 
strand breakage in the BPDE-modified nucleoids vs. the DMSO-treated nucleoids is 
indicative of the NER capacity of the cell extracts. The final repair capacity was 
calculated according to the method previously described (30) using both tail moment 
as well tail intensity. 
 
Statistical Analysis 
Results are expressed as means ± S.E. SPSS 15.0 was used for statistical analysis. The 
two-way ANOVA was used to determine the influence of MPO and NASH. To assess 
differences between four groups, a one-way analysis of variance test with Dunnet’s 
post-hoc multiple comparison correction was used. Differences were considered to be 
statistically significant when p<0.05. 
 
Results 
 
Inflammation in steatotic livers did not increase M1dG adduct levels 
To characterize the effect of NASH and/or MPO abundance, on the amount of ROS-
induced DNA damage in the liver and M1dG adduct levels were determined. We were 
able to isolate DNA from 22 patients with steatosis. MPO expression in the liver tissue 
was determined and patients were divided into groups of low versus high MPO staining 
or steatosis alone versus NASH. There were no differences between the four groups 
regarding M1dG adduct levels (Figure 6.1). This suggests that inflammation, as 
determined by the presence of MPO had no effect on hepatic DNA damage in NAFLD. 
 
Figure 6.1: Inflammation has no 
effect on M1dG DNA adduct levels. 
M1dG DNA adducts levels in human 
livers with low MPO levels and 
steatosis (n=6) or NASH (n=6) and 
high MPO levels and steatosis (n=6) 
or NASH (n=4) were determined by 
32P-postlabeling and data was 
presented as amount of M1dG 
adducts per 108 nucleotides. Values 
are mean ± S.E. 
 
 
 
 
Decreased phosphorylated H2AX under high MPO expression in the liver 
Next, we stained for histone 2AX phosphorylation (ɶH2AX). Of 18 patients we were 
able to obtain liver samples for staining. Patients without NASH and low MPO 
expression had the highest ɶH2AX levels. A у52% decrease in semi-quantitative ɶH2AX 
levels was observed in the liver samples of patients with NASH and low MPO 
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expression. Patients with high MPO expression had a further decrease towards у26% 
and у28%, of the semi-quantitative ɶH2AX levels observed in patients with steatosis 
and NASH, respectively (Figure 6.2). The patients with high MPO immunoreactivity 
showed a statistically significant decrease of у59% compared to the patients with low 
MPO staining, while patients with NASH had у19% lower semi-quantitative ɶH2AX 
levels compared to patients without NASH. 
Figure 6.2: ɶH2AX is decreased under inflammatory conditions. Phosphorylation of H2AX in 
human livers with low MPO levels and steatosis (n=3) or NASH (n=6) and high MPO levels and 
steatosis (n=6) or NASH (n=3) was microscopically evaluated. A: Data is presented as fold 
increase compared to patients with low MPO levels without NASH. Values are mean ± S.E. **p < 
0.01. B: Representative images within the four groups for ɶH2AX staining (magnification 400x) 
were equally post-microscopically enhanced to increase contrast for the brown ɶH2AX staining. 
 
Proliferation is unaltered in steatotic livers upon inflammation 
One possible explanation for the differences found in phosphorylation of H2AX is 
changes in proliferation of cells. Ki-67 staining of the same liver samples stained for 
ɶH2AX showed no difference between the four groups (Figure 6.3). This suggests that 
the differences found for the ɶH2AX staining were unlikely to be the direct result of 
differences in proliferation status. 
 
Figure 6.3: No changes in proliferation 
under inflammatory conditions. 
Human liver samples of patients with 
low MPO levels and steatosis (n=3) or 
NASH (n=6) and high MPO levels and 
steatosis (n=6) or NASH (n=3) were 
stained for Ki-67 and percentage of 
proliferating cells was determined. 
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Decreased NER gene expression in the liver of patients with high MPO 
immunoreactivity 
To investigate potential differences in DNA repair gene expression, the effect of MPO 
and NASH on the mRNA levels of 5 NER genes (XPA, XPC, ERCC4, ERCC5, and ERCC1) 
was determined (Table 6.3). Of 32 patients, mRNA levels could be determined. For 
both XPA and ERCC4 gene expression, the highest mRNA levels were found in patients 
with low MPO staining without NASH. The relative amount of mRNA of these NER 
related genes decreased in patients with NASH and high MPO immunoreactivity; 
however the differences between the groups were only statistically significant for 
ERCC4. Patients with low MPO immunoreactivity were observed to have generally 
higher NER gene expression compared to patients with high MPO immunoreactivity. 
ERCC4 mRNA relative expression levels were significantly lower with у17%. Patients 
with NASH also displayed a lower gene expression compared to patients without 
NASH. However, the difference in ERCC4 mRNA levels was not as large as compared to 
the differences in expression related to MPO. 
 
Table 6.3: Relative NER gene expression in human livers 
  XPA XPC ERCC4 ERCC5 ERCC1 
Low MPO Steatosis 1.00±0.10 1.00±0.09 1.00±0.05 1.00±0.06 1.00±0.08 
NASH 0.84±0.06 1.05±0.07 0.91±0.09 1.24±0.08 1.14±0.09 
High MPO Steatosis 0.80±0.05 0.93±0.07 0.88±0.06 1.11±0.06 1.15±0.11 
NASH 0.81±0.07 0.84±0.10 0.73±0.05* 0.84±0.09 0.91±0.12 
Data are presented as mean ± SE. Differences between low MPO levels and steatosis (n=8) or 
NASH (n=8) and high MPO levels and steatosis (n=7) or NASH (n=9) were determined.*p < 0.05. 
 
Decreased NER activity correlates with high MPO in the liver 
To investigate if the decreased ɶH2AX levels in patients with high MPO staining 
translated into a reduced functional NER capacity, we next studied NER capacity using 
a modified comet assay. NER capacity could be measured in liver samples isolated 
from 33 patients. Patients with low MPO expression without NASH had the highest 
repair capacity. A у26% and у30% lower repair capacity was observed in the liver of 
patients with low MPO immunoreactivity and NASH, when using tail moment and tail 
intensity values, respectively. The repair capacity further decreased in patients with 
high MPO expression to only у58% of the repair capacity of patients without NASH and 
low MPO staining (Figure 6.4). The group with high MPO immunoreactivity showed a 
statistically significant decrease of у33% (p=0.02) and у30% (p=0.05) compared to the 
patients with low MPO expression, when using tail moment and tail intensity values, 
respectively. On the other hand, patients with NASH had a у14% (p=0.31) and у20% 
(p=0.20) lower repair capacity compared to patients without NASH (irrespective of 
MPO abundance), when using tail moment and tail intensity values, respectively. This 
difference was not statistically significant, suggesting that the presence of high levels 
of MPO-immunoreactive cells had the largest contribution to the observed lower levels 
of DNA repair.  
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Figure 6.4: NER capacity is decreased under inflammatory conditions. Repair capacity (A: 
calculated by using tail moment. B: calculated by using tail intensity) of cell extracts isolated 
from human livers was measured and differences between low MPO levels and steatosis (n=8) 
or NASH (n=8) and high MPO levels and steatosis (n=9) or NASH (n=8) were determined. Values 
are mean ± S.E.*p < 0.05. 
 
Discussion 
 
Chronic inflammation has been shown to play a role in the development of cancer in 
various organs, in part due to the recruitment of neutrophils at the site of 
inflammation resulting in enhanced levels of oxidative stress (14,32). This oxidative 
stress may result in more DNA damage, a subsequent induction of mutation prone 
cells and ultimately increase in development in HCC (7,8,33-35). Indeed, we have 
previously shown that NER activity was significantly impaired by neutrophil activation 
in lung cells (20). There is circumstantial evidence that individuals with a reduced NER 
pathway capacity are at greater risk to develop cancer (23,24). Therefore, we proposed 
that NER inhibition upon neutrophil activation and accumulation of mutations over 
time due to oxidative stress may play a role in the development of hepatocellular 
carcinomas associated with NASH.  
To determine the amount of ROS induced DNA damage, M1dG adducts, a marker for 
oxidative damage, were measured. NER is the primary pathway that removes the 
damage caused by DNA helix distorting lesions, including M1dG adducts (36,37). When 
DNA damage is not effectively removed, these lesions can be highly mutagenic 
(25,38,39). In general, increased oxidative stress is seen as a trigger for the 
development of NASH from steatosis. However, several studies have observed similarly 
elevated levels of oxidative stress in steatosis and NASH (40-42). Indeed, in this study, 
no significant differences in M1dG adduct levels were observed in relation to the 
presence of NASH neither to the inflammation as determined by MPO expression.  
The phosphorylation of histone H2AX by the PI-3 kinases ATM, ATR and DNA-PK, is a 
well described marker for DNA damage. This occurs rapidly in response to double 
strand breaks (DSBs) (43), V(D)J recombination (44), replication fork blockage (45) and 
NER dependent DNA damage (46). In liver cells, the observation of ɶH2AX is not likely 
linked to somatic recombination events. We therefore suggest that the reduced ɶH2AX 
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is related to impairment of the recognition of DNA damage rather than absolute 
amount of damage, as the tissues showed similar DNA damage levels as inferred from 
the M1dG adducts (Figure 6.1). Furthermore, ɶH2AX is also observed in S phase cells 
most likely due to DSBs or endogenous damage leading to stalled replication forks (47). 
To determine whether the decrease in ɶH2AX that we observed with increased MPO 
(Figure 6.2) resulted simply from changes in proliferation rate, we stained for Ki-67. As 
all groups showed similar levels of Ki-67 staining (Figure 6.3), proliferation rates are 
unlikely to be the source of the differences in ɶH2AX staining. 
To investigate whether MPO immunoreactivity in the liver or the NASH phenotype 
altered NER gene expression, the mRNA levels of XPA, XPC, ERCC1, ERCC4 and ERCC5, 
were determined. There was a consistent trend that repair genes were decreased in 
patients with high MPO immunoreactivity, but only ERCC4 showed significantly lower 
levels of expression in combination with conditions of high MPO expression. This is in 
agreement with previous studies on the regulation of NER genes in response to 
inflammation, where ERCC4 was down regulated in the presence of high MPO levels 
(21). 
As DNA repair is often regulated in multiple manners in addition to transcriptional 
control, we sought to determine whether either NASH and/or higher MPO 
immunoreactivity impair overall functional NER. To this end, we used a previously 
validated modified comet assay, which predominantly assesses the cellular capacity in 
the recognition and incision phase of NER to remove bulky DNA adducts (30) and used 
both tail moment and tail intensity to assess repair capacity. Steatotic liver samples 
with higher MPO expression had a significant decrease in the activity of this part of the 
NER pathway compared to the livers with lower expression of MPO using both the tail 
moment and tail intensity. Although the repair capacity was further reduced in the 
liver samples taken from NASH patients, the contribution of MPO appears to 
dominate. A small decrease in NER capacity was also observed in patients with NASH 
compared with subjects with steatosis alone; however this was not statistically 
significant. These results suggest that in human liver samples, NER is inhibited by 
increased MPO in vivo, similar to what we have previously described for lung cells in 
vitro (20). The level of DNA adducts is the result of a balance between damage 
induction and its repair. Therefore, one would expect that the lower NER activity in 
patients with high MPO is accompanied by higher levels of the M1dG adducts. 
However, in this study we observed comparable levels between the four groups. 
Human data of both in vivo and in vitro models have demonstrated that cell death, 
particularly apoptosis, is increased in NAFLD and NASH patients (48). If DNA repair is 
decreased in these patients as observed in our study, cell death of highly damaged 
cells could prevent DNA adduct levels to accumulate.  
In this study, we have demonstrated that increased expression of MPO in the liver 
correlates with decreased NER capacity within the liver. Although the amount of 
inflammatory cells is much lower than the structural liver cells, a limitation of the study 
is that the differences found in DNA repair may partly be due to differences in the 
proportion of inflammatory cells that contribute to the tissue lysate, since whole tissue 
was used for the analysis. The observed decrease in ɶH2AX appears to be related to 
impairment of the recognition of DNA damage when MPO expression is high, as no 
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significant reduction of cell proliferation and only a small change in NER gene 
expression transcription, was observed. Although in patients with NASH there is a 
decrease in both NER capacity and H2AX phosphorylation, the major component 
determining the repair capacity appears to be MPO-immunoreactivity. This suggests 
that increased influx of neutrophils and their activation, which is often associated with 
NASH, may play an important role in the development of HCC. 
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Understanding the molecular mechanisms of benzo[a]pyrene (BaP) mediated 
carcinogenesis can be of great importance in the discovery of preventive measures or 
treatments against carcinogen-induced carcinogenesis. BaP is an environmental agent 
capable of forming bulky DNA adducts following a complex process of metabolic 
activation. When unrepaired, these adducts have the potential to form mutations and 
ultimately cancer. Increased induction of these DNA adducts and decreased repair are 
two important factors in the carcinogenicity of BaP. When people are exposed to 
similar amounts of carcinogens like BaP, large inter-individual differences are observed 
in, for instance, the formation of DNA adducts (1). There are different endogenous 
factors such as polymorphisms and oxidative stress that might influence 
carcinogenicity of carcinogens and determine someone’s susceptibility to carcinogens. 
Understanding these factors gives us a better insight in carcinogen-induced 
tumorigenesis. 
One important endogenous factor we explored is the lack of oxygen in the human 
body, better known as hypoxia. Significantly, hypoxia or more specifically hypoxia 
inducible factor ɲ (HIFɲ) stabilization has been strongly associated with multiple forms 
of cancer including lung (2), liver (3), cervix and breast cancers (4) and affect the 
clinical outcome. There are several reasons behind this phenomenon, including the 
capacity of HIFɲ stabilization to drive genomic instability and alter DNA damage repair 
pathways. Cells exposed to low oxygen levels activate the transcription factor HIFɲ as 
an adaptive response, which results in changes in gene expression. These alterations in 
gene expression are crucial in mediating cellular adaptation and survival of the cell.  
In this thesis we investigated several pathways for hypoxia-induced mutagenesis. The 
major pathway is a mechanism where HIFɲ stabilization induces BaP mutagenicity due 
to crosstalk between the HIF-pathway and the aryl hydrocarbon receptor (AhR)-
pathway. Secondly, we investigated the effect of HIFɲ stabilization on repair of BaP-
induced damage by nucleotide excision repair (NER). Finally, as changes in oxygen 
levels results in alterations in oxidative stress, (5,6), we sought to determine if this 
oxidative stress could be a second factor influencing carcinogen metabolism 
 
Hypoxia and BaP-induced DNA damage 
 
In this thesis, we propose a novel mechanism that HIFɲ stabilization modulates 
carcinogen metabolism. This may be an important mechanism in carcinogenicity, since 
HIFɲ stabilization may already occur in the early phases of disease development, since 
growth factors (7), oncogene activation and tumorsuppressor gene inactivation (8) as 
well as reactive oxygen species (9) are able to activate the HIF pathway. Also, 
alterations in the metabolism of carcinogens, to which we are continuously exposed, 
can have an important influence on carcinogenesis. Therefore, our proposed 
mechanism of HIFɲ altered carcinogen metabolism could be of major relevance for the 
pre-clinical stages of carcinogenesis. In the first three chapters of this thesis, we 
investigated gene expression, BaP metabolism, BaP metabolite formation and DNA 
damage induction and determined the effect of three different modes of HIFɲ 
stabilization: CoCl2 (chapter 2), hypoxia (chapter 3), and von Hippel-Lindau (VHL) 
deficiency (chapter 4) on them. 
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In chapter 2, A549 lung carcinoma cells were simultaneously incubated with BaP for 18 
hours, to induce the AhR-pathway, and with CoCl2 to induce the HIF-pathway. Analysis 
indicated that induction of the HIF-pathway significantly reduces the mRNA levels of 
AhR downstream targets CYP1A1 and CYP1B1. Furthermore, the lower levels of AhR 
bound to the aryl hydrocarbon nuclear transporter (ARNT) upon HIFɲ induction 
indicated competition for ARNT. These results demonstrated that induction of the HIF-
pathway leads to downstream effects in the AhR-pathway.  
Besides the examination of the level of crosstalk between the two pathways as other 
studies have done before (10,11), importantly, we also investigated the biological 
significance of this crosstalk, which to our knowledge has not been demonstrated 
before. Therefore, the effect on genetic instability by measuring mutation frequencies, 
DNA strand breaks, and BaP-7,8-dihydroxy-9,10-epoxide (BPDE)-DNA adduct formation 
was determined. The results presented in this thesis showed that the amount of BaP-
induced mutant cells and DNA strand breaks were significantly higher when the HIF-
pathway was induced, suggesting that modulation of carcinogen metabolism may be 
an important mechanism for the observed HIF mediated genetic instability (12,13).  
Other mechanisms besides competition for ARNT may also be involved in HIF 
modulated BaP genotoxicity. To explain for instance why the BPDE-DNA adduct levels 
were only 20-50% increased under HIF1 induction as compared to BaP alone, while the 
amount of BaP induced mutations were 10–20 fold increased when the HIF1 pathway 
was activated. Therefore, to further investigate mechanisms involved in the crosstalk, 
in chapter 3, the role of oxygen in the activation and detoxification of BaP was 
examined. A549 were treated in a manner similar to the previous chapter with 0.1µM 
BaP for 18 hours, but this time under different oxygen concentrations. Oxygen 
concentrations in the human body vary widely between different tissues, but largely 
fall in the 2–9% oxygen range. However, it can get as low as 1% in for instance the 
thymus and retina (14). Therefore, 0.2% oxygen was considered to be hypoxic 
conditions.  
In our experiments we observed induced phase I enzyme gene expression suggesting 
an increased BaP metabolism under hypoxia, while the observed decreased phase II 
enzyme gene expression suggests less detoxification of the BaP metabolites. Overall, 
this implies a possible increased metabolism towards the formation of BPDE. However, 
our data showed that cells under hypoxic conditions have a reduced capacity to 
metabolize BaP, resulting in lower metabolite levels. The pre-cursor metabolite (BaP-
7,8-dihydrodiol) of the reactive metabolite BPDE was however formed in higher 
concentrations. This shows that the determined gene expression patterns do not 
completely explain the observed metabolic changes. Nonetheless, the reduced BaP 
metabolism, but induced BaP-7,8-dihydrodiol formation, resulted in BPDE-DNA 
adducts accumulation over a period of 168 hours under hypoxia, whereas adducts 
were efficiently removed in 20% oxygen conditions. Ross et al showed that the 
extended time in which BPDE-DNA adducts are present in the cells, is associated with 
increased tumorigenesis (15). Since we observe this extended time in our experiment, 
it suggests that there is an increased risk of BaP-induced carcinogenesis under hypoxic 
conditions. Besides competition for ARNT, as shown in chapter 2, hypoxia itself directs 
carcinogen metabolism towards a more toxic metabolic pattern and alter kinetics of 
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metabolism leading to longer exposure to these metabolites. Subsequently, resulting 
in an increased adduct formation. These data further support the idea that modulation 
of carcinogen metabolism is an important additional mechanism for the observed HIFɲ 
mediated genetic instability.  
In chapter 4, we sought to determine whether the previously established mechanism 
holds true in a HIFɲ stabilized cell line. Therefore, naturally occurring renal cell 
carcinoma (RCC) cells deficient in VHL were used and compared with a functionally 
wild type RCC cells line with a reconstituted VHL present to investigate the effect of 
HIFɲ stabilization on carcinogen metabolism. Loss of VHL tumor suppressor protein 
function is associated with stabilization of HIFɲ regardless of oxygen tension and it is 
known that mutations in VHL are present in the majority of sporadic RCCs (16). To 
understand the mechanism by which defective VHL induces carcinogenicity will give 
better insight in the development of renal cancer. Data presented in this thesis showed 
that CYP1A1 mRNA levels were strongly diminished in RCC4-VHL cells compared to 
HIFɲ stabilized RCC4 cells. CYP1B1 mRNA levels on the other hand were unaffected 
due to loss of VHL, suggesting that CYP1A1 is the important player in carcinogen 
metabolism in RCC cells. HPLC analysis indicated that loss of VHL reduces BaP 
metabolism while increasing BaP-7,8-dihydroxydiol levels, the pre-cursor metabolite of 
BPDE. This change in carcinogen metabolism resulted in increased BPDE-DNA adduct 
levels in HIFɲ stabilized cells. Taken together, these data show that loss of VHL affects 
BaP-mediated genotoxic responses in RCC and further supports our hypothesis that 
HIFɲ stabilization affects carcinogen metabolism. 
These three studies demonstrate in different ways that HIFɲ stabilization modulates 
carcinogen metabolism. To further elucidate the mechanisms behind this effect, future 
studies are needed. First of all, the influence of specific genes involved in BaP 
metabolism needs to be better determined, since phase I gene expressions was 
downregulated under treatment with CoCl2, but upregulated under hypoxic conditions 
and phase II gene expressions seemed to influence BaP metabolism under real 
hypoxia, but not under VHL deficiency. Knock-out of these genes should explain the 
effect of the specific genes involved in carcinogen metabolism under HIFɲ stabilized 
conditions. Furthermore, the observation that under hypoxic conditions BaP 
metabolism is decreased resulting in decreased metabolite levels, except for the 
precursor of BPDE needs to be clarified. Furthermore, to fully understand the 
physiological impact of the changed carcinogen metabolism, our results need to be 
confirmed in an animal model. Finally, future studies should investigate the effect of 
HIFɲ stabilization on other carcinogens as well; starting with other polycyclic 
hydrocarbons, but from there further expanding towards other carcinogens. 
 
Hypoxia and reduced nucleotide excision repair 
 
Since BPDE-DNA adduct levels are always a balance between the induction of the 
damage and its removal, we investigated the effect of HIFɲ stabilization on the repair 
of BPDE-DNA adducts by NER, since NER is the most important pathway in removing 
these DNA adducts. Although, hypoxia is known to inhibit DNA repair mechanisms, 
surprisingly, not much is known about the effect of hypoxia on NER. In chapter 2 we 
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already suggested that HIFɲ stabilization could result in diminished NER, since our data 
showed that the amount of single strand breaks, generated during the repair of these 
adducts, is lower when the HIF-pathway is induced. In chapter 4, the observed changes 
in NER due to the stabilization of HIFɲ were further elucidated by investigating the NER 
capacity, by a previously validated modified comet assay which measures the ability of 
NER-related enzymes to incise DNA containing BPDE-DNA adducts. Our data from RCC 
cells deficient in VHL indicated that loss of VHL had no effect on DNA repair gene 
expression, but importantly the capacity to repair BPDE-DNA adducts in the HIFɲ 
stabilized RCC4 cells was markedly reduced. This confirms our initial observation in 
CoCl2 HIFɲ-stabilized cells described in chapter 2. Ineffective repair could result in 
increased cancer susceptibility as has been shown in XPA knock-out mice having 
enhanced tumorigenesis in the lung after exposure to BaP (17). Furthermore, 
individuals with a reduced NER capacity are at greater risk to develop cancer such as 
prostate (18) and breast cancer (19). Since mutations in VHL are present in the 
majority of RCCs, the reduced NER capacity could be responsible for increased 
susceptibility of renal cells, with a mutated VHL gene, to carcinogens which 
subsequently could result in the formation of RCC. 
 
Oxidative stress and increased adduct formation 
 
Since oxidative stress is an important factor in the hypoxia-induced mutagenicity (5), 
we investigated if oxidative stress itself could have an effect on the metabolism and 
carcinogenicity of BaP. As mentioned before, individuals can respond differently to 
similar exposure of BaP, which results in inter-individual differences in BPDE-DNA 
adduct levels. These differences can be partially explained by genetic differences (20). 
Although the effect of polymorphisms on BPDE-DNA adduct levels have been studied 
extensively and genes involved in carcinogen metabolism (21), DNA repair (22), and 
oxidative stress (23) have been identified, the level of exposure is often insufficiently 
characterized in large epidemiological studies that investigate the impact of genetic 
variation on DNA damage or disease. This could lead to misclassification and 
attenuation of underlying relationships. Therefore, we performed an ex vivo study 
assessing 34 SNPs based on a priori knowledge (24) and determined which SNPs were 
responsible for differences in BPDE-DNA adduct levels. In chapter 5, we present an 
important genetic polymorphism in catalase (C-262T) which to date has not been 
associated with altered BPDE-DNA adduct formation. 
It was observed that this polymorphism located in the promoter site of catalase 
resulted in an increased activity of catalase in individuals with the variant catalase 
allele compared to subjects with the wild-type allele, decreasing the levels of oxidative 
stress. Interestingly, catalase gene expression was strongly correlated with CYP1B1 
expression in lymphocytes and A549 cells. Although we did not fully elucidate the 
mechanism, knock down experiments indicated that two transcription factors (nuclear 
factor 1 (NF1) and nuclear erythroid 2-related factor 2 (Nrf2)) may play a role in the 
observed catalase-dependent CYP1B1 gene expression. Our results suggest a model in 
which the catalase polymorphism determines the amount of intracellular catalase and 
(co)regulates the expression of CYP1B1 by reducing the amount of H2O2 present in the 
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cells, which subsequently prevents the downregulation of transcription factors needed 
to transcribe CYP1B1.  
Our data indicate that oxidative stress is involved in the alteration in carcinogen 
metabolism; the proposed mechanism needs however further research. Nonetheless, 
the identification of susceptible groups carrying this specific polymorphism, which 
leads to functional changes, could result in a better risk assessment which could 
eventually result in lifestyle changes or reduction in exposure to certain carcinogens. 
 
Oxidative stress and reduced nucleotide excision repair 
 
The effect of oxidative stress on BaP-induced DNA damage may not be limited to the 
increased BPDE-DNA adduct formation, but, like HIFɲ stabilization, may also alters its 
repair by reducing NER capacity. Indeed, it was previously shown that NER activity was 
significantly impaired by neutrophil activation in lung cells in vitro (25) and that this 
was probably due to ROS formation following the influx of neutrophils (26). Based on 
these previous observations, it was speculated that in chronic inflamed livers, 
enhanced levels of oxidative stress due to the recruitment of neutrophils at the site of 
inflammation could inhibit NER compared to those with steatosis, an earlier stage of 
non-alcoholic fatty liver disease. 
Therefore, in chapter 6, the role of oxidative stress, in damage recognition and DNA 
repair in steatotic livers of 35 severely obese subjects with either nonalcoholic 
steatohepatitis (NASH) or steatosis alone was evaluated. A reduced damage 
recognition capacity, determined by staining for histone 2AX phosphorylation (ɶH2AX), 
was observed in livers with higher levels of myeloperoxidase, an indicator for 
neutrophil influx. This reduction in ɶH2AX formation was paralleled by a significant 
decrease in NER capacity. Our results confirmed the previous findings that increased 
influx of neutrophils and their activation reduces NER activity and might play a role in 
carcinogenesis. These patients might benefit from better treatment of the 
inflammation by for instance specific dietary interventions like vitamin E treatment 
preventing the development of hepatocellular carcinoma (27). Future research is 
however needed to investigate if this observed reduction in NER also applies to other 
inflammatory conditions in the human body. 
 
Overall conclusion 
 
A lot is known about BaP-induced DNA damage, especially on the effect of 
polymorphisms involved in carcinogen metabolism. However, there are more 
endogenous factors that could influence one’s susceptibility to carcinogens. Therefore, 
the main goal of this thesis was to investigate two of these endogenous factors 
(hypoxia and oxidative stress) and to better understand their effect on BaP-induced 
DNA damage and repair. Since BaP needs to be metabolic activated towards BPDE, 
alterations in the metabolism of BaP could eventually result in changed BPDE-DNA 
adduct levels and altered genetic instability. 
The first factor investigated in this thesis was hypoxia and the subsequent HIFɲ 
stabilization. At present the knowledge on HIFɲ stabilization affecting carcinogen 
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metabolism was limited to research on crosstalk between these two pathways without 
showing any phenotypic consequences. In three chapters we showed not only that 
HIFɲ stabilization caused changes in gene expression of genes involved in BaP 
metabolism, but also its effect on altered BaP metabolism, and on increased levels of 
DNA damage. More importantly, we showed the same effect in naturally occurring 
HIFɲ stabilized cells, showing the clinical relevance of this crosstalk and indicating that 
BaP metabolism can already be affected in the early stages of carcinogenesis. Besides 
hypoxia, we also determined that oxidative stress could have an effect on carcinogen 
metabolism by a polymorphism in catalase affecting CYP1B1 gene expression. 
Finally, we showed that NER capacity is reduced in HIFɲ stabilized cells, which prevent 
the repair of those BPDE-DNA adducts and we confirmed in a human model the 
inhibition of NER by oxidative stress. 
In conclusion, the results presented in this thesis shows different types of impact that 
hypoxia has on the mutagenicity of BaP. Besides increasing the BaP-induced DNA 
damage and reducing its repair by hypoxia, oxidative stress, which could be a result of 
hypoxia, plays also an important role in DNA damage inductions and DNA repair 
reduction. Overall, this thesis gives a better insight in endogenous mechanisms 
affecting BaP mutagenicity. In the future, this will offer new opportunities to 
investigate if it is possible to reduce the mutagenicity of carcinogens by influencing 
HIFɲ stabilization and reducing oxidative stress levels. Furthermore, a better 
understanding of the cause of inter-individual difference can result in a better risk 
assessment of carcinogens. 
Chapter 7 
 
 
 116
Reference list 
 
1 Rojas, M., Marie, B., Vignaud, J.M., Martinet, N., Siat, J., Grosdidier, G., Cascorbi, I., and 
Alexandrov, K. (2004) High DNA damage by benzo[a]pyrene 7,8-diol-9,10-epoxide in 
bronchial epithelial cells from patients with lung cancer: comparison with lung 
parenchyma. Cancer Lett, 207, 157-163. 
2 Jackson, A.L., Zhou, B., and Kim, W.Y. (2010) HIF, hypoxia and the role of angiogenesis in 
non-small cell lung cancer. Expert Opin Ther Targets, 14, 1047-1057. 
3 Wu, X.Z., Xie, G.R., and Chen, D. (2007) Hypoxia and hepatocellular carcinoma: The 
therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol, 22, 1178-1182. 
4 Vaupel, P., and Mayer, A. (2007) Hypoxia in cancer: significance and impact on clinical 
outcome. Cancer Metastasis Rev, 26, 225-239. 
5 Chandel, N.S., and Budinger, G.R. (2007) The cellular basis for diverse responses to oxygen. 
Free Radic Biol Med, 42, 165-174. 
6 Moller, P., Loft, S., Lundby, C., and Olsen, N.V. (2001) Acute hypoxia and hypoxic exercise 
induce DNA strand breaks and oxidative DNA damage in humans. FASEB journal : official 
publication of the Federation of American Societies for Experimental Biology, 15, 1181-
1186. 
7 Bardos, J.I., and Ashcroft, M. (2004) Hypoxia-inducible factor-1 and oncogenic signalling. 
Bioessays, 26, 262-269. 
8 Semenza, G.L. (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 3, 721-732. 
9 Cash, T.P., Pan, Y., and Simon, M.C. (2007) Reactive oxygen species and cellular oxygen 
sensing. Free Radic Biol Med, 43, 1219-1225. 
10 Gradin, K., McGuire, J., Wenger, R.H., Kvietikova, I., fhitelaw, M.L., Toftgard, R., Tora, L., 
Gassmann, M., and Poellinger, L. (1996) Functional interference between hypoxia and 
dioxin signal transduction pathways: competition for recruitment of the Arnt transcription 
factor. Mol Cell Biol, 16, 5221-5231. 
11 Gassmann, M., Kvietikova, I., Rolfs, A., and Wenger, R.H. (1997) Oxygen- and dioxin-
regulated gene expression in mouse hepatoma cells. Kidney Int, 51, 567-574. 
12 Reynolds, T.Y., Rockwell, S., and Glazer, P.M. (1996) Genetic instability induced by the 
tumor microenvironment. Cancer Res, 56, 5754-5757. 
13 Papp-Szabo, E., Josephy, P.D., and Coomber, B.L. (2005) Microenvironmental influences on 
mutagenesis in mammary epithelial cells. International journal of cancer. Journal 
international du cancer, 116, 679-685. 
14 Simon, M.C., and Keith, B. (2008) The role of oxygen availability in embryonic development 
and stem cell function. Nat Rev Mol Cell Biol, 9, 285-296. 
15 Ross, J.A., Nelson, G.B., Wilson, K.H., Rabinowitz, J.R., Galati, A., Stoner, G.D., Nesnow, S., 
and Mass, M.J. (1995) Adenomas induced by polycyclic aromatic hydrocarbons in strain 
A/J mouse lung correlate with time-integrated DNA adduct levels. Cancer Res, 55, 1039-
1044. 
16 Cohen, H.T., and McGovern, F.J. (2005) Renal-cell carcinoma. N  Engl  J  Med, 353, 2477-
2490. 
17 Ide, F., Iida, N., Nakatsuru, Y., Oda, H., Tanaka, K., and Ishikawa, T. (2000) Mice deficient in 
the nucleotide excision repair gene XPA have elevated sensitivity to benzo[a]pyrene 
induction of lung tumors. Carcinogenesis, 21, 1263-1265. 
18 Lockett, K.L., Snowhite, I.V., and Hu, J.J. (2005) Nucleotide-excision repair and prostate 
cancer risk. Cancer Lett, 220, 125-135. 
19 Latimer, J.J., Johnson, J.M., Kelly, C.M., Miles, T.D., Beaudry-Rodgers, K.A., Lalanne, N.A., 
Vogel, V.G., Kanbour-Shakir, A., Kelley, J.L., Johnson, R.R., and Grant, S.G. (2010) 
Summary and general discussion 
 
 117 
Nucleotide excision repair deficiency is intrinsic in sporadic stage I breast cancer. Proc Natl 
Acad Sci U S A, 107, 21725-21730. 
20 Eder, E. (1999) Intraindividual variations of DNA adduct levels in humans. Mutat Res, 424, 
249-261. 
21 Rojas, M., Cascorbi, I., Alexandrov, K., Kriek, E., Auburtin, G., Mayer, L., Kopp-Schneider, A., 
Roots, I., and Bartsch, H. (2000) Modulation of benzo[a]pyrene diolepoxide-DNA adduct 
levels in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphism. 
Carcinogenesis, 21, 35-41. 
22 Zhao, H., Wang, L.E., Li, D., Chamberlain, R.M., Sturgis, E.M., and Wei, Q. (2008) Genotypes 
and haplotypes of ERCC1 and ERCC2/XPD genes predict levels of benzo[a]pyrene diol 
epoxide-induced DNA adducts in cultured primary lymphocytes from healthy individuals: a 
genotype-phenotype correlation analysis. Carcinogenesis, 29, 1560-1566. 
23 Rojas, M., Godschalk, R., Alexandrov, K., Cascorbi, I., Kriek, E., Ostertag, J., Van Schooten, 
F.J., and Bartsch, H. (2001) Myeloperoxidase--463A variant reduces benzo[a]pyrene diol 
epoxide DNA adducts in skin of coal tar treated patients. Carcinogenesis, 22, 1015-1018. 
24 Wilms, L.C., Boots, A.W., de Boer, V.C., Maas, L.M., Pachen, D.M., Gottschalk, R.W., 
Ketelslegers, H.B., Godschalk, R.W., Haenen, G.R., van Schooten, F.J., and Kleinjans, J.C. 
(2007) Impact of multiple genetic polymorphisms on effects of a 4-week blueberry juice 
intervention on ex vivo induced lymphocytic DNA damage in human volunteers. 
Carcinogenesis, 28, 1800-1806. 
25 Gungor, N., Godschalk, R.W., Pachen, D.M., Van Schooten, F.J., and Knaapen, A.M. (2007) 
Activated neutrophils inhibit nucleotide excision repair in human pulmonary epithelial 
cells: role of myeloperoxidase. Faseb J, 21, 2359-2367. 
26 Gungor, N., Haegens, A., Knaapen, A.M., Godschalk, R.W., Chiu, R.K., Wouters, E.F., and 
van Schooten, F.J. (2010) Lung inflammation is associated with reduced pulmonary 
nucleotide excision repair in vivo. Mutagenesis, 25, 77-82. 
27 Singal, A.K., Jampana, S.C., and Weinman, S.A. (2011) Antioxidants as therapeutic agents 
for liver disease. Liver Int, 31, 1432-1448. 
 
 
 
 
 
Nederlandse 
samenvatting 
 
 
 
 
 
Nederlandse samenvatting 
 
 
 120
Volgens berekeningen zijn er in 2008 wereldwijd ongeveer 12,7 miljoen nieuwe 
gevallen van kanker geconstateerd en zijn er dat jaar maar liefst 7,6 miljoen mensen 
overleden aan deze ziekte. Omdat de wereldbevolking groeit en vergrijst en omdat in 
opkomende economiën slechte gewoontes zoals roken worden overnemen zal dit 
aantal de komende jaren alleen maar toenemen (1). Al sinds jaar en dag is bekend dat 
omgevingsfactoren zoals sigarettenrook, alcohol, voeding en blootstelling aan 
schadelijke stoffen op het werk de oorzaak zijn van het overgrote deel van het aantal 
doden als gevolg van kanker (2). Het merendeel van de kankerverwekkende stoffen 
(carcinogenen) dat aanwezig is in de omgeving moet eerst omgezet (gemetaboliseerd) 
worden tot een nieuwe stof voordat deze stoffen echt schadelijk zijn (3). Daarom 
kunnen veranderingen in het metabolisme van deze stoffen van invloed zijn op de 
carcinogeniciteit (de mate waarin een stof kanker kan veroorzaken) van een stof. Uit 
onderzoek is gebleken dat wanneer verschillende mensen worden blootgesteld aan 
dezelfde hoeveelheden van een carcinogene stof, er grote individuele verschillen 
worden waargenomen in de hoeveelheid schade aan het DNA (4). Er zijn verschillende 
endogene factoren (factoren aanwezig in het lichaam) die de carcinogeniciteit van 
carcinogenen kunnen beïnvloeden en zo iemands gevoeligheid bepalen. Zo is er al veel 
bekend over de effecten die polymorfismen (mutaties in het DNA die bij grote delen 
van de bevolking voorkomen) hebben op het metabolisme van carcinogenen. Er zijn 
echter meerdere endogene factoren die van invloed kunnen zijn op iemands 
gevoeligheid voor die carcinogenen, zoals de aanwezigheid van een ontsteking of 
oxidatieve stress (een overschot aan vrije radicalen en een tekort aan anti-oxidanten). 
Bovendien kunnen diezelfde factoren misschien van invloed zijn op het herstel van de 
schade die veroorzaakt wordt door de carcinogenen. 
 
Introductie en doelstellingen van dit proefschrift 
 
Benzo[a]pyreen (BaP) is een carcinogeen dat in grote mate om ons heen aanwezig is. 
Dat komt omdat het ontstaat bij incomplete verbranding. Zo is het aanwezig in 
uitlaatgassen, sigarettenrook en verbrand vlees. BaP is een lipofiele stof. Hierdoor 
passeert het gemakkelijk het celmembraan. Eenmaal in het cytoplasma van de cel 
bindt het zich aan de aryl hydrocarbon receptor (AhR), waarna het zich samen 
verplaatst naar de celkern. In de celkern bindt het zich aan de aryl hydrocarbon 
receptor nuclear translocator (ARNT) en activeert het de genexpressie van bepaalde 
genen door zich te binden aan het DNA. Deze route staat bekend als de AhR-pathway. 
BaP staat vooral bekend om zijn vermogen om zijn eigen metabolisme te stimuleren 
door het induceren van de expressie van de cytochroom P450 isovormen CYP1A1 en 
CYP1B1, twee van de belangrijkste enzymen in de detoxificatie en activatie van BaP (5). 
Het detoxificatieproces van BaP kan grofweg verdeeld worden in twee fasen. Tijdens 
fase I wordt er een epoxide groep aan BaP gebonden door CYP1A1 en CYP1B1. De 
resulterende metabolieten kunnen dan tijdens fase II geconjugeerd worden doordat er 
een sulfaat, glutathion of glucuronide zuur aan gebonden wordt. De ontstane 
metaboliet is oplosbaar in water en kan zo makkelijk verwijderd worden uit het 
lichaam. Dit proces wordt gestuurd door de zogenoemde fase II-enzymen (6). BaP kan 
echter ook omgezet worden tot BaP-7,8-dihydroxy-9,10-epoxide (BPDE), wat aan het 
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DNA bindt en zogenoemde DNA-adducten vormt. Deze adducten moeten verwijderd 
worden door het nucleotide excision repair (NER)-mechanisme. Als deze adducten 
echter niet verwijderd worden, kunnen er mutaties in het DNA ontstaan die 
uiteindelijk tot kanker kunnen leiden.  
In dit proefschrift ligt de focus van het onderzoek op twee endogene zuurstof-
gerelateerde factoren (hypoxie, ofwel een tekort aan zuurstof, en oxidatieve stress). 
Uit eerder onderzoek is gebleken dat deze factoren van invloed zouden kunnen zijn op 
het metabolisme van carcinogenen (7) en het herstel van DNA-schade (8). Ons doel 
was om deze factoren verder te onderzoeken en de biologische significantie van deze 
factoren (door het veranderen van het metabolisme van carcinogenen en het  herstel 
van DNA-schade) op het ontstaan van kanker te bewijzen. 
De eerste endogene factor die we onderzocht hebben is hypoxie. Hypoxie, of meer 
specifiek, de stabilisatie van het hypoxia-inducible factor ɲ (HIFɲ) eiwit is sterk 
geassocieerd met meerdere vormen van kanker zoals long- (9), lever- (10) en 
baarmoederhals- en borstkanker (11) en is van invloed is op iemands prognose. Als er 
voldoende zuurstof aanwezig is, worden hydroxylgroepen aan HIFɲ gebonden door 
prolyl-4-hydroxylase (12). Het gehydroxyleerde HIFɲ wordt daarop herkend door een 
ubiquitine ligase complex dat het von Hippel-Lindau-eiwit (VHL) bevat. Na binding van 
VHL wordt HIFɲ afgebroken (13). Hypoxie voorkomt daarintegen de hydroxylase-
activiteit waardoor HIFɲ niet wordt afgebroken, maar zich verplaatst naar de celkern, 
waar het zich aan ARNT bindt en HIF1 vormt (14). HIF1 bindt zich hierna aan het DNA 
waar het de transcriptie van een groot aantal genen verhoogt. Dit proces staat bekend 
als de HIF-pathway. Deze veranderingen in genexpressie zijn cruciaal voor om de cel te 
laten overleven. 
In dit proefschrift onderzochten we verschillende manieren van hypoxie-geïnduceerde 
carcinogeniciteit, maar de belangrijkste focus lag op het feit dat beide pathways ARNT 
nodig hebben en er dus sprake kan zijn van competitie tussen de twee pathways. 
Daarnaast onderzochten we het effect van HIFɲ-stabilisatie op de herstel van BaP-
geïnduceerde schade door NER. Omdat veranderingen in de zuurstofconcentraties kan 
resulteren in veranderingen in oxidatieve stress (15,16), hebben we onderzocht of 
oxidatieve stress een tweede endogene factor kan zijn die van invloed is op het 
metabolisme van carcinogenen en op het herstel van de carcinogeen-geïnduceerde 
schade. 
 
Hypoxie en BaP-geïnduceerde DNA-schade 
 
In dit proefschrift introduceren we een nieuw mechanisme waarbij HIFɲ-stabilisatie 
het carcinogeenmetabolisme moduleert. Dit kan een belangrijk mechanisme zijn in de 
carcinogeniteit van carcinogenen, aangezien HIFɲ al kan stabiliseren in de beginfase 
van de ontwikkeling van kanker. Dit komt omdat groeifactoren (17), activatie van 
oncogene en deactivatie van tumorsuppressorgenen (18) en de aanwezigheid van 
zuurstofradicalen de HIF-pathway kunnen activeren (19). Bovendien kunnen 
veranderingen in het metabolisme van carcinogenen waar we continu blootgesteld aan 
worden van grote invloed zijn op het ontstaan van kanker. Daarom kan ons 
voorgestelde mechanisme van groot belang zijn voor de preklinische stadia van de 
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ontwikkeling van kanker. In de eerste drie hoofdstukken van dit proefschrift hebben 
we genexpressie, BaP-metabolisme, de vorming van BaP-metabolieten  en DNA-schade 
onderzocht en bepaald wat het effect is van drie verschillende manieren van HIFɲ-
stabilisatie: CoCl2 (hoofdstuk 2), hypoxie (hoofdstuk 3), en von Hippel-Lindau (VHL)-
deficiëntie (hoofdstuk 4). In hoofdstuk 2 zijn A549-cellen afkomstig van een 
longcarcinoom gelijktijdig blootgesteld aan BaP (om de AhR-pathway te activeren), en 
CoCl2 (om de HIF-pathway te activeren). Analyse gaf aan dat het activeren van de HIF-
pathway de mRNA niveaus reduceert van de AhR-pathway genen CYP1A1 en CYP1B1. 
Bovendien is er minder AhR gebonden aan ARNT als de HIF-pathway wordt 
geïnduceerd. Deze resultaten toonden aan dat de activatie van de HIF-pathway effect 
heeft op de AhR-pathway. Naast het onderzoek naar het niveau van competitie tussen 
deze twee pathways zoals andere studies al eerder hebben gedaan (20,21), hebben we 
ook gekeken naar de biologische significantie van deze competitie. Dit was namelijk tot 
op heden nog niet aangetoond. Hiervoor hebben we het effect van genetische 
instabiliteit bepaald door het meten van de hoeveelheid gemuteerde cellen, DNA-
breuken en BPDE-DNA adducten. De resultaten zoals beschreven in dit proefschrift 
laten zien dat de hoeveelheid BaP-geïnduceerde mutante cellen en de hoeveelheid 
DNA-breuken significant hoger zijn als de HIF-pathway wordt geactiveerd, wat 
aangeeft dat veranderingen van het metabolisme van carcinogenen een belangrijk 
mechanisme kunnen zijn voor de in andere onderzoeken waargenomen HIF-
gemedieerde genetische instabiliteit (22,23).  
Behalve de competitie voor ARNT zijn er echter ook andere mechanismen zijn die de 
HIF gemoduleerde BaP-genotoxiciteit bepalen. Zo zagen wij bijvoorbeeld dat het 
niveau van het BPDE-DNA-adduct slechts tussen de 20 en 50% verhoogd was als de 
HIF-pathway was geïnduceerd ten opzichte van BaP alleen, terwijl de hoeveelheid BaP-
geïnduceerde mutaties 10 tot 20 maal hoger waren wanneer de HIF1 pathway was 
geactiveerd. Om mogelijke andere mechanismen te onderzoeken die betrokken zijn bij 
HIF-geinduceerde BaP-carcinogeniciteit, hebben we in hoofdstuk 3 de rol van zuurstof 
in de activatie en detoxificatie van BaP onderzocht. A549-cellen werden op 
vergelijkbare wijze behandeld als in het voorgaande hoofdstuk, maar dit keer werden 
de cellen blootgesteld aan verschillende concentraties zuurstof. Zuurstofconcentraties 
in het menselijk lichaam variëren sterk tussen de verschillende weefsels. Over het 
algemeen liggen ze tussen de 2 tot 9%, met uitzondering van sommige weefsels zoals 
de thymus en de retina, waar de zuurstofconcentratie op slechts 1% ligt (24). Daarom 
hebben we gekozen voor een concentratie van 0,2% zuurstof. Deze is representatief 
voor hypoxische omstandigheden.  
In deze experimenten zagen we een toename in de genexpressie van fase I-enzymen. 
Dit is een indicatie voor een verhoogd BaP-metabolisme tijdens hypoxie, terwijl de 
waargenomen verminderde genexpressie van fase II-enzymen een verminderde 
verwijdering van de BaP-metabolieten aangeeft. Over het algemeen betekent dit een 
mogelijk verhoogd metabolisme, wat resulteert in een verhoogde vorming van BPDE. 
Uit onze gegevens bleek echter dat de cellen onder hypoxische condities een 
verminderde capaciteit hebben om BaP te metaboliseren, wat resulteerde in lagere 
hoeveelheden metabolieten die aanwezig zijn. De precursor metaboliet (BaP-7,8-
dihydrodiol) van de reactieve metaboliet BPDE was echter in hogere concentraties in 
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de cel aanwezig. Dit toont aan dat de vastgestelde genexpressiepatronen de 
waargenomen metabole veranderingen niet volledig verklaren. Desalniettemin 
toonden we aan dat het verminderde BaP metabolisme, maar geïnduceerde BaP-7,8-
dihydrodiol vorming onder hypoxie leidde tot een accumulatie van BPDE-DNA-
adducten over een periode van 168 uur, terwijl adducten efficiënt werden verwijderd 
bij 20% zuurstof.  
Ross et al. toonden aan dat de tijd waarin BPDE-DNA-adducten aanwezig zijn in de 
cellen geassocieerd wordt met een verhoogde tumorvorming (25). Omdat in ons 
experiment de adducten onder hypoxische condities voor een langere tijd aanwezig 
zijn in vergelijking met niet-hypoxische condities, suggereert dit dat er een verhoogd 
risico is op BaP-geïnduceerde carcinogenese onder hypoxische condities. Naast de 
competitie voor ARNT, zoals aangetoond in hoofdstuk 2, tonen we in hoofdstuk 3 aan 
dat hypoxie het carcinogeenmetabolisme in de richting van een meer toxische 
metaboolpatroon stuurt en dat de veranderde kinetiek van het metabolisme leidt tot 
meer blootstelling aan deze metabolieten. Dit resulteert vervolgens in een verhoogde 
adductvorming. Deze gegevens ondersteunen het idee dat de modulatie van het 
carcinogeenmetabolisme een belangrijk extra mechanisme is in de waargenomen 
HIFɲ-gemedieerde genetische instabiliteit. 
In hoofdstuk 4 hebben we geprobeerd te bepalen of het eerder vastgestelde 
mechanisme ook geldt in een HIFɲ-gestabiliseerde cellijn. Daarom hebben we cellen 
van een niercelcarcinoom (RCC) gebruikt die een niet-functionerend VHL-gen hebben. 
Deze werden vergeleken met RCC-cellen waar een functionerend VHL-gen in terug was 
gebracht (RCC4-VHL-cellen). Het niet-functioneren van het VHL-tumorsuppressoreiwit 
resulteert in de stabilisatie van HIFɲ ongeacht de zuurstofconcentratie en het is 
bekend dat de meeste RCCs een mutatie hebben in het VHL-gen (26). De resultaten uit 
dit proefschrift laten zien dat CYP1A1 mRNA-niveaus sterk zijn afgenomen in de RCC4-
VHL-cellen in vergelijking met HIFɲ-gestabiliseerde RCC4-cellen. De mRNA-niveaus van 
CYP1B1 werden daarentegen niet beïnvloed door het verlies van VHL. Dit geeft aan dat 
CYP1A1 de belangrijkste speler is in het carcinogeenmetabolisme in RCC-cellen. HPLC-
analyse toonde aan dat door het verlies van VHL het BaP-metabolisme vermindert, 
terwijl er wel hogere niveaus van BaP-7,8-dihydroxydiol aanwezig zijn (de 
precursormetaboliet van BPDE). Deze verandering in het carcinogeenmetabolisme 
resulteert in een verhoogd aantal BPDE-DNA-adduct in HIFɲ gestabiliseerde cellen. Al 
deze gegevens tonen aan dat het verlies van VHL van invloed is op BaP-gemedieerde 
genotoxische reacties in RCC. Dit ondersteunt onze hypothese dat HIFɲ-stabilisatie 
carcinogeenmetabolisme beïnvloedt. 
De drie studies uitgevoerd in dit proefschrift tonen op verschillende manieren aan dat 
HIFɲ-stabilisatie carcinogeenmetabolisme moduleert. Om dit mechanisme verder te 
ontrafelen, zijn er uiteraard meer studies nodig. Omdat we in ons onderzoek zagen dat 
de genexpressie van fase I-enzymen verminderd was na behandeling met CoCl2, maar 
geïnduceerd onder hypoxische omstandigheden, moet allereerst de invloed van 
specifieke genen in het BaP-metabolisme beter worden bepaald. Bovendien leek 
veranderde genexpressie van fase II-enzymen onder echte hypoxie het BaP-
metabolisme te beïnvloeden, maar was dat niet het geval toen er sprake was van VHL-
deficiëntie. Het uitschakelen van specifieke genen zal meer inzicht geven in de werking 
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van deze genen en hun invloed op het carcinogeenmetabolisme onder 
omstandigheden waarin HIFɲ gestabiliseerd is. Voorts hebben we waargenomen dat 
onder hypoxische omstandigheden het BaP-metabolisme vermindert. Dit resulteerde 
in verminderde metabolietvormen (behalve bij de voorloper van BPDE). Om bovendien 
volledig te begrijpen wat de fysiologische impact is van het gewijzigde 
carcinogeenmetabolisme, moeten onze resultaten bevestigd worden in een diermodel. 
Ten slotte kunnen toekomstige studies onderzoek doen naar het effect van HIFɲ-
stabilisatie op andere carcinogenen, te beginnen bij andere polycyclische 
koolwaterstoffen en dat verder uitbreiden naar andere carcinogenen. 
 
Hypoxie en verminderde nucleotide excision repair 
 
Adduct-niveaus van BPDE-DNA zijn altijd een evenwicht tussen het ontstaan van de 
schade en het herstel ervan. Daarom onderzochten we het effect van HIFɲ-
stabilisering op het herstel van BPDE-DNA-adducten door NER; de belangrijkste route 
voor het verwijderen van deze DNA-adducten. Hoewel het bekend is dat hypoxie DNA-
herstelmechanismen kan remmen, is er verrassend weinig bekend over het effect van 
hypoxie op NER. In hoofdstuk 2 hebben we al gesuggereerd dat HIFɲ-stabilisatie zou 
kunnen leiden tot verminderde NER, omdat uit onze gegevens bleek dat het niveau 
van enkelstrengsbreuken die tijdens het herstel van deze adducten ontstaan, lager is 
wanneer de HIF-pathway wordt geïnduceerd. In hoofdstuk 4 werden de waargenomen 
veranderingen in NER als gevolg van de stabilisatie van HIFɲ verder bekeken. De 
gegevens toonden in RCC-cellen met een niet werkend VHL-eiwit aan dat het verlies 
van VHL-functie geen effect heeft op de genexpressie van NER-genen, maar dat het 
vermogen om BPDE-DNA adducten te herstellen in de HIFɲ-gestabiliseerde RCC4-
cellen aanmerkelijk verminderd is. Dit bevestigt onze eerdere observatie in cellen 
waarin HIFɲ-is gestabiliseerd door CoCl2 beschreven in hoofdstuk 2. Ineffectief herstel 
van adducten kan leiden tot een verhoogde gevoeligheid van kanker, zoals is 
aangetoond in een muizensoort waarin NER niet meer werkte. In deze muizen werd 
een verhoogde tumorvorming in de longen waargenomen nadat ze blootgesteld waren 
aan BaP (27). Bovendien lopen mensen met een verminderde NER-capaciteit een 
groter risico om kanker te ontwikkelen, zoals prostaat-(28) en borstkanker (29). 
Aangezien mutaties in VHL aanwezig zijn in de meeste niercarcinoma, kan de beperkte 
capaciteit van NER verantwoordelijk zijn voor verhoogde gevoeligheid van niercellen 
met een gemuteerd VHL-gen aan carcinogenen. Dit kan vervolgens leiden tot (de 
vorming van) nierkanker. 
 
Oxidatieve stress en een verhoogde adductvorming 
 
Omdat oxidatieve stress een belangrijke factor is in hypoxie-geïnduceerde 
carcinogenese (15), hebben wij onderzocht of oxidatieve stress zelf een effect kan 
hebben op het metabolisme en de carcinogeniteit van BaP. Zoals eerder aangegeven 
kunnen individuen verschillend reageren op dezelfde blootstelling aan BaP, waardoor 
individuele verschillen in BPDE-DNA adductniveaus waargenomen worden. Deze 
verschillen kunnen gedeeltelijk verklaard worden door genetische verschillen (30). 
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Hoewel het effect van polymorfismen op BPDE-DNA adduct-niveaus uitgebreid is 
bestudeerd en genen die betrokken zijn bij carcinogeen metabolisme (31), DNA herstel 
(32), en oxidatieve stress (33) zijn geïdentificeerd, wordt het niveau van blootstelling 
vaak onnauwkeurig bepaald in grote epidemiologische studies die de impact van de 
genetische variatie onderzoeken op DNA-schade of ziekte. Dit kan leiden tot 
misclassificatie en verzwakking van de onderliggende relaties. Daarom hebben we een 
ex vivo-studie uitgevoerd naar 34 polymorfismen op basis van a prior-kennis (34). We 
hebben polymorfismen geïdentificeerd die verantwoordelijk waren voor verschillen in 
BPDE-DNA adductniveaus. In hoofdstuk 5 presenteren we een belangrijk genetisch 
polymorfisme in catalase (C-262T), die tot op heden niet is in verband gebracht met 
veranderde BPDE-DNA adductvorming. Dit polymorfisme in de promotor van catalase 
zorgde voor een verhoogde activiteit van catalase in individuen met het homozygote 
variante catalase allel in tegenstelling tot personen met het wild-type allel, wat 
resulteerde in verminderde oxidatieve stress. Interessant is dat de genexpressie van 
catalase sterk gecorreleerd is aan CYP1B1-expressie in lymfocyten en A549-cellen. 
Hoewel we niet volledig het mechanisme hebben kunnen verklaren, toonden 
knockdownexperimenten aan dat twee transcriptiefactoren (nuclear factor 1 (NF1) en 
nucleaire erytroïde 2-gerelateerde factor 2 (Nrf2) mogelijk een rol spelen in de 
waargenomen catalase-afhankelijke CYP1B1 genexpressie. Onze resultaten suggereren 
een model waarbij het polymorfisme in catalase de hoeveelheid intracellulaire catalase 
bepaalt en zo de expressie van CYP1B1 beïnvloedt door de hoeveelheid H2O2 in de 
cellen te verminderen. Dit voorkomt vervolgens de afname van transcriptiefactoren 
die nodig zijn om genexpressie van CYP1B1-enzymen te induceren. Deze gegevens 
tonen aan dat oxidatieve stress van invloed kan zijn op verandering in het 
carcinogeenmetabolisme. Het voorgestelde mechanisme moet echter verder 
onderzocht worden. Wel kan de identificatie van gevoelige groepen die dit specifieke 
polymorfisme hebben, leiden tot een betere risicobeoordeling. Dit kan uiteindelijk 
resulteren in specifiek advies over leefstijlveranderingen of verlaging van blootstelling 
van deze specifieke groepen aan bepaalde carcinogenen. 
 
Oxidatieve stress en een verminderd herstel van DNA adducten 
 
Het effect van oxidatieve stress op BaP-geïnduceerde DNA-schade kan niet alleen 
resulteren in verhoogde BPDE-DNA adduct vorming, maar net als bij HIFɲ-stabilisatie 
leiden tot verminderde NER-capaciteit. Er is eerder aangetoond binnen onze afdeling 
dat NER-activiteit aanzienlijk werd verminderd door in vitro-activatie van neutrofielen 
in longcellen (35) en dat dit vermoedelijk veroorzaakt werd door het ontstaan van 
oxidatieve stress na de influx van neutrofielen in het weefsel (8). Op basis van deze 
eerdere observaties wilden we onderzoeken of dit ook het geval was bij chronisch 
ontstoken lever. Daarom werd in hoofdstuk 6 de rol van oxidatieve stress in 
schadeherkenning en DNA-herstel in steatotische levers van 35 ernstig obese 
patiënten met ofwel non-alcoholische steatohepatitis (NASH; ontstoken lever) of 
steatose (leververvetting) vergeleken met elkaar. Door gebruik te maken van een 
kleuring voor histon-2AX-fosforylering (ɶH2AX) toonden we aan dat er sprake is van 
een verminderde herkenning van de schade in levers met hogere niveaus van 
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myeloperoxidase, een indicator voor influx van neutrofielen. Deze verminderde 
ɶH2AX-vorming ging gepaard met een significante afname van de NER-capaciteit. Onze 
resultaten bevestigen dus de eerdere bevindingen dat de influx van neutrofielen leidt 
tot een verminderde NER-activiteit. Dit zou een rol kunnen spelen bij het ontstaan van 
kanker. Deze patiënten zouden kunnen profiteren van een betere behandeling van de 
ontsteking of van specifieke aanpassingen in hun dieet, zoals extra vitamine E die de 
ontwikkeling van hepatocellulair carcinoom kan beperken (36). Nader onderzoek is 
echter nodig om te bevestigen of deze waargenomen verlaging in NER ook geldt voor 
andere ontstekingsaandoeningen in het menselijk lichaam. 
 
Algemene conclusie 
 
Er is al veel bekend over BaP-geïnduceerde DNA-schade en welke factoren hierop van 
invloed kunnen zijn, in het bijzonder over het effect van polymorfismen die betrokken 
zijn bij het metabolisme van carcinogenen. Er zijn echter meer endogene factoren die 
de gevoeligheid voor carcinogenen kunnen beïnvloeden. Daarom was het doel van dit 
proefschrift om twee van deze endogene factoren (hypoxie en oxidatieve stress) 
verder te onderzoeken om zo meer inzicht te krijgen in het effect dat ze hebben op de 
BaP-geïnduceerde DNA-schade en het herstel van die schade. Omdat BaP 
gemetaboliseerd moet worden tot BPDE voordat het kan reageren met het DNA, 
kunnen veranderingen in het metabolisme van BaP uiteindelijk resulteren in een 
veranderd BPDE-DNA adduct niveau en veranderde genetische instabiliteit. De eerste 
endogene factor die is onderzocht in dit proefschrift was hypoxie en de 
daaropvolgende HIFɲ-stabilisatie. Momenteel is de kennis over de invloed van HIFɲ-
stabilisatie op carcinogeenmetabolisme beperkt tot de competitie tussen de HIF-
pathway en de AhR-pathway. Echter is nog nooit aangetoond of dat deze competitie 
ook daadwerkelijk klinische gevolgen heeft. In drie hoofdstukken hebben we laten zien 
dat niet alleen HIFɲ-stabilisatie veranderingen veroorzaakt in genexpressie van genen 
die betrokken zijn bij BaP-metabolisme, maar dat dit ook leidt tot een veranderd BaP-
metabolisme en tot verhoogde DNA-schade. Hetzelfde effect toonden we aan in de in 
het lichaam voorkomende door HIFɲ gestabiliseerde cellen, wat de klinische relevantie 
van deze competitie aangeeft. Dit toont aan dat BaP-metabolisme al kan worden 
beïnvloed in de vroege stadia van carcinogenese.  
Behalve de invloed vanhypoxie hebben we ook vastgesteld dat oxidatieve stress een 
effect kan hebben op het carcinogeenmetabolisme. We hebben een relatie kunnen 
leggen tussen een polymorfisme in catalase dat invloed heeft op de genexpressie van 
CYP1B1. Tot slot toonden we aan dat de NER-capaciteit wordt verminderd in HIFɲ-
gestabiliseerde cellen, waardoor het herstel van BPDE-DNA adducten wordt 
verminderd. Bovendien hebben we in een humaan model bevestigd dat oxidatieve 
stress in staat is om NER te remmen.  
Kortom, de resultaten van dit proefschrift tonen de verschillende soorten impact aan 
die hypoxie heeft op de mutageniteit van BaP. Naast het verhogen van de BaP-
geïnduceerde DNA-schade en het verminderen van het herstel door hypoxie, speelt 
ook oxidatieve stress een belangrijke rol in het veroorzaken van DNA-schade en het 
verminderde herstel van deze schade. Over het geheel genomen geeft dit proefschrift 
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een beter inzicht in de endogene mechanismen die van invloed kunnen zijn op de BaP-
mutageniteit. Dit kan in de toekomst leiden tot onderzoek dat bekijkt of het mogelijk is 
om de mutageniteit van kankerverwekkende stoffen te verminderen door HIFɲ-
stabilisatie te beïnvloeden en oxidatieve stress te verminderen. Het begrijpen van de 
moleculaire mechanismen die de carcinogeniciteit van BaP bepalen kan bovendien van 
groot belang zijn in het bepalen van preventieve maatregelen of het ontdekken van 
nieuwe behandelingen tegen carcinogeen-geïnduceerde tumoren. Bovendien kan een 
beter idee over de oorzaken van de interindividuele verschillen leiden tot een betere 
risico-evaluatie van kankerverwekkende stoffen. 
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